# Laboratory Evaluations for Integrative and Functional Medicine
## Chapter 6: Organic Acids

Richard S. Lord and J. Alexander Bralley

Mitochondrial Function Assessment. ...................................................................................................327
Fatty Acid Metabolism Markers........................................................................................................327
Adipate and Suberate..................................................................................................................329
Ethylmalonate. ............................................................................................................................329
Carbohydrate Metabolism Markers..................................................................................................331
Lactate and Pyruvate...................................................................................................................331
β-Hydroxybutyrate......................................................................................................................335
Oxalate........................................................................................................................................335
Central Energy Pathway Markers.....................................................................................................336
Citrate, Isocitrate, and cis-Aconitate...........................................................................................336
α-Ketoglutarate. ..........................................................................................................................338
Succinate.....................................................................................................................................338
Fumarate and Malate...................................................................................................................340
Hydroxymethylglutarate. ............................................................................................................340

B-Complex Vitamin Markers.................................................................................................................341
Vitamins B1, 2, 3, and 5.........................................................................................................................341
α-Ketoisovalerate, α-Ketoisocaproate, and α-Keto-β-Methylvalerate..........................................341
Vitamin B6.........................................................................................................................................343
Xanthurenate...............................................................................................................................343
Biotin. ...............................................................................................................................................344
β-Hydroxyisovalerate. .................................................................................................................344

Methylation Pathway Markers..............................................................................................................347
Vitamin B12........................................................................................................................................347
Methylmalonate...........................................................................................................................347
Folic Acid..........................................................................................................................................348
Formiminoglutamate...................................................................................................................348

Neurotransmitter Metabolism Markers. ...............................................................................................350
Catecholamines.................................................................................................................................351
Vanilmandelate and Homovanillate.............................................................................................351
Serotonin. .........................................................................................................................................352
5-Hydroxyindoleacetate (5-HIAA)...............................................................................................352
NMDA Modulators. ..........................................................................................................................355
Kynurenate and Quinolinate.......................................................................................................355
Picolinate.....................................................................................................................................359
Oxidative Damage and Antioxidant Markers........................................................................................360
Cell Proliferation. .............................................................................................................................360
p-Hydroxyphenyllactate (HPLA)..................................................................................................360
DNA Oxidative Damage....................................................................................................................361
8-Hydroxy-2'-deoxyguanosine (8-OHdG)....................................................................................361
Homogentisate (HGA).................................................................................................................362
Detoxification Markers. ........................................................................................................................363
Xylene exposure................................................................................................................................363
2-Methylhippurate.......................................................................................................................363

Ammonemia......................................................................................................................................364
Orotate. .......................................................................................................................................364
Hepatic Phase I and II Activity.........................................................................................................364
Glucarate.....................................................................................................................................364
Glutathione Status............................................................................................................................366
α-Hydroxybutyrate (2-Hydroxybutyrate)....................................................................................366
Pyroglutamate (5-Oxoproline).....................................................................................................367
Sulfate. ........................................................................................................................................369

Intestinal Dysbiosis Markers................................................................................................................370
Bacterial and Protozoal Phenolic Products.......................................................................................374
Benzoate and Hippurate..............................................................................................................375
Phenylacetate and Phenylpropionate. .........................................................................................376
Cresol and Hydroxybenzoate......................................................................................................378
Hydroxyphenylacetate.................................................................................................................378
Hydroxyphenylpropionate. .........................................................................................................380
3,4-Dihydroxyphenylpropionate.................................................................................................382
Bacterial Products from Tryptophan.................................................................................................384
Indican. .......................................................................................................................................384
Products of Dietary Carbohydrate....................................................................................................384
d-Lactate......................................................................................................................................384
Tricarballylate.............................................................................................................................387
Products of Fungi (Yeast)..................................................................................................................387
d-Arabinitol.................................................................................................................................387
Putative Yeast Markers and Promising Bacterial Markers.................................................................388
Actions to Consider for Elevated Dysbiosis Markers. ......................................................................388

Case Illustrations..................................................................................................................................391
6.1 — Carnitine Insufficiency in Schizophrenia...............................................................................391
6.2 — α-Ketoglutarate Dehydrogenase Deficiency. ..........................................................................391
6.3 — Apparent Succinate Dehydrogenase Deficiency.....................................................................392
6.4 — Signs of HMG-CoA Lyase Deficiency in Autism.....................................................................392
6.5 — Specific Ketoisovaleric Aciduria as a Sign of Genetic Abnormality.......................................393
6.6 — Undetectable Quinolinate......................................................................................................393
6.7 — Redox Stress in COPD. ..........................................................................................................394
6.8 — Three Glutathione Demand Scenarios...................................................................................394
6.9 — Scenarios for Abnormal Benzoate and Hippurate..................................................................395
6.10 — An Unusual Microbial Phenyl Compound Pattern...............................................................396
References.............................................................................................................................................397
Notes:

Table 6.1 — Summary of Abnormalities for Organic Acids in Urine

Name

Potential Intervention

Metabolic Pathway

Fatty Acid Oxidation
Adipate

H

Suberate

H

Ethylmalonate

H

See text for other interventions in genetic disorders

Pyruvate

H

B1, up to 100mg TID with B complex support;
For concurrent H Lactate: lipoic acid, 500mg TID

Lactate

H

Coenzyme Q10, 50 mg TID

## β-Hydroxybutyrate

H

Chromium picolinate, 200 µg BID

l-Carnitine, 500–1000 mg TID;

l-Lysine (if low), 500 mg TID; B2, 100mg BID

Fatty acid oxidation

Carbohydrate Metabolism
Aerobic/anaerobic energy
production
Balance of fat and CHO metabolism

Energy Production (Citric Acid Cycle)
H
L

Aspartic acid, 500 mg; magnesium citrate, 500 mg

Cis-aconitate

H

Cysteine, 1000 mg BID; Check for iron deficiency

Isocitrate

H

Lipoic acid, 25 mg/kg/day
Magnesium, 400 mg; manganese, 20 mg

a-KG, 300 mg; arginine, 1000 mg; glutamine, 1–5 g
B-complex, 1 TID; lipoic acid 100 mg

L

Isoleucine, 1000 mg TID; valine, 1000 mg TID

## Succinate

CoQ10, 50 mg TID, magnesium, 500 mg

L

Tyrosine, 1000 mg BID; phenylalanine, 500 mg BID

Malate

H

CoQ10, 50 mg TID, B3, 100 mg TID

Hydroxymethylglutarate

L,H CoQ10, 50 mg TID

H
Fumarate

a-Ketoisovalerate

H

a-Ketoisocaproate

H

## Xanthurenate
β-Hydroxyisovalerate
Methylmalonate or
Propionate

Valine catabolism

B-complex, 1 TID; lipoic acid 100 mg

Leucine catabolism

H

Isoleucine catabolism

H

Vitamin B6, 100 mg/d

Tryptophan catabolism (hepatic)

H

Biotin, 5 mg/day; magnesium, 100 mg BID

Isoleucine catabolism

H

B12, 1000 µg TID

Valine or odd-chain
fatty acid catabolism

H

Folic acid, 400 µg/d

Histidine catabolism

a-Keto-β-methylvalerate

## Formiminoglutamate

Renal ammonia clearance

(L) Substrate-limited CoQ10 synthesis
(H) HMG-CoA reductase inhibition

## B-Complex Vitamin Markers

Citric Acid Cycle Intermediates

L
H

a-Ketoglutarate

Arginine, 1–3 gm/day

Citrate

Neurotransmitter Metabolism
(L) Tyrosine-limited or
(H) Tyrosine-depleting epinephrine
& norepinephrine catabolism

Vanilmandelate

L,H Tyrosine, 1000 mg BID-TID, between meals and
phenylalanine hydroxylase cofactors as needed

Homovanillate

L,H Contraindicated for patients taking MAO inhibitors

(L) Tyrosine-limited or
(H) Tyrosine-depleting
DOPA catabolism

5-Hydroxyindolacetate

5-Hydroxytryptophan, 50–100 mg TID;
L,H magnesium, 300 mg; vitamin B6, 100 mg
(5-HTP may be contraindicated with SSRI’s)

(L) Tryptophan-limited or
(H) Tryptophan-depleting
Serotonin catabolism

Kynurenate

H

B6, 100 mg; magnesium, 300 mg

Quinolinate

H

Magnesium, 300 mg

Inflammation-stimulated
macrophage and astrocyte
kynurenine pathway activity
Table 6.1 continued on following page...

Table 6.1 continued from previous page...
Name

Potential Intervention

Metabolic Pathway

Oxidative Damage and Antioxidant Markers
p-Hydroxyphenyllactate

H

Vitamin C to bowel tolerance*

Prooxidant and carcinogen

8-Hydroxy-2’deoxyguanosine

H

Antioxidants (Vitamins C, E, lipoic acid)

DNA oxidation product

Detecting and Monitoring Inborn Errors of Metabolism
Homogentisate

H

Low protein diet; vitamin C, 1000 mg TID

Tyrosine catabolism

2-Methylhippurate

H

Avoidance of xylene; glycine, 2–5 gm/d; B5 100 mg TID

Hepatic conjugation

Orotate

H

Arginine, 1–3 gm/day; a-KG, 300 mg TID
Aspartic Acid, 500 mg BID; magnesium, 300 mg

Ammonia clearance,
Pyrimidine synthesis,

Glucarate

H

Glycine, GSH, NAC, 500–5000 mg/day

Detox. liver enzyme induction

a-Hydroxybutyrate

H

Pyroglutamate

H

Sulfate

L

Detoxification Indicators

H
H

p-Hydroxybenzoate

H

p-Hydroxyphenylacetate

H

Tricarballylate

H

These compounds may reflect intestinal overgrowth,
usually accompanied by microbial hyperpermeability.
Take appropriate steps to ensure favorable gut
microflora population.
Glutamine, 10–20 gm daily, digestive aids (betaine,
enzymes, bile) and free-form amino acids help to
normalize gut permeability.

p-Cresol

H

Phenylpropionate

Phenylacetate

Glycine, 2–5 gm/d; vitamin B5, 100 mg TID

H

Detox & anti-oxidant functions

3,4Dihydroxyphenylpropionate
D-Arabinitol

D-Lactate

Hepatic Phase II glycine conjugation
Intestinal bacterial overgrowth

H

Hippurate

Renal amino acid recovery

Dysbiosis Markers (Products of Abnormal Gut Microflora)
Benzoate

Hepatic GSH synthesis

NAC, 1000 mg, glutathione, 300 mg
Taurine, 500 mg BID

General bacterial or
L. acidophilus overgrowth

H

Clostridial overgrowth

H

Intestinal yeast overgrowth

* Bowel tolerance is usually up to 100 mg/kg, as determined by 500 mg dosing repeated every 30 minutes.

Table 6.2 — Common Patterns Seen In Results From Organic Acids In Urine

Pattern

Potential Intervention

Explanation

Pyruvate and Lactate High

Lipoic acid, 500 mg

Pyruvate dehydrogenase complex deficiency

Citrate, cis-Aconitate and Isocitrate High
- and Orotate High
Glucarate High
- and bacterial markers High
β-Hydroxyisovalerate High
- and bacterial markers High
Hydroxymethylglutarate High
- and succinate, fumarate, malate High

Arginine, 500 mg BID
Restore orthobiosis

Heavy renal ammonia excretion
Hepatic urea cycle capacity exceeded
Hepatic Phase I and II up-regulation
Intestinal bacterial origin of toxin load

Biotin, 5 mg/d and
restore orthobiosis

Displacement of biotin-forming
species by opportunistic bacteria

CoQ10

Inhibition of CoQ10 synthesis and mitochondrial
CoQ10 insufficiency (possibly statin drugs)

Unlike amino acids and fatty acids, the category of
compounds called organic acids contains no essential
nutrients. Instead of directly measuring nutrient concentrations, abnormal concentrations of organic acids
provide functional markers for the metabolic effects of
micronutrient inadequacies, toxic exposure, neuroendocrine activity, and intestinal bacterial overgrowth. As
such, organic acid testing can indicate the functional
need for essential or conditionally essential nutrients,
diet modification, antioxidant protection, detoxification
and other therapies. Table 6.1 summarizes the relationships between specific organic acid abnormalities and
potential nutrient interventions, and Table 6.2 shows
some of the common patterns of abnormalities found in
urinary organic acid profiles.
All bodily functions are powered by the release of
chemical energy. Each day, the energy content of the
food for an average person could raise the temperature
of about 7 gallons of water to the boiling point. The
energy is released through a process of controlled oxidation, where chemical bonds are broken and energy is released. Fats, carbohydrates and amino acids are converted into carboxylic acids before they flow on to the final
conversion to carbon dioxide (Figure 6.1). The organic
acids that are formed as intermediates in this process
are normally absent from urine or present at very low
concentrations. When specific reactions are blocked due
to insufficient enzymes or cofactors, the organic acids
that precede the blocked step accumulate and spill into
urine. Genetic polymorphisms in enzyme structure that
lead to decreased cofactor binding are another major

cause of nutrient deficiencies described by the term,
genetotrophic. Individuals with faulty enzyme binding
can have increased nutrient needs that will not be revealed by measures of vitamin concentrations in blood.
Research has noted mutant enzymes with poor binding
affinity account for more than 50 known genetic conditions that can be stabilized with nutrient intakes.3
The familial cerebral degenerative disease, maple
syrup urine disease (MSUD), provides an example of
genetotrophic variations. High urinary levels of the
branched-chain keto acids (BCKA) derived from valine,
leucine and isoleucine produce an odor similar to that of
maple syrup. Elevated BCKA levels are caused by failure
of the branched-chain keto dehydrogenase enzyme to
oxidize them. This enzyme is highly sensitive to the lack
of vitamin B1-derived thiamin pyrophosphate. Since it
is required in a major energy-producing pathway, the
appearance of elevated BCKA in urine is a sensitive test
for lack of activity due to either simple thiamin deficiency or inborn errors of metabolism. Variants of maple
syrup urine disease are due to degrees of impairment
of this enzyme (Table 6.3). Genetic variants in which
the enzyme is not expressed result in severe clinical
consequences in infancy, including failure to thrive and
encephalopathy with lethargy, increased or decreased
tone and seizures. Similar conditions precipitated by
infection or stress may develop in adults with mild levels
of functional impairment due to a high requirement for
thiamin.2, 3 Many other such inborn errors of metabolism that produce specific organic acidurias have been
reported, and several reviews are available.4-6
Urinary organic acid analysis for metabolic profiling has traditionally been used for detection of neonatal

## Introduction

Table 6.3 — Maple Syrup Urine Disease Variants*

Variant

Enzyme Activity

Organic Aciduria

Clinical Presentation
Symptoms within the first several days of life.
Infant death or prominent abnormalities.
Developmental delays

Classical

< 3%

a-ketoisocaproate,
a-ketoisovalerate,
a-keto-β-methylvalerate

Intermediate

3–30%

Similar to classic phenotype,
though quantitatively less severe

Developmental delays, irritability, seizures

Intermittent

5–20%

Normal BCAAs when well, similar
to classic phenotype when ill

Symptoms appear with illness, stress or high
protein intake. Normal early growth and
development. Age of onset varies.

2–40%

Profiles improve with
thiamine therapy
(lower levels in urine)

Large doses of thiamine will increase the
enzyme activity and break down leucine,
isoleucine and valine. Normal early growth
and development. Age of onset varies.

Thiamin-responsive
(10–1000 mg/day)

*National Center for Biotechnology Information

FATS

Fatty Acids, Glycerol
Cholesterol

Adipate
Suberate
Ethylmalonate

CARBOHYDRATES

PROTEINS

Glucose & Other Sugars

Amino Acids

Pyruvate

B1, B2, B3, B5, Lipoate

Carnitine

Keto Acids

Lactate

B1, B2, B3, B5, Lipoate

Acetyl CoA

Citrate

Oxaloacetate
B3

Asp

## β-Hydroxybutyrate

Citric Acid Cycle cis-Aconitate

B3, Mg, Mn

NADH

## Succinate

Succinyl-CoA

a-ketoglutarate
NADH

B2

Isocitrate

NADH

Fumarate

Tyr
Phe

Glu
His
Arg
Pro
Gln

Cysteine, Fe ++

Malate

B1, B2, B3, B5, Lipoate

Leu
Ile
Val
Met

Mg

NADH

FADH2

NADH
Dehydrogenase

ADP + Pi

Coenzyme Q10

ATP

th

syn

Bio

esis

Hydroxymethylglutarate (HMG)

Cytochromes
O2

H2O

energy

(Muscle, nerve function, maintenance, repair)

Figure 6.1 — Urinary Markers of Nutrients Involved in Central Energy Pathways
Intermediates shown in bold purple font on this condensed version of central energy biochemical pathways are compounds
normally included on profiles of urinary organic acids. This figure can be useful for patient education regarding the
information gained from performing the profile since most people can understand the importance of deriving energy
from dietary fat, carbohydrate and protein. Essential nutrient requirements for specific steps are shown in light blue boxes.
Elevations of the substrates for those steps can indicate functional insufficiency of the associated nutrient. Amino acid
abbreviations shown in green rectangles indicate the points of entry of their catabolic products into the citric acid cycle.

Morning urine has become widely accepted for primary study of metabolic disorders. Urination is generally
the first post-sleep activity because the cortisol-stimulated, anabolic sleep period requires the metabolic, energyyielding pathways that produce water. Prior to waking,
cortisol peaks and then drops, initiating a shift to greater
utilization of catabolic pathways. For these reasons, the
first morning urine usually contains a greater array of
metabolic by-products than at any other time of the day
and is relatively free of the metabolic effects of strenuous
muscle activity. The convenience of such collections
also leads to high patient compliance. In one laboratory
methodology, organic compounds are extracted from the
overnight urine sample and analyzed by gas chromatography with mass spectrometric detection (GC-MS).
The basic methodologies are well known,14 but improvements are regularly reported.15 Most recently, significant
advances have come from the use of liquid chromatography with tandem mass spectrometric detection (LC-MS/
MS).16, 17 This technology allows more reliable analyte
recovery due to greatly simplified sample preparation.
This method does not require organic solvent extraction.
It also provides a shorter run time and greater sample
throughput.
The information content of an organic acid profile
is high, but the interpretation is simplified by keeping in
mind that the results supply answers to a few questions
of clinical relevance:

inborn errors of metabolism. Testing organic acids to
assess special nutrient requirements of individuals is discussed in a variety of sources.6, 8-11 Organic acid profiling
has also been useful in identification of the source of
toxicants from the environment12 and the gut.13 Various
nutrient-related abnormalities that might appear on a
typical quantitative report of organic acids in urine are
summarized in Table 6.1. The supplementary nutrient amounts are given as guides for starting points to
improve clinical outcomes for adults.
The term “organic acid” refers to a broad class of
compounds used in fundamental metabolic processes
of the body. Chemically, organic acids share the common features of water solubility, acidity, and ninhydrin
negativity (no primary or secondary amines). The term
is generally considered to include all carboxylic acids,
with or without keto-, hydroxyl-, or other non-amino
functional groups, but does not include most amino acids. Some nitrogen-containing compounds are included,
such as pyroglutamate, or amino conjugates such as
hippurate (benzoylglycine). Short-chain fatty acids are
also contained in this group. With adjustments of the
method for extraction of the compounds from urine, the
analysis may include neutral compounds that possess no
acid group, in which case the naming of the entire set as
“organic acids” is somewhat inaccurate.

Notes:

1. Are there signs of inborn errors of metabolism?
2. Is mitochondrial energy production
adversely affected?
3. Are functional nutrient deficiencies present?
4. Does altered neurotransmitter
turnover reveal symptom origins?
5. Are antioxidant nutrients protecting
against oxidative stress?
6. Is there a high toxin load and is this
adversely affecting detoxification capacity?
7. Are symptoms related to excessive growth
of bacteria and fungi in the gut?
Each of several compounds reported in the
typical profiling of organic acids in urine will be discussed briefly to indicate why they are related to these
clinical questions.

Detecting and
Monitoring Inborn Errors
of Metabolism

Mitochondrial
Function Assessment

Because of the centrality of ATP in all life processes,
the factors affecting mitochondrial ATP synthesis have diverse implications for human health. The basic sequence
of chemical reactions responsible for the transformation
of the chemical energy in foodstuff into ATP has been
understood for several decades. However, routine clinical
assessments of mitochondrial function and interventions
to improve it are quite a recent development. Once again,
we find much of the early work coming from attempts to
discover neonatal diseases that produce profound metabolic consequences. Six chapters in the current edition
of the book Metabolic and Molecular Origins of Disease are
devoted to disorders of mitochondrial function, where
neuromuscular symptoms are the most frequent initial
presentation.6, 32 The scope of other symptoms found in
mitochondrial deficiencies is shown in Table 6.4. The
origins of these symptoms are restricted to diseases found
to be genetic polymorphisms in the respiratory chain
components. The scope and numbers of individuals
expands broadly when insufficiencies of carnitine and
coenzyme Q10 are added to inherited traits that negatively
impact mitochondrial efficiency. Examples of the more
subtle effects of mitochondrial inefficiency are obesity,
diabetic tendency for intramuscular fat accumulation and
the age-associated decline in insulin sensitivity.33, 34, 605

Since the reporting of isovaleric acidemia in 1966,
there has been a rapidly growing list of disorders characterized by elevated urinary excretion of organic acid
metabolic intermediates.6,7 Laboratory tests were developed using GC/MS technology to detect inborn errors of
metabolism (IEM) that could lead to premature death or
retardation in infants. Today qualitative measurements of
certain organic acids (and amino acids) are widely performed on neonates using LC/MS/MS technology. These
tests screen for extremely high levels of compounds that
are not being metabolized due to significant inborn genetic lesions. Quite often, treatments based upon dietary
modification and nutrient supplementation are introduced to modulate the effects of the genetic abnormality.
More recently, organic acid methods have been
developed to measure lower levels of these compounds
for the purpose of identifying more subtle metabolic
imbalances related to nutrient deficiencies and toxicities.
Metametrix Clinical Laboratory pioneered the clinical
application of quantitative analysis of lower levels of organic acids for these purposes in the early 1990’s. Other
laboratories have since developed the test for clinical
use. These tests are increasingly being used to identify
biochemical imbalances that underlie chronic diseases
and that can be treated by specific nutrient supplementation. Organic acid testing to assess special nutrient

requirements of individuals is discussed in a variety of
sources.6, 8–11 This testing has also been useful in identifying the source of toxicants from the environment12 and
the gut.13 Although the methods used to detect more
subtle metabolic imbalances require instrument calibration at much lower concentrations than those used for
neonatal screening, extremely high levels can also be
identified.

Table 6.4 — Top Frequencies of Clinical

Symptoms in Mitochondrial
Respiratory Deficiencies35

Symptom

Occurrence in
Affected Individuals

Truncal hypotonia

36%

Growth failure

31%

Cardiomyopathy

24%

Intrauterine growth restriction

20%

Encephalopathy

20%

Liver failure

20%

Cranial nerve involvement

18%

Myopathy

13%

Spasticity

11%

Gut involvement

8%

## Fatty Acid Metabolism Markers
The three organic acids in this category are markers of carnitine sufficiency. Fatty acid metabolism by
mitochondrial β-oxidation is the dominant energy-yielding pathway in most tissues. It involves the transfer of
fatty acids (as fatty acyl-Coenzyme A esters) across the
mitochondrial outer and inner membrane prior to the
catabolic action of the fatty acid β-oxidation complex
(Figure 6.2). The transfer is dependent on the formation

BILE DUCT

Nucleus
En

cR
mi
las
dop

ic

Intestinal
Bacteria

ul
um

Hepatocyte

Adipate

Carnitine
Shuttle

ATP

Peroxisomes

Fatty Acids

CO2 + H2O

Suberate

FADH2

Ethylmalonate

Butyrate

Receptors

Mitochondria

CAPILLARY

Lipoprotein

Figure 6.2 — Mitochondrial Fatty Acid Metabolism Markers
In all tissues except brain, most ATP generation is derived from oxidation of fatty acids. The process is initiated by entry
of the fatty acid into the matrix of mitochondria. The rate limiting step for entry is the formation of fatty acyl carnitine by
one of three enzyme systems that operate on medium, long or very long chain fatty acids. Even a slight interruption of this
dynamic pathway causes increased amounts of fatty acids to be processed via omega oxidation occurring in peroxisomes.
The lower efficiency of peroxisomal processing allows intermediates to escape and be lost when the blood is filtered in the
kidneys. Adipate and suberate are biochemical markers that reflect the degree to which mitochondrial entry is impaired due
to insufficiency of carnitine or other genetotrophic factors. See Figure 5.4 (Fatty Acids) for carnitine shuttle details.

of fatty acyl-carnitine, and this reaction is governed by
carnitine concentration. The extreme importance of fatty
acid oxidation to provide cellular energy is indicated
by the redundancy of systems. Both β- and ω-oxidation systems are contained in peroxisomes. When the
mitochondrial system fails to meet demands, peroxisomes can take over to a limited degree, but lack of the
double membrane containment of the mitochondrion
means that the system is less efficient because substrates
may escape and be lost as renal excretory products. Examples of human mitochondrial β-oxidation deficiency
are well known to produce infant death, though some
individuals exhibit normal development for a few weeks
or months.36 As usual, the severe manifestations of such

enzyme polymorphism is always accompanied by less
severe forms that manifest as milder and, frequently,
later syndromes.37-40
Carnitine can be synthesized from the essential
amino acid, l-lysine. However, limitations of available
lysine due to dietary deficiency or digestive impairment
or genetic polymorphism of the required enzymes can
cause carnitine requirements to exceed biosynthetic
capacity. Therefore, carnitine is a conditionally essential
dietary component. The most extensive clinical evidence
for the conditional essentiality of carnitine comes from
management of cardiomyopathy.41-44 Some treatment
regimens have included carnitine to assist mitochondrial
fatty acid oxidation along with a peroxisomal proliferation agonist for stimulation of the secondary role of
peroxisomal oxidation.45

needed for sustaining levels of flavin adenine dinucleotide (FAD), the critical cofactor at the succinate dehydrogenase step of the citric acid cycle (CAC) (see below).
Thus, riboflavin insufficiency is a secondary indication
of elevated adipate and suberate. A further effect of riboflavin insufficiency is succinate accumulation that causes
inhibition of enzymes required for mitochondrial fatty
acid processing. This scenario is indicated when succinate, adipate, and suberate are concurrently elevated.

Ethylmalonate
COOH

HOOC

CH3

Ethylmalonate accumulation
is traced
Ethylmalonic
Acid to different pathways than the long-chain fatty acid oxidation
origins of adipate and suberate. Although the exact
origin is somewhat unclear, current evidence suggests
that ethylmalonate is formed from butyrate. Patients
with ethylmalonic aciduria also have elevated levels of
butyryl-CoA (and isobutyryl-CoA from isoleucine catabolism).53, 54 Circulating butyrate, a short-chain fatty acid
with four carbons, may be derived from intestinal bacterial metabolism. Butyryl-CoA is normally carried by carnitine into oxidative pathways. Just as for the long-chain
fatty acids, carnitine may be insufficient to clear butyrate
or riboflavin may be insufficient to sustain FAD, causing
slowing of the rate of oxidation. Under these conditions
free butyrate is available for other reactions, including
carboxylation to form ethylmalonate. Thus, urinary
ethylmalonate elevation shares carnitine and riboflavin
dependencies with adipate and suberate, but the precursor arises from different metabolic sources. This may
explain why in evaluating large numbers of organic acid
profiles some individuals have elevated adipate and suberate with normal ethylmalonate, whereas others show
the opposite pattern.
Patients with ethylmalonic acidurias should not be
treated with medium-chain triglycerides that produce
metabolic stress from the accumulation of mediumchain fatty acyl-carnitines.55 Glycine (250 mg/kg/d) has

Adipate
HOOC

Adipic Acid

HOOC

COOH

Suberate

COOH

Adipate (adipic acid) and suberate (suberic acid)
Suberic Acid
are six- and eight-carbon-long
dicarboxylic acids,
respectively. Low carnitine availability or impaired
enzyme activity can slow fatty acid oxidation by decreasing the transport of fatty acids into the mitochondria as discussed in Chapter 5, “Fatty Acids”. Need for
extra carnitine may be indicated when urinary levels
of adipate and suberate are elevated.46-49 Adipic and
suberic acids are by-products of an alternative fatty acid
oxidation pathway that is utilized when mitochondrial
oxidation is limited.50, 51 The principal alternate pathway
occurs in peroxisomes where multiple types of oxidizing
enzymes are present, in contrast to the constrained fate
of fatty acids undergoing β-oxidation in mitochondria
(Figure 6.2). Once the dicarboxylic acids are formed,
they diffuse away from the peroxisomal sites to be excreted in urine.
A secondary cause of elevated adipate and suberate is riboflavin insufficiency.52 Once they are inside
the mitochondria, fatty acids cannot undergo oxidative
metabolism without riboflavin coenzymes. Riboflavin is

Notes:

MCT
MCT + Glycine
Lysine
Leucine

Change from baseline (ug/mg creatinine)
-1

Ethylmalonate

Methylsuccinate

Glutarate

Adipate

Figure 6.3 — Urinary Organic Acids in Short Chain

Acyl Dehydrogenase Deficiency53

These data are derived from results reported for a single
neonate with SCAD deficiency.53 Compared to control
urine, her mean baseline ethylmalonate was very elevated
(5.2 vs < 0.3 µg/mg creatinine). The bars show how oral
challenge with medium-chain triglycerides (MCT) or
lysine produced large increases of ethylmalonate over an
already elevated baseline. Addition of glycine to the MCT
formula had no additional effect, while leucine showed an
apparent stimulation of the metabolism of ethylmalonate,
causing lower post-treatment concentrations. Changes for
methylsuccinate, glutarate and adipate were much smaller
and of low significance.

Urinary Organic Acids in SCAD
respectively, of the general population. The A625 allele
confers susceptibility to the development of ethylmalonic aciduria.60 Neonatal SCAD deficiency may present as
acidosis with ammonemia and elevated liver enzymes.53
The related genetic disorder of multiple acyl-CoA
dehydrogenase deficiency (MAD), also known as glutaric
aciduria type II disorders, is characterized by elevated
urinary ethylmalonate. Therapy with vitamin B2 may
partially or totally reverse the associated symptoms,
such as profound muscle weakness.61,62 Ethylmalonate
elevation is also found in glutaric aciduria type II disorders that can appear as adult onset with episodic acute
pancreatitis.62 In this case and in a rat model where ethylmalonic aciduria had been induced by experimental
riboflavin deficiency, the organic aciduria was reduced
by adding l-carnitine, demonstrating the joint action of
vitamin B2 and carnitine in these conditions.63
These disorders have multiple clinical presentations
due to the varieties of genetic polymorphisms of the
enzymes.64 In one affected family, a child born prematurely had unexplained cholestasis and hepatomegaly in
the first year of life, whereas the mother displayed only
hemolytic complications of pregnancy and other siblings
had no signs of hypotonia, developmental delay, or
episodes of ketotic hypoglycemia.65 Other presentations
include ophthalmoplegia and multicore myopathy,66 vascular lesions of the skin and acrocyanosis,54 or neonatal
neurologic dysfunction with only transient ethylmalonic
aciduria.67 The metabolism of short-chain fatty acids is
impaired in these conditions, as shown in Figure 6.3.
Ethylmalonic aciduria can be caused by exposure
to toxicants instead of the more commonly encountered
nutrient-induced or genetic focal metabolic interferences. Ingestion of the ackee plant results in SCAD inhibition due to the presence of the toxin, hypoglycin. This
dietary-related illness has been called Jamaican vomiting
illness because of the high frequency due to common
use of ackee in that country. It has also been reported in
the United States from ingestion of canned ackee.68 Ethylmalonate excretion may also be stimulated by isoleucine loading, indicating that it may be an intermediate
produced in the isoleucine catabolic pathway.69
Patients with elevations of adipate, suberate or ethyl­
malonate generally have variants of the genetic polymorphisms that affect the formation of fatty acyl carnitine
formation and metabolism. These patients may have normal serum carnitine, requiring greater concentrations to
overcome their enzyme polymorphisms. There is another

been found to be a useful adjunct in addition to carnitine and vitamin B2 in the treatment of these patients.49
An interesting association of ethylmalonate and obesity
is found in a report on lean and fatty Zucker rats. The
“fatty” rats excrete high levels of ethylmalonate and adipate, indicating impaired oxidation of short chain fatty
acids. When the lean rats were fed diets enriched with
medium-chain triglycerides or sodium butyrate, their
excretion of ethylmalonate rose almost as high as the
fatty rats on basal diet. The fatty rats appear to have impaired ability to clear butyrate that is an optimal primer
for synthesis of long-chain fatty acids, thus offering an
explanation for their tendency for obesity.56 No similar
studies have been reported in humans.
The enzyme that controls the butyrate oxidative
pathway is short-chain acyl-CoA dehydrogenase (SCAD).
Its activity may be lowered by genetic mutations resulting in increased urinary ethylmalonate excretion.48, 57
Monitoring for elevation of urinary ethylmalonate can
signal the onset of ethylmalonic encephalopathy in affected individuals.58, 59 A variant SCAD allele (A625) resulting from a guanine to adenine polymorphism occurs
in homozygous or heterozygous form in 7 and 34.8%,

form of systemic carnitine deficiency associated with idiopathic dilated cardiomyopathy (IDCM) that may present with normal levels of the organic acids.41 Since serum
carnitine is low in these cases, they may arise from an
inability to synthesize carnitine from lysine. Serum carnitine levels increase when patients with both IDCM and
celiac disease are placed on gluten-free diets.41
The patterns of organic acid elevations in milder
carnitine insufficiency vary. Depending on severity,
symptoms may include periodic mild weakness, nausea,
fatigue, hypoglycemia, “sweaty feet” odor and recurrent
infections.70 Abnormalities have been reported in children with attention deficit disorders. Patients may also
exhibit a Reyes-like syndrome in dicarboxylic aciduria,
which has been associated with various metabolic toxins
from viral infections that affect mitochondrial function.
Patients with low carnitine respond well to therapeutic
riboflavin.71 Case Illustration 6.1 shows an instance
where carnitine marker abnormalities were found in a
patient with schizophrenia.

the metabolic impairment. That evidence is frequently
supplied by reading the rest of the laboratory report
where organic acid profiles are generated.

Lactate
OH
H3C
COOH

Pyruvate
Lactic Acid
O
H3C
COOH

Abnormalities of urinary excretion of pyruvate and
Pyruvic Acid
lactate provide useful insight
to basic metabolic factors
due to their position in the energy production process.
Pyruvate and lactate are anaerobic breakdown products
of glucose. Under conditions favoring anaerobic metabolism, pyruvate is reduced to lactate by the action
of lactate dehydrogenase. Conditions favoring aerobic
metabolism increase the clearance of pyruvate by oxidation to acetyl-CoA, avoiding the buildup of lactate.
Mitochondrial conversion of pyruvate to acetyl-CoA
requires the pyruvate dehydrogenase complex (PDC),
the enzymatic gatekeeper for generation of acetate units
to drive the citric acid cycle. The three-step operation
of the PDC is carried out by enzymes E1, E2 and E3 as
described in Figure 6.4.76 The cycle of reactions requires
cofactors derived from thiamin, riboflavin, niacin, lipoic
acid and pantothenic acid (the dietary essential precursor of coenzyme A). Pyruvate is decarboxylated at E1,
and the acetyl residual group is transferred to coenzyme
A at E2. The disulfide must be regenerated by oxidation
as the right-hand lipoyl arm swings to the E3 subunit for
oxidation by the bound FAD. To complete the sequence,
the reduced FADH2 group is oxidized back to FAD
by reduction of NAD. Differences in binding affinities
alter the impact of individual cofactor status on the
overall process of pyruvate conversion to acetyl-CoA to
maintain ATP formation via the CAC. Thiamin, which
binds on the E1 subunit, is usually the most strongly

Refer to Case Illustration 6.1

The use of aspirin can change the interpretation of
results for the three marker compounds because salicylic
acid is an inhibitor of fatty acid β-oxidation and may
lead to elevated markers.72 The β-oxidation enzymes
involved also respond to environmental toxin exposure
with altered lipid metabolism that can lead to impaired
immune responsiveness and mitochondrial DNA damage.73 Supplementation of carnitine and riboflavin is
indicated when adipate, suberate, or ethylmalonate are
elevated.74 However, some inborn errors of metabolism
produce ethylmalonic aciduria that is unresponsive to
carnitine or riboflavin.54

## Carbohydrate Metabolism Markers
The operation of the central energy pathway of
glycolysis, the catabolism of glucose, generates large, dynamic pools of lactate and pyruvate. Oxidation of fatty
acids and ketone bodies similarly generates pools of βhydroxybutyrate and acetoacetate. When these pathways
are perturbed, excretion of their intermediates can shift
in response to the metabolic acidosis.4 Although some
patterns of abnormalities for these compounds may be
indicative of specific micronutrient insufficiencies, they
usually require further evidence to specify the origin of

Notes:

concurrent severe depression of pyruvate. This metabolic
consequence is because of the necessity of cycling NAD+
to allow alternative energy yield from glycolysis (see
Figure 6.6). The reduced cofactor (NADH) produced in
oxidation of glucose is reconverted to the oxidized form
(NAD+) as pyruvate is reduced to lactate. The regenerated NAD+ allows another molecule of glucose to enter
the pathway. Because of these metabolic relationships,
when simultaneous elevation of both lactate and pyruvate
is found, normal mitochondrial ATP output is indicated
with blockage of the PDC, causing poor clearance of
pyruvate with increased conversion to lactate.
Because of the multiplicity of causes, lactic aciduria
is the most common organic aciduria associated with inborn errors of metabolism. In addition to PDC cofactor
deficiencies and mitochondrial function factors, lack of
oxygen can slow lactate clearance. Experimental anoxia
in sheep produces immediate elevation of urinary lactate
due to down-regulation of the oxidative pathways.78
Lack of oxygen or coenzymes results in inactivation of
the citric acid cycle and a decrease in mitochondrial
activity. The effectiveness of CoQ10 supplementation for
normalization of high lactate77–79 demonstrates that a
blockage at the electron transport level of mitochondrial

dependent nutrient for the PDC although genetic polymorphism of one of the three enzymes may generate
specific alterations in other cofactor binding. Large doses
of thiamin have been shown to increase the function of
the PDC.3
Lactate (or lactic acid) is a principal product of
glucose oxidation in skeletal muscle. There is a chiral center in lactate, so laboratories should designate
whether they are reporting the l or d forms or the total
concentration of both entantiomers. Because d-lactate is
discussed later in this chapter, it is important to understand that the human metabolic product being discussed
here is l-lactate. The “l” enantiomeric designation will
be dropped for brevity, and the “d” form will always
be specified. Although many of the studies cited refer
to blood lactate, blood and urinary lactate levels are
strongly correlated.595
Since lactate is processed through pyruvate for oxidation in the CAC, lactate also can accumulate if any PDC
cofactors are insufficient, if a structural polymorphism is
present for any enzyme of the PDC or if CoQ10 deficiency
creates a block in the final oxidative phosphorylation
stage of energy production.77 Lack of mitochondrial ATP
formation can induce a strong elevation of lactate with

CO2

R

(B1)
Thiamin pyrophosphate
S

Lipoic Acid

CH3
C=O

S

S

S

HS

CoA

(B2)
Flavin
adenine
dinucleotide

=

C

Pantothenic Acid (B5)

N

FAD

(B3)
Nicotinamide
adenine
dinucleotide
FADH2

Pyruvate

E1

E2

E3

Acetyl-CoA

Figure 6.4 — The Pyruvate Dehydrogenase Complex
The large enzyme complex contains multiple copies of three subunits, E1, E2 and E3. This figure emphasizes the bound
cofactors, thamin pyrophosphate on E1, two lipoyl groups in peptide linkage to lysine side chains of E2 and flavin adenine
dinucleotide on E3. An isoenzyme that carries out similar oxidative decarboxylation of branched chain amino acids is
illustrated in Chapter 4, “Amino Acids,” Figure 4.13. A third isoenzyme carries out the oxidative decarboxylation of
α-ketoglutarate. The three forms differ in amino acid sequence for E1 and E2, while maintaining the same gene for E3.
That means that genetic polymorphisms of E2 will manifest metabolic interferences in all of the keto acid pathways similar
to that found in simple B-vitamin deficiency. Generic alterations of pathway-specific E1 or E2 can produce specific
abnormalities in pyruvate or α-ketoglutarate levels.

Concentration (mg/dL)
Lactate
Pyruvate
Hours after Infusion

Figure 6.5 — Thiamin Effects on Blood Lactate

and Pyruvate83

Changes of blood lactate and pyruvate after intravenous
administration of thiamine hydrochloride (125 mg/kg)
in a 2-month-old female with congenital lactic acidosis.
The sudden rise of vitamin B1 to high concentrations in
blood causes rapid intracellular uptake and conversion to
the thiamin pyrophosphate (TPP) form with subsequent
enzyme saturation and metabolic correction of abnormal
levels of metabolites. Within four hours the metabolites fall
to near-normal levels even though genetic polymorphism
has produced defective TPP binding. The effect is shortlived, however, showing the need for regular vitamin
administration to sustain the metabolic effect.

function is common. As noted, elevated lactate, therefore, is a sign of potential CoQ10 insufficiency. Detecting
deficiencies of the other vitamin-derived cofactors of
the PDC that can contribute to lactate elevation will be
covered in later sections
Clinical Associations: Elevated levels of pyruvate
have been traced to insufficiency of thiamin.80 Animal
studies have also identified increased levels with insufficient pantothenic acid.81 Pyruvate elevation in the brain
accompanies the encephalopathy associated with alcohol
use in the thiamin-responsive Wernicke-Korsakoff
syndrome.82 Infants with thiamine-responsive congenital
lactic acidosis often respond to thiamin stimulation (see
Figure 6.5). Clinical features are variable, but detection
through laboratory assessments of lactate and pyruvate
can allow early initiation of thiamin therapy that can
prevent permanent brain damage.83 Dietary supplementation with pyruvate has been found to prevent fatty
liver caused by chronic alcohol ingestion in laboratory
animals.84 The beneficial effect of pyruvate is explained
as a stimulation of glucogenesis, which results in inhibition of fatty acid synthesis.
Lactate accumulation has been reported in asthma,85
mitochondrial encephalomyopathy,86 HIV-infected
patients87 and diabetics using biguanide medications.88, 89
The lactic acidosis produced when HIV-infected patients
were treated with nucleoside-analogue reverse transcriptase inhibitors, was found to be reduced by treatment
with two or more cofactors (thiamin, riboflavin, CoQ10,
and l-carnitine), which lead to a lower overall mortality.90 After glucose loading, lactate and pyruvate levels are
significantly increased in patients with type 2 diabetes.
Short-term treatment with 600 mg of lipoic acid orally
prevented the hyperglycemia-induced increments of
lactate and pyruvate.91 This effect was mediated through
increased activity of the pyruvate dehydrogenase enzyme, indicating that the coenzyme role of lipoate may
be inadequate without the supplemental lipoic acid.
A case of lactic acidosis and marked hepatic steatosis was normalized with administration of 50 mg of
riboflavin per day.92 Both lactate and pyruvate may be
elevated by alcohol consumption prior to specimen collection.93 This effect may be due to the niacin-depleting
effect of alcohol. The conversion of lactate to pyruvate
(Figure 6.6) and the further oxidation of pyruvate are
NAD-dependent reactions.
Lactic acidosis with increased excretion of hydroxybutyrate and fumarate were biochemical signs of the

metabolic disturbance found in a 42-year-old woman
who presented with a 10-year history of ophthalmoplegia, malabsorption resulting in chronic malnutrition,
muscle atrophy, and polyneuropathy.94,95 The underlying
biochemical lesion in this mitochondrial, multisystem
disorder was found to be genetically defective cytochrome C oxidase (complex IV of the respiratory chain).
This case illustrates the potential for graded metabolic
effects from genetic polymorphic expressions. Interestingly, this defect did not manifest until adulthood.
Compensatory mechanisms maintained nominal function until the genetic weakness became manifest, which
was most likely due to accumulation of environmental
insults and dietary inadequacy. As we age, metabolic
systems function less efficiently. How many of our “degenerative diseases” are genetic weaknesses manifesting
as our systems become less efficient?
Investigators studying of the metabolic profile of
cancer proposed that apoptotic resistance, thought to
promote tumor growth, is produced when mitochondrial glucose oxidation is inhibited. This inhibition is
thought to be due to stimulation of pyruvate’s reduction

be reversed by a medication (dichloroacetic acid) used
to increase the function of the PDC enzyme. A urinary
profile showing high lactate and low pyruvate in a paNAD+
tient with cancer, is evidence of the effect in that patient.
A number of chronic nutrient insufficiencies will be
discussed that can contribute to low-level mitochondrial
NADH
activity restrictions.
PDC and
Mitochondrial
Studies in rats have shown an increase in lactate
Oxidation
excretion when dietary carbohydrate is switched from
O
fructo-oligosaccharides to maltodextrin, indicating
that lactate production by intestinal bacteria may have
H3C
COOH
Pyruvate
shifted (see below in this chapter for discussion of dNADH
NADH
lactate).97 Although such variations in humans may be
encompassed by the normal range limits set by clinical
LDH
+
+
laboratories, definitive studies of such dietary effects in
NAD
NAD
humans have not been done. Patients with moderate lacLactate
OH
tic aciduria may carry mild enzyme defects that manifest
as symptoms only when metabolic stressors exceed the
COOH
H 3C
ability to maintain normal function. The age of onset
and the degree and duration of functional loss depend
Figure 6.6 — Conversion of Pyruvate to Lactate
on an individual’s ability to maintain organ reserve. The
+
Regenerates NAD
incidence of such latent defects can be high relative to
The kinetics for lactate dehydrogenase catalysis of
more severe forms of genetic disorders. Since there are a
pyruvate reduction to lactate allow for the reaction to be
Figure 6.5 Lactate and pyruvate conversion with transfer of electrons to NAD
very large number of amino acid substitutions possible
easily reversed with net synthesis of pyruvate from lactate.
However, when the PDC is inhibited, the normal transfer
for every enzyme, it is logical to assume that for every
of electrons that regenerates NAD+ falls behind. In order
serious enzyme polymorphism that produces profound
to allow cellular energy flow to continue, the reduction
organic acidurias there can be less severe forms in larger
of pyruvate to lactate becomes strongly favored over the
oxidation of lactate to pyruvate. The outcome is lowering
numbers of individuals that produce moderate abnorof urinary pyruvate and elevation of lactate.
malities. The less severe forms may become clinically
significant only when triggering events occur. The
example of multiple forms of PKU known to be caused
to lactate in preference to its oxidation to acetyl-CoA.96
by over 400 single nucleotide polymorphisms was deThe inactivity of the mitochondria produces a need for
scribed in Chapter 4, Amino Acids, and the organic acNADH oxidation that is reflected as high lactate produc- idurias involved in multiple forms of maple syrup urine
tion and depletion of pyruvate as discussed above and
disease described above further illustrate this point.
illustrated in Figure 6.6. The study also found that the
suppressed oxidative metabolism of cancer cells could

Glucose

Of Further Interest…

Notes:

Metabolic Acidosis:
• Increased levels of organic acids
due to their increased production
or failure to be removed
• Narrowly defined as either diabetic
or lactic acidosis, but more broadly
includes elevated levels of any
organic acids in body fluids
• High anion gap due to organic acids

## β-Hydroxybutyrate
OH
COOH

ß-Hydroxybutyric Acid

β-Hydroxybutyrate is a ketone body. Ketone bodies are a feature of metabolic acidosis due to failure
of glucose utilization as with diabetes. Ketone body
production increases in diabetes because the oxidation
of free fatty acids is stimulated, and excess acetyl-CoA
is converted to the four-carbon organic acid, β-hydroxybutyrate. This acetyl-CoA spillover phenomenon
occurs because the control of ATP production from fatty
acids cannot be regulated as well as from carbohydrate
oxidation. Individuals with normal blood glucose who
respond to insulin do not produce high concentrations
of ketone bodies because their production of energy
from glucose is well controlled. Elevations of β-hydroxybutyrate in an overnight urine collection may indicate
inefficient utilization or mobilization of glucose.95
Chromium and vanadium supplementation have been
found to support carbohydrate utilization by improving
the action of insulin.98–99 Defects in cytochrome oxidase
enzymes of the electron transport system are another
reason for elevated hydroxybutyrate.100 These enzymes
are heme dependent, thus iron deficiency could be the
origin of their lowered activity.
Restriction of dietary carbohydrate, a common
dietary approach to weight loss, produces elevated
β-hydroxybutyrate. As in the diabetic association, the
diet induces dependency on fat oxidation, leading to
acetyl-CoA spillover.101 Any severe caloric restrictions
such as fasting produce this same effect.102

Dietary Contributions to Urinary Oxalate: Oxalic
acid is a product of the glyoxylate pathway that is present in human tissues and in oxalate-accumulating plants
and some microorganisms. Both diet and intestinal flora
can contribute to human oxaluria. Many leafy vegetables
and some fruits contain appreciable oxalate, but may not
produce significant urinary oxalate increases because the
calcium and other divalent elements in the foods have
already complexed with the oxalate, rendering it unavailable for absorption. Therefore urinary oxalate levels
do not directly correlate with dietary oxalate content.103
Peanuts and almonds contain sufficient free oxalate to
raise urinary levels.104 Spinach, rhubarb, beets, nuts,
chocolate, tea, wheat bran, and strawberries can cause a
significant increase in urinary oxalate excretion, though,
again, the increases are not in proportion to oxalate
content, due to calcium content.103 Soy products contain up to 50 mg of oxalate per serving, but their even
higher content of phytate prevents oxalate absorption
and makes them of low risk for contributing to urinary
oxalate in most individuals.105
Oxalate Status Modulation by Intestinal Bacteria: Some intestinal bacteria can produce oxalate,
whereas others degrade it.106 The total oxalate degrading
activity in the stool is inversely related to urinary oxalate
excretion, and calcium oxalate stone-forming individuals frequently are lacking oxalate-degrading bacterial
activity.107 Daily administration of a mixture containing
8 × 1011 freeze-dried lactic acid bacteria (Lactobacillus
acidophilus, Lactobacillus plantarum, Lactobacillus brevis, Streptococcus thermophilus, Bifidobacterium infantis)
for 4 weeks produced a reduction of urinary oxalate
from average values of 55 to 28 mg/24 h 1 month
after the treatment period in 6 patients with idiopathic
calcium-oxalate urolithiasis and mild hyperoxaluria
(> 40 mg/24 h).108 However, at 1- and 2-year post-treatment follow-up visits, lack of intestinal colonization
was found with such lactic acid bacteria. Oxalobacter
formigenes appears to have therapeutic potential for longterm lowering of urinary oxalate by oral application as
a probiotic agent.109, 110 Studies in vitro have shown that
O. formigenes, detected in human feces by 16S rDNA
amplification, actively metabolizes oxalate, helping to
lower intestinal assimilation of oxalate.111
Production and Deposition of Oxalate in Human Tissues: The rate of oxalate production in human
tissues is low in most individuals, but deficiency in the
liver-specific peroxisomal enzyme, alanine-glyoxylate

## Oxalate
O

OH

HO

O

Oxalic acid is primarily known in medicine for
its role in the formation of calcium oxalate kidney
Oxalic
stones. At neutral pH, oxalate,
theAcid
smallest possible
dicarboxylic acid, forms complexes with calcium that
have limited solubility. Because individuals who have
a tendency to form renal oxalate stones frequently
experience intense pain on passage of a large stone, the
issue of management of oxalate stone formation has
been extensively investigated.

Citrate
OH
HOOC

Citric Acid

Isocitrate
COOH
HOOC

Dietary carbohydrate, fat, and protein (amino acids)
are catabolized to the common metabolic intermediate
acetyl-CoA. The subsequent metabolic conversions responsible for extracting energy from the bonds between
carbon and hydrogen with ultimate consumption of oxygen and release of carbon dioxide and water are known
as central energy pathways.
COOH
OH

Isocitric Acid

cis-Aconitate

COOH

HOOC

COOH

Aconitic Acid

The CAC is not only the final common pathway of
energy release from food components, but is also the
source of basic structural or anabolic molecules that
are drawn away from the cycle to support organ maintenance and neurological function. Therefore, the CAC
serves both anabolic and catabolic functions of the body,
representing the “crossroads” of food conversion and
utilization (see Figure 6.1).
Conversions of the CAC intermediates are under
the control of enzymes, many of which require vitaminderived cofactors and essential elements for their
function. This fundamental pathway of energy flow
is critical for all organ systems. Abnormal spilling of
CAC intermediates in urine can indicate mitochondrial
inefficiencies in energy production. Detection of such
abnormalities can explain the biochemical basis of
excessive fatigue and weakness and guide ways to
improve energy production by supplying specific Bcomplex vitamins. Since the compounds that make up
the pathway are related in a cyclic manner, a block at
any step can cause accumulation of multiple compounds
that precede that step. In cytochrome-c oxidase
deficiency, inefficient utilization of NADH, the primary
product of the CAC, has been shown to cause citrate,
malate, fumarate, and α-ketoglutarate elevations.118 In
such conditions of genetic origin, interventions must
focus on optimizing other ways of managing energy
demands if approaches to enhancing formation of

## Central Energy Pathway Markers

COOH
COOH

aminotransferase results in the congenital defect in
glyoxylate metabolism known as primary hyperoxaluria
type I that is associated with over 50 disease-producing
mutations.112 Whether oxalate accumulation is due to
absorption of intestinal oxalate or endogenous production, the effects can be more general than kidney stones.
In addition to the crystallization of calcium oxalate in
the kidney, musculoskeletal and systemic manifestations can be produced from oxalate crystals deposited in
bone, skin, vessels, and inside the joints.113 Maintaining
high urinary magnesium and citrate can be a helpful
way to avoid renal calculi and oxalate crystal deposition
disease, as discussed further under “Citrate. Isocitrate,
and cis-Aconitate” below.114 Calcium supplementation
can reduce renal stone disease,115 and the enhancement
of calcium absorption by vitamin D is well known. Polymorphism in the vitamin D receptor gene has been proposed as a marker for calcium oxalate stone disease.116
In addition, oxalate-induced free radical oxidative stress
may be reduced by antioxidant therapy.117 Hyperoxaluric rat kidney shows high levels of superoxide and
H2O2-generating enzymes such as glycolic acid oxidase
and xanthine oxidase, and accumulation of transition
metal ions, iron, and copper that increases formation of
hydroxyl radicals.117
Analytical Issues: Urinary oxalate may be measured by enzymatic assay, but there are several interfering
compounds that can produce false-positives. Application
of GC/MS requires derivitization of the two carboxyl
groups, leading to extreme difficulty with controlling
losses of the product because of the small molecular
weight of the simple two-carbon compound. Attempts
to develop such methods have shown variability far
outside of acceptable limits.596 These limitations may be
overcome by using LC/MS-MS techniques, where urine
is simply diluted with a solution of internal standard and
injected onto the liquid chromatography column. Columns must be chosen to allow elution of the highly polar
oxalate ion without excessive spreading of the peak.

Low urinary citrate is related to urolithiasis. Both
cystine and calcium calculi are increased when citrate excretion is low. Hypocitraturia is the most common metabolic abnormality (found in 52% of patients) associated
with the nearly 5-fold increase of urolithiasis in children
from 1994 to 2005 in one hospital.123 A similar conclusion was drawn from measurement of urinary citrate
in patients with cystic fibrosis.124 Urinary citrate was
highly inversely correlated with cystine excretion when
18 children with cystine stones were compared with 24
healthy children. Cystine excretion decreased by 43%,
whereas urinary citrate increased almost 3-fold when the
patients were treated with1 mEq/kg potassium citrate
and 15 mg/kg α-mercaptopropionylglycine daily.125 This
mercapto compound reacts with renal free cysteine in a
mechanism independent of citrate concentration. Highprotein, low-carbohydrate diets decrease the excretion of
citrate, raising the risk of kidney stones.126, 127
A pattern of high cis-aconitate with low isocitrate is consistent with a defective aconitase enzyme.
Aconitase, which requires cysteine and iron as cofactors, is one of the mitochondrial matrix enzymes most
sensitive to oxidative damage.128 In rats, normal rates
of oxidative damage produce an age-related decline
of aconitase activity.129 Significant evidence exists for
iron regulation of aconitase,130-136 so iron deficiency
would also tend to produce an effect like that seen on
these reports. The aconitase responses are tied to iron
and nitric oxide effects through cellular regulation
involving mitochondrial ATP production.137 Signs of
oxidative damage that might produce elevated cisaconitate may be investigated by inspecting for high
xanthurenate and 8-hydroxy-2'-deoxyguanosine. As
discussed below under “Xanthurenate,” accumulation

the heme cofactor for the oxidase enzyme (including
iron supply) are ineffective. Coenzyme Q10 deficiency
can also result in elevated CAC intermediates (see
“Hydroxymethylglutarate” below). Toxic effects of drugs
like gentamicin are, in part, due to loss of mitochondrial
integrity. Such drugs inhibit isocitrate dehydrogenase,
the enzyme that converts isocitrate into α-ketoglutarate.
Lipoic acid, used at 25 mg/kg/d, protects against such
cytotoxic effects.119 Isocitrate dehydrogenase activity also
requires the presence of magnesium, manganese, and
NAD from vitamin B3.
Citrate is frequently the most abundant organic acid
in urine. The range of normal values is broad because
citrate excretion varies with changes in renal metabolism
and acid-base disturbances.120 Citrate elevation can be
utilized as a marker of ammonia accumulation due to
arginine insufficiency.121,122
Ammonia, a common metabolic byproduct, is toxic
and must be neutralized via the urea cycle or excreted.
Whenever the ammonia clearance capacity of the urea
cycle is exceeded, the rise of blood ammonia triggers increased ammonia excretion by the kidneys. The
anionic properties of citrate, cis-aconitate and isocitrate
are used to counterbalance the cationic ammonium ion
excretion. Abnormally high levels of these three organic
acids in urine can indicate that this renal ammonia
removal mechanism is being used. A caveat about such a
conclusion, however, is that elevation of the entire CAC
intermediate group is a sign of functional coenzyme Q10
insufficiency. This scenario is discussed further under
“Succinate.” Orotate elevation is an additional, sensitive
and specific marker for ammonia build-up due to levels
that exceed the capacity of the hepatic urea cycle (see
“Orotate” later in this chapter).
Low levels of citrate, isocitrate, and cis-aconitate
may occur due to the multiple pathways that draw CAC
intermediates away for biosynthesis, such as the initiation of heme synthesis by succinate. When this happens,
enzymes that serve to refill the cycle should be activated.
Aspartic acid is a preferred substrate for the anaplerotic
(refilling) pathway that restores CAC levels. By a single
vitamin B6-dependent transamination step, aspartate is
converted into oxaloacetate, the immediate precursor of
citrate. The reaction yields a net gain of cycle intermediates, a result that cannot be achieved from the flow of
acetyl-CoA. Catabolism of phenylalanine and tyrosine
produces fumarate, and several amino acids are converted into α-ketoglutarate (see Figure 6.1).

Notes:

against mitochondrial damage from otherwise lethal
doses of cyanide in rats.144
Levels of α-KG can also serve to mark an aspect of
the carbohydrate and fat metabolic relationship. When
metabolic conditions, such as insulin intolerance, act to
stimulate fatty acid (especially palmitate) synthesis, the
rising levels of palmitoyl-CoA cause an effective inhibition of glutamate dehydrogenase. Since this enzyme is
the gatekeeper of the dominant pathway for production
of α-KG, mitochondrial α-KG may be depleted when
fatty acid synthesis is stimulated.145 To state the corollary, low urinary α-KG is a marker for up-regulated fatty
acid synthesis, increased palmitic acid in plasma and cell
membranes, and increased serum triglycerides.

	α-Ketoglutarate
HOOC

COOH
O

## Succinate

COOH

HOOC

Succinic Acid
Succinate is a CAC intermediate
that donates
electrons directly to complex II in the electron transport
system via succinate dehydrogenase. Succinate dehydrogenase is the part of the electron transport chain that
acts to initiate the sequence to transport electrons from
succinate to oxygen. Succinate cannot play its role in
cellular energy production when CoQ10 is inadequate
because the electrons must be passed directly to bound
CoQ10. Elevated succinate excretion is a marker for
increased requirement for both CoQ10 and riboflavin.146
Clinical signs of CoQ10 and riboflavin deficiencies include fatigue, lassitude and myocardial and neurological
degeneration.147 CoQ10 depletion can be tissue specific.
For example, a 4-year-old boy who presented with
progressive muscle weakness, seizures, and cerebellar
syndrome had greatly reduced muscle CoQ10 without
corresponding CoQ10 deficits in lymphoblasts or skin
fibroblasts.79 His muscle mitochondria had severely
restricted ability to utilize succinate. A laboratory report
with abnormalities indicative of succinate dehydrogenase deficiency is shown in Case Illustration 6.3. The
feature that distinguishes this scenario is the pattern of
very low cis-aconitate and isocitrate. CoQ10 insufficiency
would generally cause high levels of these intermediates,
not low levels as seen in this instance.

The oxidation of isocitrate produces α-ketogluα-Ketoglutaric Acid
tarate (α-KG), also known as 2-ketoglutarate or 2oxoglutarate. In the next reaction of the CAC, α-KG
is oxidized in an energy-releasing step that requires a
dehydrogenase enzyme complex, called α-ketoglutarate
dehydrogenase complex (KGDC), which is similar to
the pyruvate dehydrogenase complex described above.
Low activity of this enzyme has been shown to produce
elevated excretion of α-KG.139 The same five B vitamins
are necessary for the action of KGDC, so elevations of
α-KG can signal B-complex deficiencies. α-Ketoglutarate
dehydrogenase deficiency can range from near absence
to marginal reduction in activity, with outcomes ranging
from severe neonatal acidosis to interruptions of normal
development by infections.139 Clinical signs, neuroimaging results, and biochemical correlations associated with
movement disorders in childhood organic acidurias have
been the subject of review.140

of this tryptophan catabolite has capacity for generating reactive oxygen species.138 Elevated 8-hydroxy-2'deoxyguanosine provides evidence of increased rates
of DNA oxidative damage as discussed below under
“8-hydroxy-2'-deoxyguanosine.”

Refer to Case Illustration 6.2

The compounds that make up the CAC can be
derived from amino acids as discussed above. This may
explain the energy-boosting effect people often report
when they take free-form amino acid supplements. The
effect is due to the conversion of specific amino acids
directly into depleted CAC intermediates needed for the
energy-producing cycle, such as α-KG, succinyl-CoA,
fumarate and oxaloacetate. The fatigue-reducing effect
of supplementation of aspartate salts and ketoglutaric
acid has been attributed to such a mechanism.141,142 The
importance of α-KG in cell energetic balance is shown
by the effectiveness of oral α-KG for reducing toxic consequences of cyanide poisoning where the availability
of oxygen is the primary deficit.143 Administration of a
single 2 g/kg oral dose of α-KG protected brain and liver
Refer to Case Illustration 6.3

The reaction in which succinate is converted into
fumarate depends on the presence of flavin adenine
dinucleotide (FAD) derived from riboflavin. Riboflavin
administration has been shown to produce dramatic
regression of neurological impairment in cases of deficits
in the complex II respiratory chain succinate dehydrogenase enzyme (Figure 6.7).71,146
When succinate levels drop below normal, leucine
and isoleucine are effective precursors that are converted

Carbohydrates

into succinate to assure functioning of the CAC. Since
this conversion requires adequacy of vitamin B12, functional adequacy of B12 should be assured when amino
acids are used to raise succinate. Individuals with inherited disorders such as fumarase deficiency, in which
the final steps of amino acid conversion to succinate are
blocked, exhibit serious neurologic symptoms, especially
encephalopathies.149

Pyruvate

Citrate

Fumarate

Cholesterol

Malate

A
Coenzyme Q10

Hydroxymethylglutarate

Acetyl-CoA

α -KG

B
Spilling in urine
due to blocks at
A and B

## Succinate

NADH
Complex I

Complex II

Complex III

Complex IV

Fe2+

Fe2+

FADH2

Quinone e
Pool

−

Fe

3+

e−

Fe3+

Oxygen
e−

(CoQ10)

A

HMG CoA Reductase Inhibitors

B

CoQ10 Deficiency

Figure 6.7 — Markers of Coenzyme Q10 Synthesis and Function
Elevation of organic acids in urine can reveal inhibition of the coenzyme Q10 biosynthetic pathway (A) or interruptions of
the electron transport system (B) from inability to sustain adequate CoQ10 levels in the inner mitochondrial membrane. Both
endogenous regulators and statin drugs act at the HMG-CoA reductase enzyme gateway for two-carbon unit entry into the
pathway that leads to synthesis of cholesterol and CoQ10. Accumulation of intermediates of the citric acid cycle, on the other
hand, signals a functional insufficiency of inner mitochondrial membrane CoQ10 to sustain the flow of electrons.

Fumarate

suggesting an abnormality in fatty acid synthesis
regulation by malate.151
Low fumarate and malate concentrations in urine
are a sign that the refilling reactions for the CAC are not
keeping up with losses of intermediates to other pathways. Amino acid catabolism supplies a major portion of
compounds that resupply the CAC (see Figure 6.1). The
addition of tyrosine or phenylalanine can help supply
fumarate when this intermediate is low.
Genetic origins of fumarate accumulation are
known. In the citric acid cycle, fumarate is converted to
malate by the enzyme fumarate hydratase, also simply
called fumarase. Fumarase deficiency produces an autosomal recessive encephalopathy. It is characterized by
a clinical history of generalized seizures, psychomotor
deterioration, and massive fumaric aciduria.152-154

HOOC
COOH

Malate

Fumaric Acid
OH

Hydroxymethylglutarate

Notes:
HOOC
HO

COOH
CH3

β-Hydroxy-β-methylglutaryl-CoA,
commonly
Hydroxymethylglutarate
referred to as hydroxymethylglutarate (HMG) is the
metabolic precursor of both cholesterol and CoQ10
(Figure 6.7). Low levels of HMG may reflect inadequate
synthesis and possible deficiency of CoQ10. The conversion of HMG to mevalonic acid is the rate-limiting
step in the isoprenoid pathway that yields cholesterol
and CoQ10. Statin pharmaceuticals used to lower serum
cholesterol do so by inhibiting the HMG-CoA reductase;
however, they also simultaneously inhibit the endogenous synthesis of CoQ10 and cause accumulation of
HMG.155
CoQ10 is utilized in the mitochondrial oxidative
phosphorylation pathway for ATP synthesis and is a
potent antioxidant. CoQ10 has been used extensively as
a cardiovascular protective agent and has been shown
effective in clinical trials of Parkinson’s disease.156 Depletion of CoQ10 in skeletal muscles can cause a myopathy
characterized by easy fatiguability of muscle and aching
muscles.157 In extreme cases it can cause fatal rhabdomyolysis. Supplementation with CoQ10 for patients on
statin drugs is widely recommended because the therapy
produces decreased muscle CoQ10 levels that can lead
to drug-related myopathy.157-159 Testing of urinary HMG,
along with functional markers of CoQ10 insufficiency
and serum CoQ10, can optimize patient management

Malic Acid
The removal of electrons from
succinate in the reaction shown in Figure 6.7 generates fumarate. Fumarate is
then converted to malate. Because of the sequential nature
of these reactions in the mitochondrial matrix, fumarate
and malate elevations serve as additional markers to substantiate the extent of metabolic interference from CoQ10
deficiency or cytochrome oxidase defects.94 Malate is also
actively pumped across the mitochondrial membrane as a
way of transporting reducing equivalents in or out of the
mitochondria. Methylmalonate inhibits the malate transporter, suggesting that elevated malate may also appear
as part of the pattern of vitamin B12 deficiency. This effect
has been suggested as an explanation of the hypoglycemia
and ketosis produced in methylmalonic aciduria.150
Elevated malate also could result from fatty
acid synthesis stimulation. The fatty acid synthesis
product palmitoyl-CoA is known to inhibit the malate
dehydrogenase enzyme.145 Urinary malate elevation
due to CoQ10 insufficiency is difficult to predict,
however, because of individual variation in regulation
of mitochondrial oxidation. In type 2 diabetic men,
for example, lower insulin sensitivity is associated
with lower glucose-stimulated rise in cytosolic malate,

COOH

HOOC

## Vitamins B1, 2, 3, and 5
α-Ketoisovalerate
CH3
COOH
H3C
O
α-Ketoisovaleric Acid
α-Ketoisocaproate
COOH

H3C
H3C

O

α-Ketoisocaproic Acid

α-Keto-β-Methylvalerate

CH3

COOH

H3C

O

When hepatic or
small intestinal Acid
enzymes remove
α-Keto-ß-methylvaleric
the amino groups from the branched-chain amino acids
(BCAA) valine, leucine, and isoleucine, they form the
branched-chain keto acids (BCKA), α-ketoisovalerate,
α-ketoisocaproate, and α-keto-β-methylvalerate, respectively. In most current biochemical literature, these
compounds are named 2-oxo acids, rather than α-keto
acids. In medical discussions, the older Greek letter
designation still prevails.
These compounds have been discussed in the
introduction to this chapter with reference to maple
syrup urine disease. Although that discussion noted the
specific response to thiamin, the enzymes require cofactors derived from five B-complex vitamins: B1, B2, B3, B5,
and lipoic acid. Elevations of the branched-chain keto
acids provide functional assessments of the sufficiency
of these vitamins, especially thiamin.14, 160 The molecular lesion site involving the branched-chain keto acid
dehydrogenase (BCKAD) enzyme has been discussed
in more detail in Chapter 4, “Amino Acids.” The keto
acids were also discussed in Chapter 2, “Vitamins,” in
the “Assessment of Status” section under each of the
relevant vitamins. Figure 6.8 provides an overview of
the amino acid pathways where the marker compounds
are formed. Recall also that regarding the branchedchain keto acids, the enzyme required is similar to the
pyruvate dehydrogenase complex discussed above under
“Lactate and Pyruvate.”

with supplemental CoQ10 by helping to differentiate the
patient needing 120 mg/d from those for whom 30 mg/d
is sufficient.
Although it may seem paradoxical, cases where low
serum CoQ10 levels are found with low urinary HMG
suggest that CoQ10 inadequacy may be associated with
low as well as high levels of HMG. The rationale for this
association is that a block earlier in the pathway inhibits
the formation of HMG, producing low levels in urine,
whereas a block subsequent to the formation of HMG
produces high levels. Either mechanism may lead to
reduced formation of CoQ10.
A rare genetic disorder results in elevated HMG
due to deficiency of the enyzme HMG-CoA lyase that
is required for the catabolism of leucine. Leucine is
metabolized to HMG, which can then either be split into
acetate groups by HMG-CoA lyase or enter the steroid
biosynthesis pathway via HMG-CoA reductase. However, since HMG-CoA reductase is under strong feedback
regulation, the HMG tends to accumulate. Infants with
this condition present with symptoms resembling Reye’s
syndrome, neurologic dysfunction (such as obtundation,
combativeness, and/or posturing), tachypnea, vomiting,
hypoglycemia, hyperammonemia, hepatomegaly, and elevated transaminases in blood, but without ketosis.2 The
behavioral characteristics make this disorder likely to be
diagnosed as autism. Such an apparent case is shown in
Case Illustration 6.4, where greatly elevated HMG was
found with concurrent high CoQ10, indicating that the
HMG was passing into the pathway for CoQ10 synthesis.

Refer to Case Illustration 6.4

## B-Complex Vitamin Markers
All of the compounds in this category are metabolic intermediates in the degradation of amino acids
(Figure 6.8). These pathways are highly active, with
large flux of substrates for individuals with normal
caloric intake. Once again, vitamin insufficiencies result
in slower rates of those reactions where the vitamin-derived cofactor is essential for enzyme activity. Because
of the specificity of individual enzymes utilizing the
vitamin-derived coenzymes, discrete patterns of elevated
excretion of specific intermediates signal functional deficiencies of individual vitamins.

{

α-Ketoisovalerate
α-Ketoisocaproate
α-Keto-β-Methylvalerate

Valine
Leucine
Isoleucine
Transamination

Thiamin (B1)
Riboflavin (B2)
Niacin (B3)
Lipoate
Pantothenate

BCKA Dehydrogenase

Adenosylcobalamin (B12)
Amino Acid Catabolism

Methylmalonyl-CoA
dismutase

## Methylmalonate

Biotin

β-Hydroxyisovalerate

CO2 + H2O

Figure 6.8 — Biochemical Markers For Vitamins B1, B2, B3, B5, Lipoic Acid, Vitamin B12 and Biotin

Catabolism of the branched chain amino acids, valine, leucine and isoleucine creates intermediates that can serve as markers
of restricted rates of metabolism when they accumulate due to insufficient levels of their cofactor forms to sustain the
dependent enzymes. There are three separate steps of isoleucine breakdown that signal insufficiencies of the thiamin group
shown, vitamin B12 or biotin, depending on which intermediate spills into urine. This pathway schematic shows the relevant
enzyme substrates that accumulate in each scenario.

There are six genes that encode the human BCKAD
complex, where 100 mutations have been identified.161
The accumulation of branched-chain keto acids has
been shown to be a potential cause of the predominant
neurological features of MSUD via their induction of
oxidative stress in glioma cells.162 The oxidative stress
is further shown to be due to high rates of nitric oxide
production and inhibition of phosphocreatine formation.163 Additional neuronal damage may occur due to
glutamate toxicity because the BCKA inhibit uptake of
Notes:
glutamate by cerebral cortical slices from rats.164 On the
other end of the clinical spectrum of keto acid disorders,
patients with renal insufficiency who are placed on lowprotein diets frequently have low branched-chain amino
acids and may benefit from supplementation.165 Adding
BCKAs improved renal function in such patients along
with improving levels of plasma amino acids.166 Patients
taking the hypolipidemic agent, clofibrate, may have
diminished levels of urinary BCKA because the drug
stimulates their metabolism by the BCKAD complex.167
A different metabolic lesion has been reported to
produce isovaleric acidemia without affecting the other
BCKA. The enzyme, isovaleryl-CoA dehydrogenase, that
acts subsequent to the BCKAD reaction in the valine catabolic pathway is specific for the isovaleryl group, so only
valine is affected. Of the two variants that have been reported, the one responsible for type II isovaleric acidemia
produces a mutation that interferes with the anchoring
of the enzyme to the inner mitochondrial membrane.168
This autosomal recessive inborn error was the first
organic acidemia recognized in humans. Although it can
cause significant morbidity and mortality, early intervention with a protein-restricted diet and supplementation

with carnitine and glycine are effective for promoting
normal development in affected individuals.75
Refer to Case Illustration 6.5

The common pattern seen in simple deficiency of
thiamin or other B-complex vitamins is one of increasing
levels for all three branched-chain keto acids. When all
three are above their 95th reference limit, a more severe
thiamin deficiency or BCKAD polymorphism is indicated. In this scenario, it is common to also find elevated
pyruvate and α-ketoglutarate because of their similar
enzyme cofactors. Milder variants of nutrient insufficiency may show fewer elevations. In such instances,
supplementation with branched-chain amino acids
challenges the capacity of the pathway and may reveal
abnormalities. Very severe abnormalities of specific
markers can reflect genetic abnormalities, as illustrated
in Case Illustration 6.5.

thranilate has a strict requirement for pyridoxal-5-phosphate derived from vitamin B6.170 Dietary deficiency of
B6 quickly manifests as slower rates of the B6-dependent
step, with accumulation of 3-hydroxykynurenin, which
causes accumulation of kynurenin.171 These compounds
are rapidly converted to xanthurenate and kynurenate,
respectively, which appear at elevated concentrations
in urine. In most individuals the urinary xanthurenate
rises to the higher concentrations, sometimes appearing
as the only positive marker.172, 173 Elevated kynurenate
provides biochemical confirmatory evidence of B6 insufficiency, especially when quinolinate is not high. As
discussed below under “Kynurenate and Quinolinate,”
cells of the immune system and brain express only the
first several enzymes of the hepatic kynurenin pathway,
resulting in net accumulation of quinolinic acid rather
than nicotinic acid.
There are important consequences of the tissuespecific gateways for initiation of kynurenin synthesis.
In general, however, the pathway in which kynurenic,
xanthurenic and quinolinic acids are formed from
l-tryptophan serves the following functions:

## Vitamin B6

## Xanthurenate

OH

N

OH

1. Clearance of excess l-tryptophan
2. Maintenance of nicotinic acid levels
3. Regulation of glutamatergic neuronal activity
4. Enhancement of macrophage defense functions

COOH

Xanthurenic Acid

Xanthurenic acid is the first to be discussed of
several tryptophan metabolites arising from the pathway
that converts tryptophan to nicotinic acid. Vitamin B6
insufficiency leads to elevated excretion of xanthurenate
and kynurenate because of a pyridoxal-5-phosphatedependent step in this metabolic pathway, called the
kynurenin pathway (Figure 6.14).169
The liver regulates tryptophan levels in plasma
through the kynurenin pathway that is initiated by the
heme enzyme, tryptophan-2,3-dioxygenase (TDO)
or indoleamine-2,3-dioxygenase (IDO) (see “NMDA
Modulators” below). Postprandial tryptophan in excess
of what can be utilized for protein synthesis enters
this pathway to be converted into nicotinate, offering
obvious additional benefit from the high-protein meal.
However, the enzyme kynureninase that converts the
intermediate 3-hydroxykynurenin into 3-hydroxyan-

Dietary tryptophan is an essential amino acid that
often is the rate-limiting amino acid in biosynthetic reactions. Therefore, there is little need for the tryptophan
clearance function in most individuals except following
high-protein meals. When an l-tryptophan load is received, the kynurenin pathway should become active in
the liver. The extra metabolic load is the basis of using a
3 to 5 g l-tryptophan challenge to increase the sensitivity for detecting marginal vitamin B6 status.174 Although
the excretion of both kynurenate and xanthurenate are
increased when vitamin B6 is insufficient to maintain
this function, xanthurenate is the principal product that
appears in most cases. This is due to the further metabolism of kynurenate to citric acid cycle intermediates in
the liver. Lower rates of renal clearance for kynurenate
are indicated by measurements of plasma levels of both
compounds in piglets on long-term parenteral vitamin
B6 supplements.175

Biotin

β-Hydroxyisovalerate

lenge of l-tryptophan (adults: 2 g) as long as laboratory
reference range adjustments are allowed for such dosing.
Xanthurenic acid forms complexes with insulin,
decreasing circulating concentrations and reducing
activities of the hormone.181, 182 Significantly elevated
excretion of xanthurenate has been found in diabetic
patients and animal models of diabetes.183 Xanthurenate excretion has been proposed as a marker to both
monitor and detect diabetes.184 In women with chemical
diabetes of pregnancy, xanthurenic acid seems to dominate, reducing the concentration of active insulin in the
plasma. In pregnant women with gestational diabetes,
excessive amounts of urinary xanthurenate were found.
Treatment with 100 mg of pyridoxine daily for 14 to 23
days restored the urinary xanthurenic acid to normal in
all patients tested.185 In women who received pyridoxine
for 14 days oral glucose tolerance also improved.186

Elevated urinary xanthurenate may be produced
from dietary tryptophan even when there is no extra
tryptophan challenge. In such cases, vitamin B6 insufficiency is significant enough to interfere with even the
normal conversion of dietary tryptophan. When piglets
were used to study vitamin B6 deficiency, urinary levels
of kynurenate and xanthurenate were elevated early
in vitamin B6 deficiency, and continued to rise as the
deficiency worsened.171 Since challenge of the hepatic
kynurenin pathway by tryptophan is necessary for
xanthurenate production, patients may be advised to eat
a large portion of a high protein-content food or take a
tryptophan supplement on the evening of the specimen
collection. This advice applies to several of the organic
acid markers dereived from pathways of amino acid
catabolism.
Dietary tryptophan can be used to form nicotinic
acid, sparing the need for dietary niacin for making
NAD+ and NADP+. If dietary tryptophan is limiting,
then dietary niacin is required. However, even if the supply of tryptophan is in excess, niacin cannot be formed
in the absence of vitamin B6. The kynurenine pathway
offers an excellent example of the complex interplay of
essential nutrients. Eating disorders that restrict vitamin
B6 or protein may manifest signs of the niacin deficiency
disease, pellagra, including photosensitivity, dermatitis,
diarrhea and dementia.176 Estrogen hormones inhibit
the initial conversion of tryptophan to kynurenine, offering an explanation of the twofold excess of females
over males in many outbreaks of pellagra.177, 178 Other
estrogenic effects that produce higher pathway intermediates may be due to increased losses of vitamin B6 by
individuals with high estrogen levels.104
Vitamin B6 deficiency produces elevated xanthurenate that, in turn, produces increased oxidative stress.
The hydroxylated quinone structure of xanthurente has
been shown to bind iron, producing a complex that
increases DNA oxidative damage that may be shown by
increased production of 8-hydroxy-2'-deoxyguanosine.138
This means that, in addition to indicating a need for
therapy with vitamin B6, elevated xanthurenate leads to
suspicion of antioxidant insufficiency.
Interpretation of elevated urinary xanthurenate
should take into account kynurenin pathway modulation by steroid hormones177 and bacterial endotoxins,179
plus decreased flux of tryptophan through the pathway
for individuals on low-protein intake.180 The low dietary
protein effect may be minimized by using an oral chal-

H3C

OH
COOH

H3C

Biotin is obtained from food, and is also produced
ß-Hydroxyisovalerate
by predominant organisms (especially bifidobacteria)
in the healthy human gut. Biotin deficiency was once
thought to be rare because such small amounts are
required and clinical signs of deficiency are non-specific.187 It was thought that only certain disorders of infancy, such as Leiner’s disease (desquamative erythroderma) and other forms of seborrheic dermatitis, are clinical
manifestations of biotin deficiency. Recent findings are
shifting the clinical outlook for biotin deficiency.
Biotin is a cofactor in acetyl-CoA carboxylase, pyruvate carboxylase, methylcrotonyl-CoA carboxylase, and
propionyl-CoA carboxylase. The biochemical function
of biotin-requiring enzymes is the insertion of carboxyl.
Methylcrotonyl-CoA carboxylase catalyzes an essential step in the metabolism of leucine. Because leucine
turnover amounts to many grams per day, its catabolism
is a high-flux process that offers a biochemical marker of
biotin deficiency. The product formed after the first three
steps of the pathway, β-methylcrotonyl-CoA, requires
a biotin-dependent carboxylation to allow the flow to
continue. Deficiency of biotin causes accumulation

Normal Range for Biotin
(umol/24 h)
β-Hydroxyisovaleric acid

Biotin

(nmol/24 h)

Adapted from Mock 1997
Normal Range for β-Hydroxyisovaleric acid

Figure 6.9 — Human Biotin Deficiency and

β-hydroxyisovalerate Excretion

Within about ten days, 24 hour urinary biotin excretion
falls below normal levels when the biotin-binding protein
avidin is fed to human subjects. The biotin-dependent
metabolic intermediate, β-hydroxyisovalerate, however,
rises above normal ranges by the third day, showing the
functional impact of insufficient biotin on amino acid
metabolism far ahead of total body biotin depletion.

of this biotin-dependent intermediate, and its hydrated product, β-hydroxyisovalerate, spills in urine.
β-Hydroxyisovaleric aciduria appears early in people
who are made biotin deficient by consuming the biotinbinding protein, avidin. After starting avidin administration, elevated β-hydroxyisovalerate appears at the
third day, whereas serum biotin concentrations remain
in the normal range until the tenth day (Figure 6.9).
The effects are completely reversible.
Additional studies have confirmed the high sensitivity and specificity of elevated β-hydroxyisovalerate
for detection of biotin insufficiency.188 Even antibioticinduced disruptions of gastrointestinal bacterial biotin
synthesis can produce biotin insufficiency detectable
by elevated β-hydroxyisovalerate.189 In addition to
increased β-hydroxyisovalerate, biotin deficiency may
produce elevations of lactate and alanine in urine and
accumulations of odd-chain fatty acids (C 15:0 – C29:0)
in plasma or red blood cell membranes.190 The lactate
and alanine effect results from decreased rates of gluconeogenesis in biotin deficiency. The fatty acid effect is
due to initiation of long-chain fatty acid synthesis with
the three-carbon chain of propionate. The sequence of
elongations produces abnormally high levels of fatty
acids with chain lengths of 13 to 31 carbons in plasma
and erythrocyte membrane lipids.191 See Chapter 5,

“Fatty Acids” for further discussion of odd chain fatty
acid abnormalities.
Heritable disorders of biotin metabolism lead to the
condition called multiple carboxylase deficiency (MCD),
in which the activities of enzymes that have absolute
requirements for biotin to carry out carboxylation reactions are deficient.190 β-Hydroxyisovalerate is a compound that is elevated in biotin deficiency and multiple
carboxylase insufficiency.188 Biotin deficiencies of various
degrees have been shown to develop in normal pregnancies192 and in patients on long-term anticonvulsant therapy.193 When β-hydroxyisovalerate was used to assess
biotin in pregnant women, 9 out of 13 women studied
were biotin depleted, even in early pregnancy.194 Symptoms of biotin deficiency include alopecia, skin rash,
Candida dermatitis, unusual odor to the urine, immune
deficiencies and muscle weakness. Six human missense
mutations that produce MCD have been shown to be
responsive to biotin therapy because normal circulating
biotin levels are 100 times lower than the concentrations
needed for half saturation of the enzyme. Dietary biotin
supplementation can easily result in saturation of the
available mutant enzyme with restoration of activity.195
Biotin from food or from intestinal microbial
synthesis is absorbed in the upper small intestine and
transported to tissues bound to several blood proteins.
The enzymes that use biotin as a cofactor are called
carboxylases because they use carbon dioxide to insert
carboxyl groups into substrates. Cellular biotin must
be incorporated into the carboxylase enzymes by the
action of other enzymes called synthases (Figure 6.10).
If these enzymes are not fully active, higher biotin
concentrations can increase enzymatic activity and
enhance the reaction rate. The carboxylase enzymes
have critical roles in major pathways for the utilization
of energy from amino acids (where β-hydroxyisovalerate
is formed), the synthesis of fatty acids for cell membrane
replacement, and the maintenance of blood glucose via
Notes:

Dietary Biotin
Small Intestinal Microbial Synthesis

Tissue
Biotin
Pool
Carboxylase
Synthase(s)

Biotinidase

Loss in Urine

BIOTIN
UTILIZATION

Biocytin in blood

BIOTIN
RECOVERY

Carboxylases
with bound biotin

Proteases

Carboxylation Reactions

CARBOHYDRATES
PROTEINS
Gluconeogenesis
Amino acid catabolism LIPIDS
Blood glucose
Fatty
acid
sythesis
Cell energy
New tissue membranes

Figure 6.10 — Defects in Biotin Pathways

The activity of cellular carboxylase enzymes is determined by the total biotin pool size and the rates of formation and
degradation. Cellular biotin is covalently bound to carboxylase enzymes by their respective carboxylase synthases. When
they are degraded by proteases, the enzymes release biotin as biocytin that may be recovered when biotinidase is active.
Thus, dietary, intestinal and genetic factors interact to determine individual biotin status. β-Hydroxyisovalerate is a substrate
for one of the biotin-requiring enzymes in leucine catabolism.

gluconeogenesis. At cell death, the biotin may be recovered if there is sufficient activity of the enzyme biotinidase, which acts on the biotin-peptide fragments called
“biocytin.” The major factors shown as boxed text in
Figure 6.10 contribute to the maintenance of carboxylation actions. Biotin insufficiency can be caused by lack
of biotin-rich foods or genetic variations in the enzymes.
Antibiotic overuse also may contribute to biotin insufficiency by lowering the population of biotin-producing
organisms and favoring the overgrowth of non-biotin
Table 6.5 — Biotin Doses for 2-Year-Old Male

with Biotinidase Deficiency

Biotin Dose

Clearing Signs/Symptoms

6 mg

Truncal ataxia
Convulsions
Alertness

20 mg

Leukocyte carboxylase

30 mg

Dermatitis (returned at 25 mg)

As the daily biotin dose was increased (shown in the left-hand column),
the patient’s signs and symptoms cleared in the order shown in the
right-hand column.
producing species. Lactobacillus acidophilus inoculation of broiler chickens fed a diet marginally deficient in
biotin caused decreased liver biotin content and reduced
growth rates, presumably due to competition by the
probiotic for dietary biotin.196
A case involving biotinidase deficiency illustrates
the use of biotin replacement. A 2-year-old male patient
presented with ataxia, seizures, and a history of normal
development for 19 months, and then experienced loss
of language and developmental milestones and progressive gait disturbances.197 On physical examination,
the patient was obtunded with eczematous dermatitis,
truncal ataxia, and a fine volitional tremor on the arms.
Symptoms of ataxia, tremors, loss of language development, gait disturbances, and dermatitis cleared only after
increasing biotin intake to 30 mg/d. The data presented
in Table 6.5 are from this report. After 1 year of highdose biotin, the symptoms did not return and there was
no further progression of hearing loss, but there was
some attention disorder with hyperactivity.
Over 20 point mutations that cause deficiency of
the biotin-dependant enzyme, propionyl-CoA carboxylase (PCCA) have been identified in North America and

Europe. Along with the ensuing propionic acidemia,
the accumulation of other toxic metabolites can impair
mitochondrial function, especially affecting the basal
ganglia and other regions of the brain with high rates of
aerobic metabolism. Clinical presentations vary widely
because of the variety of enzyme polymorphisms and
triggering events that can range from protein overloading to fasting or febrile infections.198 Table 6.6 shows
typical symptoms found in patients with propionic
acidemias categorized by age of onset. A case of novel
PCCA mutations has been reported in which the patient
had unremarkable medical history until 4.5 years old. A
simple infection caused her to become comatose, whereupon the diagnosis of two new missense mutations of
PCCA was made. In spite of combined therapy with
biotin and carnitine, restriction of protein intake, high
caloric nutrition, and correction of acidosis, the girl died
2 days after admission due to cardiac arrhythmias.199

Table 6.6 — Propionic Acidemias

Vomiting, lethargy, neurologic
symptoms, and keto-acidotic coma

Neonatal

Abnormal psychomotor development,
mental and psychological disabilities

Late-onset

Severe movement disorders, basal
ganglia lesions

29-year-old

Dystonia, choreoathetosis

ing from vitamin B12 deficiency and the rapid improvement of symptoms vitamin B12-deficient patients experience with administration of intramuscular vitamin B12.
By combining measures of MMA and tHCYS, the various
permutations of abnormalities may be used to specify
insufficiencies as shown in Table 6.7.
Vitamin B12 deficiency has been demonstrated to be
present in over 12% of the free-living elderly population
in the United States203 and is especially common in the
early stages of HIV infection.204 About 40% of patients
with acquired cobalamin deficiency have neuropsychiatric syndromes characterized by progressive and variable
damage to the spinal cord, peripheral nerves and cerebrum.205 Methylmalonic acidemia is frequently accompanied by propionic acidemia. Acute or chronic vomiting
and dehydration were the most common symptoms and
physical findings, respectively, in emergency presentations of patients with methylmalonic acidemia, propionic acidemia, or branched-chain amino acidemia
(MSUD).206
Occasionally a patient is found to have elevated
urinary MMA even though vitamin B12 supplementation has produced elevated serum cobalamin levels.
This situation might be produced by poor conversion
of supplemental cobalamin to adenosyl and methylcobalamin. Several genetic defects of these steps, defined
as cobalamin complementation groups have been
identified.207 Alternatively, specific polymorphism of
the methylmalonyl-CoA mutase enzyme could prevent
cofactor or substrate binding that would not respond
to increased adenosylcobalamin concentrations. Mild
polymorphisms of this type could be relatively common,
since it is possible that the specific clinical consequence
of methylmalonic aciduria could be benign. One reported case of this type showed psychomotor delay.208 In the
benign polymorphism scenario, all other B12 metabolic
functions may be working perfectly, and the test returns
a false-positive because the pathway step that we have

Methylation
Pathway Markers

## Methylmalonate
COOH

HOOC

## Vitamin B12

CH3

Methylmalonic Acid

Methylmalonyl-CoA is produced in the multistep
process of breaking down the amino acids isoleucine,
valine, methionine, and threonine, or from catabolism
of odd-chain fatty acids.200 Methylmalonate (MMA)
is converted into succinic acid by a vitamin B12-dependent enzyme, methylmalonyl-CoA mutase (see
Chapter 2, “Vitamins”). The lack of vitamin B12 impairs
this conversion as well as the one in which methionine
is recovered from homocysteine (tHCYS), leading to accumulation of both tHCYS and MMA. Thus, an increase
in MMA or tHCYS, can signal a vitamin B12 deficiency.201
Research studies have looked at both blood and urine
levels of MMA, and have found overnight fasting urinary
MMA concentrations to have a strong linear relation to
serum MMA.202 Vitamin B12 deficiency adversely affects
both energy-yielding and methylation pathways. Such
biochemical impairment helps explain the fatigue result-

picked happens to be one that is mildly faulty in some
individuals. A third alternative is that the intracellular
cofactor concentration has been increased sufficiently to
saturate the enzyme, but the turnover is insufficient to
process excessive amounts of propionate. Clinical and
biochemical benefit in two patients with methylmalonic
aciduria following metronidazole therapy suggests that
an antibiotic with specific activity against anaerobic
bacteria can be effective for removing the propionate
precursor of MMA. The virtual elimination of propionic acid from the stool of these patients suggests that
propionic acid derived from fecal bacterial metabolism
contributes substantially to MMA production. This novel
treatment for these disorders of intermediary metabolism indicate the importance of microbial gut flora in
normal human metabolism.209

Histidine

## Formiminoglutamate
THF

Formimino-THF

in the Catabolism of Histidine

After meals containing protein, lack of adequate
tetrahydrofolate (THF) cofactor slows the postprandial
catabolic clearance of histidine, causing spilling of
formiminoglutamate into urine.

diminish.214 High urinary FIGLU appears about 90 days
after a period of insufficient folate availability. Urinary excretion of FIGLU in one group of folate-deficient patients
was 113 mg/24 h, compared with 16 mg/24 h in healthy
controls or vitamin B12-deficient individuals,215 after 15 g
of histidine hydrochloride was administered in three 5 g
doses at 4 h intervals (urinary collection started after the
first dose). This experiment resulted in the recommendation that folic acid-deficient individuals should be treated
with 1 mg of folic acid along with 5 g of histidine for 3 to
5 days to overcome anemia of folic acid deficiency (see
Chapter 4, “Amino Acids,” under “Histidine”).
Since its function is to accept a single carbon group
from the substrate in the FIGLU reaction, the simple
folic acid form of the cofactor is needed. Another form
of folate, 5-methylfolate, functions as a methyl-donor
in the methionine-homocysteine pathway. Deficiency of
this form of folate results in high levels of tHCYS. Elevated tHCYS increases the risk of ischemic heart disease,
stroke, and deep vein thrombosis.216 Differences in binding affinity and in the forms of folate make it possible to
have elevated FIGLU with normal tHCYS. The FIGLU
pathway can be thought of as folate loading, whereas the
tHCYS pathway is folate unloading. Addition of methyl
groups in the tHCYS pathway requires loaded (methyl-)
folate, whereas removal of formimino groups in the FIGLU pathway requires only folic acid. Therefore, simple
folic acid supplementation (not methyl forms) is needed
to normalize FIGLU elevations.
A serum folate concentration of less than 0.3 ng/mL
is evidence of deficiency, but false-normal values are

## Formiminoglutamate

COOH

H
N

Formiminoglutamic Acid

Formiminoglutamic acid (FIGLU) is an intermediate in the deamination of the amino acid histidine. Folic
acid is the cofactor required by the enzyme formiminotransferase that converts FIGLU to glutamic acid
(Figure 6.11). Folate accepts the formimino group from
FIGLU to yield N5-formimino-THF. Descriptions of the
“FIGLU Test” to determine folate sufficiency appeared as
early as 1965.210 FIGLU excretion increases in folate deficiency, especially when histidine is administered as an
oral load.211 Up to 15 g of oral histidine has been used
as a FIGLU metabolic challenge for adults. Additionally,
FIGLU excretion has been used to measure the influence
of drugs or alcohol on functional folate status.212,213
Functions of folate include amino acid metabolism,
cell division and replication, and nucleic acid synthesis,
purine and pyrimidine synthesis in particular. Consequently, deficiency of folate can lead to inhibition of
DNA synthesis, impaired cell division, and alterations
in protein synthesis. Mild folate deficiency is characterized by low plasma folate and hypersegmentation of
polymorphonuclear leukocytes. After about 4 months
of low folate intake, red blood cell folate concentrations
Glutamate

Figure 6.11 — The Formiminoglutamate Step

## Folic Acid

HN

Glutamate
Formiminotransferase

Table 6.7 — Differentiating B12, Folate, and B6 Deficiency

Scenario

Markers

Potential Deficiency
Homocysteine ↑ with no other test result

Either B12, folate or B6 , or methyl donor compounds
Methylmalonate ↑ with Homocysteine and FIGLU normal

B12
Homocysteine ↑ with normal methylmalonate

B6 or folate
Both Homocysteine ↑ and methylmalonate ↑

B12, folate, and B6
Homocysteine ↑ with MMA and FIGLU normal

B6 and possible methyl donor compounds
HCys, MMA and FIGLU all ↑

B6, B12, folate and methyl donor compounds

ence the likelihood of a folate deficiency. Methotrexate
(MTX) is a competitive inhibitor of dihydrofolate (FH2)
and prevents recycling of folate to its usable THF form.
Oral contraceptive use has been shown to impair folate
metabolism as measured by serum folate, erythrocyte
folate and FIGLU.218 Vitamin B12 deficiency results in
reduced folate uptake across gut and other cell walls,
and reduced cell retention. Ascorbate protects folate
from oxidative destruction, thus low dietary vitamin C
influences folate status. Chronic alcohol consumption
impairs folate coenzymes and, in folate deficiency, causes
possible malabsorption of enterohepatically-circulated
folates.219
A wide variety of clinical conditions can suggest
folate evaluation. Extra folate may be needed to improve
endothelial function and lower risk of heart disease.220,221
Women with inadequate folate have a 53% higher risk of
breast cancer, and folate adequacy reduces the increased
breast cancer risk from alcoholic beverage consumption.222,219 Patients with small cell carcinoma of the lung
who were losing weight had elevated FIGLU. It was
demonstrated that these individuals had high demands
for one-carbon units supplied by folate.223 Cigarette

frequently found due to the response of serum levels to
transient dietary intake changes that do not correspond
to tissue repletion of the nutrient. The period of deficiency that must pass before erythrocyte folate drops below
normal levels is longer than that resulting in hyperhomocysteinemia. Changes in leukocyte folate levels occur
at the same rate as erythrocyte. Leukocyte folate thus
is not a valuable early marker for deficiency. Combination assays of the methylation pathway markers FIGLU,
methylmalonate, and homocysteine in urine have been
proposed as the most sensitive and cost-effective means
for routine diagnosis of megaloblastic anemia.217
Elevated tHCYS is a sensitive marker of folate
inadequacy at the biochemical level. However, it is not
necessarily due to folate deficiency. Serum folate can
be used as a confirmatory test. A differential diagnosis
of vitamin B12, folate and vitamin B6 deficiencies can
be made with simultaneous assay of MMA, FIGLU and
tHCYS (Table 6.7). If only MMA is elevated (Scenario 2),
only B12 supplementation may be needed. In Scenario 5,
folate is indicated, and though B12 may not be needed
according to the normal MMA, the tHCYS elevation may
be signaling a need for methyl donor compounds like
betaine, dimethylglycine or subcutaneous injection of
methyl-B12. If all of the markers are found to be elevated
(Scenario 6), then the full spectrum of cofactors and
methyl donating nutrients should be considered.
Folate deficiency can occur for a number of reasons.
Since humans cannot synthesize folate and it must be
provided by the diet, poor dietary intake of folate-rich
foods or excessive intake of processed foods increases
the chances of insufficiency. Impaired absorption, inadequate utilization due to a metabolic block, increased
demands, increased excretion or increased destruction of
folate all contribute to folate insufficiency. Prescription
drugs, lack of specific nutrients, genetic enzyme defects,
many diseases, and alcoholism are factors that can influ-

Notes:

concentrations in other tissues largely unrelated to CNS
levels. An exception is the reflection of CNS levels of
serotonin by platelet or platelet-rich plasma serotonin
concentrations and corresponding associations with
serotonin-related pathologies.229-231 Even when 24-hour
collection specimens are used, urinary serotonin is
found to vary widely among healthy males under clinically controlled conditions.232 Healthy male smokers
who were treated with the selective serotonin reuptake
inhibitor Paroxetine had median platelet serotonin decrease by 16% after 24 hours, whereas urinary serotonin
increased by 89%.233
Regarding dopamine, even in the extreme chronic
elevation conditions of neuroblastoma, direct urinary
dopamine to creatinine ratios were far less revealing than
the dopamine catabolite vanilmandelic acid.234 Urinary
dopamine levels rise significantly and reproducibly only
in cases with large, inoperable bilateral carotid body
tumors.235 In a retrospective study of 5,933 adults and
467 children conducted over a 57-month period, high
24-hour urinary dopamine levels were found in less than
3% of adults, and those instances were associated with
overcollection, drug effects, and neural crest tumors.236
Sleep has effects on dopamine excretion, as shown in
a study that found roughly equivalent reductions for
urinary dopamine and its catabolic product homovanillic acid in healthy adults with periodic leg movements
in sleep.237 Although renal dopamine synthesis rates
may be reflected as changes in urinary dopamine,238,
studies specifically seeking evidence of dysregulation of dopaminergic activity in the brain have failed to
find any relationship with urinary dopamine levels.240,
Therefore, whatever clinical utility may be claimed
for measurement of urinary neurotransmitter concentrations should not be associated with any effects related to
actual levels in brain or spinal cord neurons.

Neurotransmitter
Metabolism Markers

smoking-associated increase in pancreatic cancer is reduced when folate function is assured.224 Smoking seems
also to be associated with elevated homocysteine levels
in patients with early atherosclerotic development.225
Patients with Crohn’s disease should be evaluated for
folate adequacy to control homocysteine-associated
thrombotic events.226 Demands for folate increase with
gestation.227 Supplementation of folate in women of
childbearing years not only prevents neural tube defects,
but also prevents megaloblastic anemia, which can complicate pregnancies.
Analytical difficulties have challenged accurate
FIGLU determinations, partly because the compound
contains both negatively charged organic acid and
positively charged amino groups, making it zwitterionic
at neutral pH. An improved method for simultaneous
determination of multiple zwitterionic metabolic products in urine by ion exchange chromatography coupled
with tandem mass spectrometric detection has been
developed.17 This method allows these compounds to be
measured accurately over the full range of normal physiological variation as well as for the elevated concentrations found in patients with folate deficiency.

Neurotransmitter disorders have been recently
described as “an enigmatic and enlarging group of
neurometabolic conditions caused by abnormal neurotransmitter metabolism or transport.”228 Accurately
determining the central nervous system (CNS) level of
neurotransmitters has proven difficult. This may be in
part because neurotransmitters are rapidly formed and
degraded in nervous tissue, leaving neurotransmitter
Notes:

## Catecholamines
Vanilmandelate (VMA)
HO

H3C

COOH

O
OH
Vanilmandelate

Homovanillate (HVA)
O

HOOC

COOH

anxiety and fatigue. Because these neurotransmitters are
products of the amino acid tyrosine, treatments aimed at
improving protein digestion and supplementation with
tyrosine may normalize CNS levels.243 The relationship
of tyrosine to epinephrine also gives rise to the antihypertensive role of tyrosine.244
Elevated levels of VMA and HVA signal an increased
rate of synthesis and degradation in normal tissue or
abnormal production by tumor tissue. Neuroblastic
tumors frequently cause a profound elevation in VMA,
which may be expressed as the VMA/HVA ratio.245 The
incidence of elevated values appears to increase as a
function of tumor size, and small tumors are not likely
to result in positive urinary measurements.246 Elevation
of VMA along with specific elevation of cardiac troponin
I are, together, precursors to myocardial injury.247
In the absence of such disease processes, increased
catecholamine synthesis results from the synergism of
pituitary adrenocorticotropic hormone (ACTH) and
adrenal cortisol. This constitutes the widely recognized
chronic stress response that manifests as heightened
sympathetic reactions to stress.
The use of specific dopamine reuptake inhibitors
like risperidone can cause shunting of dopamine away
from uptake into presynaptic vesicles and into the methylation pathway that leads to (nor)epinephrine. Patients
on such drugs frequently have low HVA with elevated

CH3

Homovanillic Acid

Vanilmandelate, also known as vanilmandelic
or vanillyl-mandelic acid (VMA), is the main urinary
metabolite of the catecholamines, epinephrine, and
norepinephrine. Homovanillate (HVA) is the main metabolite of dopamine that appears in urine (Figure 6.12).
In controlled laboratory animal experiments, low
urinary levels of VMA and HVA have been associated
with low CNS levels of these neurotransmitters.242 Low
levels of these neurotransmitters are associated with
symptoms that include depression, sleep disturbances,

Tyrosine

Dihydroxyphenylalanine

Norepinephrine

Epinephrine

COOH

COOH

Dopamine

CH2–CH–NH2

CH2–CH–NH2

CH2–CH2–NH2

HO-CH-CH2-NH

HO-CH-CH2-NH2

CH3

BH4

B6

Cu

SAMe

Vit. C
OH
OH

OH

OH

OH

OH

Homovanillate

OH

OH
OH

Vanilmandelate

Figure 6.12 — Catecholamine Turnover Markers
Adrenergic neurons and adrenal medullary cells utilize tyrosine to produce dopamine, norepinephrine and epinephrine. The
urinary products homovanillate and vanilmandelate reflect the overall rates of biosynthesis and breakdown in these pathways.

HVA levels were higher in the workers exposed to aluminum, although serum aluminum was not significantly
different.260 Compared with controls, the exposed workers in this study had significant differences in neurobehavioral tests.

Serotonin
## 5-Hydroxyindoleacetate (5-HIAA)
HO

H
5-Hydroxyindoleacetic Acid

Catabolic breakdown of serotonin leads to excretion of 5-hydroxyindoleacetate (5-HIAA) (Figure 6.13).
Abnormally high levels of this metabolite result from the
use of serotonin-specific reuptake inhibitor (SSRI) drugs,
5-hydroxytryptophan supplementation, or increased release of serotonin from any of three primary sites: central
nervous system, intestinal argentaffin cells, or platelets.
The effect of an SSRI can cause strong elevations of
5-HIAA. We have found that patients who show no elevation of urinary 5-HIAA in response to SSRIs concurrently often report poor antidepressive responses to the
drug. This observation suggests that some people may
have an unusual serotonin receptor characteristic that
prevents the reuptake inhibition of the drug. Antidepressant drugs show a wide range of relative selectivity for
serotonin over noradrenaline and dopamine as shown
in Table 6.8. The drugs with greater serotonin selectiveness are more likely to cause urinary 5-HIAA elevation.
Conversely, there are individuals who, in the absence of
any known drug effect, have greatly increased 5-HIAA
excretions. Such individuals provide evidence of a nonpharmacological effect that blocks serotonin reuptake
or otherwise leads to serotonin degradation. Xenobiotic
compounds are candidates for this action because some,
such as acrylamide, are known to interact with serotonin
receptors.261
A principal reason for difficulty with interpretation of urinary 5-HIAA is the lack of tissue-specific
knowledge of its origin. Although serotonergic neurons
in the brain have been most intensely studied, they
also are abundant in the spinal cord and other tissues,
notably the gastrointestinal tract. Spinal cord serotonin
may participate in neurotransmission of somatomotor,

COOH
N

VMA. A patient who displays increased psychoses
when using drugs like risperidone may be displaying a
(nor)epinephrine overload.
The dopamine theory of schizophrenia was developed from multiple observations of the effectiveness of
neuroleptic drugs that block brain dopamine receptors
and are effective in treating psychoses of diverse origins.
The brain dynamically regulates dopamine synthesis
in response to stimuli, resulting in phasic increases of
dopamine and its catabolic product, HVA.244, 248 Thus,
it has been proposed that HVA levels in cerebrospinal
fluid (CSF) vary as a function of psychosis rather than
being related to the diagnosis of schizophrenia per se.249
Plasma HVA levels predicted the number of in-patient
drug-free days and the duration of illness in schizophrenic patients,246, 250 as well as pateint response to
risperidone treatment.251
Dietary copper deficiency results in higher dopamine and lower norepinephrine levels in rats due to
lower activity of dopamine-β-monooxygenase, even
though the copper deficiency leads to greater production
levels of the enzyme as well as tyrosine monooxygenase.252, 253 Similar, though more dramatic changes have
been reported in heart and spleen from pigs.254, 255 These
catecholamine changes may be reflected as elevated
levels of HVA and suppressed levels of VMA in urine
due to copper deficiency. The urinary HVA/VMA ratio
test has been found to be a sensitive and specific tool
to screen for the copper deficiency disorder of Menkes
disease.256 This ratio may be of similar clinical utility for
less severe copper insufficiency states. (See “Copper” in
Chapter 3, “Nutrient and Toxic Elements.”)
Interpretation of urinary HVA must take into account dietary influences. A large fraction of ingested
quercetin is metabolized by intestinal bacteria to homovanillic acid.257 Significant elevations of serum HVA
can result from quercetin ingestion by healthy adults.
Serum HVA levels rose 5- to 20-fold during the first 24 h
after 1,200 mg doses of quercetin by 4 healthy adults.258
The estimated average daily dietary consumption of
quercetin of about 30 mg is unlikely to produce significant elevations of HVA in urine. However, urinary HVA
levels can also be raised by ingestion of bananas, which
have high concentrations of dopamine relative to other
foods.236, 259
Occupational exposure to low levels of aluminum
can affect the neurobehavioral function and metabolism
of monoamine neurotransmitters. Both urine VMA and

B6

5-Hydroxytryptophan

Serotonin

B2,Cu++

5-Hydroxyindoleacetate

BH4
Tryptophan

Figure 6.13 — Formation and Clearance

of Serotonin

The availability of tryptophan in serotonergic neurons
determines their ability to sustain serotonin levels.
Anything that increases serotonin turnover, such as
increased neuronal activity or drugs that block synaptic
re-uptake cause increased rates of 5-hydroxyindoleacetate
formation and higher concentrations of the catabolic
product in urine.

only those who show high variability in 5-HIAA excretion in overnight urine experience watery diarrhea.272
Cerebrospinal fluid 5-HIAA and HVA showed
highly significant positive correlations with Alzheimer’s
disease.273 These monoamine disturbances may be in
response to the pathophysiology of this disease. Experimental allergic neuritis also exhibits elevated serotonin
precursors, indicating that they may play a role in the
clinical course of this disorder.274 5-HIAA is also greatly
increased in the first attack of chronic relapsing allergic
encephalomyelitis, indicating a potential explanation of
neurological signs.264

autonomic and pain signals.262 Formation of both
serotonin and 5-HTP within the spinal cord have been
shown to be stimulated by administration of 5-HTP,
and the increase is enhanced in experimentally induced
encephalomyelitis (EAE), an experimental model system
for human multiple sclerosis.263 Spinal cord generation
of 5-HIAA increases in the initial inflammatory phase
of the disease and decreases after destruction of nerve
fibers.264 Decreased serotonin reuptake by damaged neurons and disruption of the blood-brain barrier have been
suggested as mechanistic explanations. Such rationale
allows understanding of how serotonin may enter the
CNS from 5-HTP produced in the periphery.263 The inflammatory phase in the more caudal regions of the spinal cord also results in marked elevation of quinolinate
in rats with induced EAE.265 Quinolinate is discussed
further in the next section. Tryptophan supplementation
increases survival in EAE.266
Carcinoid tumors composed of chromaffin tissue
can release large amounts of serotonin.268, 269 Urinary
5-HIAA has been recommended for diagnosis of some
types of carcinoid tumor cases.270 Investigations of the
pathogenesis of serotonin secretion and high 5-HIAA
excretion in carcinoid heart disease showed no association with transforming growth factor beta or fibroblast
growth factor.271 Among patients with carcinoid tumors,

Table 6.8 — Relative Selectivity of New Antidepressants for Serotonin

5HT vs.
Norepinephrine
Selectivity

Likelihood for
elevation of
5-HIAA AND VMA
Low

Paroxetine

Over Noradrenaline and Dopamine Uptake230

Sertraline

5HT vs.
Dopamine
Selectivity

Likelihood for
elevation of
5-HIAA AND HVA

Citalopram

3900

Low
Paroxetine

1800
Fluvoxamine

1600

Fluvoxamine
Clomipramine

1200

Fluoxetine
Fluoxetine
Venlafaxine

3.1

Imipramine
Nefazodone

1.1

Amitriptyline
Clomipramine
Sertraline
Imipramine

0.65

Venlafaxine
Amitriptyline

0.91

Nefazodone

-

Antidepressive
Drug
Citalopram

1500

High

Antidepressive
Drug

High

The values show the relative selectivity for serotonin reuptake versus either noradrenaline or dopamine. Citalopram, with a ratio of 1500:1, is highly selective for
serotonin receptors, so it produces increased turnover of serotonin with corresponding tendency to deplete tryptophan pools with little effect on tyrosine demand
for noradrenaline production. Amitriptyline, on the other hand, has a ratio near 1:1, so it tends to cause increases in both neurotransmitters, thus increasing
the urinary concentrations of their catabolic products, 5-HIAA and VMA. For most of the drugs, the effects on dopamine relative to serotonin parallel those for
noradrenaline. A notable exception is that a patient using clomipramine is unlikely to show elevated HVA along with the elevating effect on 5-HIAA. The data do
not indicate the potencies for serotonin uptake. Thus, while citalopram is more selective than sertraline, it is a less potent serotonin reuptake inhibitor.

Table 6.9 — Serotonin Content

of Selected Foods

Food
Butternuts
Black Walnuts
English Walnuts
Plantain
Pecans
Pineapple
Kiwi fruit

5.8

Plums

4.7

Tomatos

3.2

Haas Avacado

1.6

Dates

1.3

Banana

0.9

affect the biosynthetic pathway for conversion of
guanosine triphosphate into BH4 via sepiapterin (see
Chapter 2, “Vitamins,” Figure 2.9). Mutation of the
sepiapterin reductase gene causes a loss of monoamine
neurotransmitters due to restriction of the insufficiency
of BH4. These patients have progressive psychomotor retardation, dystonia, and severe dopamine and serotonin
deficiencies, indicated by low levels of 5-hydroxyindoleacetic and homovanillic acids.283
Oxidation products of dopamine, epinephrine,
norepinephrine, serotonin and melatonin may act as
cumulative neruotoxins.23 The toxic effects of such products may interfere with one-carbon metabolism.24 Such
metabolic toxicant effects add potential significance to
findings of elevated VMA, HVA, and 5-HIAA, which are
the oxidized products of the neurotransmitters.
Severe neonatal epileptic encephalopathy has been
associated with decreased hepatic activity of the enzyme
aromatic-l-amino acid decarboxylase (AADC). An infant
with AADC deficiency showed improved clonic contractions with vitamin B6 therapy, apparently restoring activity to the vitamin B6-requiring enzyme that catalyzes the
conversion of 5-hydroxytryptophan and l-dihydroxyphenylalanine to serotonin and dopamine, respectively.
Urinary and CSF concentrations of VMA, HVA, and HIA
were decreased in the infants who responded to supplementation of vitamin B6 with improvement of clonic
contractions and lip-smacking automatisms, but died in
the third week of life.284

Serotonin mg/100 g

Grapefruit

Because of the magnitude of total body serotonin
synthesis, increased rates of serotonin turnover indicated
by elevated urinary 5-HIAA can lead to depletion of the
essential amino acid precursor, l-tryptophan. A very
high 5-HIAA result calls attention to potential deficiency
of tryptophan. The diversion of tryptophan away from
the kynurenin pathway also causes an increased risk of
niacin deficiency in carcinoid cancer patients.275 Plasma
amino acid analysis provides a useful, direct measure of
this amino acid (see Chapter 4, “Amino Acids”).
Since several commonly consumed foods contain
appreciable concentrations of serotonin, patients should
be advised to eliminate those foods for at least 12 hours
before gathering specimens for urinary 5-HIAA testing.
Table 6.9 shows serotonin content for some foods with
especially high levels. A single high serotonin meal made
up entirely of the foods shown in bold font in Table 6.9
produced a rise of urinary 5-HIAA to 5.6 µg/mg creatinine from a fasting concentration of 0.85 µg/mg
creatinine.276
The measurement of urinary 5-HIAA is sufficiently
sensitive to allow establishment of a low population normal limit. Individuals with values below this limit have
very low total body turnover of serotonin. Serotonin is
required for control of gut motility as it activates smooth
muscle activity. Inadequate serotonergic activity contributes to constipation.278 However, increased serotonin
output in response to constipation is the dominant effect
that has been reported.279 Ethanol consumption also
causes lowered 5-HIAA excretion, due to serotonin metabolism interference.280 When urinary 5-HIAA levels are
low, increased consumption of foods high in tryptophan,
including chicken, red meat, dairy products, nuts, seeds,
bananas, soybeans and soy products, tuna, shellfish, and
turkey can minimize the need for oral tryptophan or
5-hydroxytryptophan.
Acute appendicitis has been shown to produce
sharp elevation of 5-HIAA in controlled studies on
rats.281 The potential for serotonin production by enterochromaffin cells is illustrated by the magnitude of
urinary 5-HIAA increase in acute appendicitis. Sensitivity and specificity of 98% and 100% were found for discriminating appendicitis in clinically suspected patients,
using a cutoff of 20 µmol/L.282
Figure 6.13 shows the requirement for tetrahydrobiopterin to catalyze the initial hydroxylation reaction
to form 5-hydroxytryptophan. Human tissues may
be unable to produce sufficient BH4 when mutations

Kynurenate

OH

COOH

Quinolinate

NMDA Modulators

N

Kynurenic Acid

N

juxtaposition of signals, this pathway serves to either
activate or inhibit neuronal responses to acute and
chronic stress.293, 294
Kynurenic acid (KYNA) is an endogenous ligand
that antagonizes all types of ionotropic glutamate receptors. It has preferential affinity for the glycine-binding site of the N-methyl-d-aspartate (NMDA) receptor
that governs synaptic plasticity, learning and memory.
Intrathecal kynurenic acid has antinociceptive effects. It
interacts with endomorphin-1 in rats to decrease pain
perception.255 Other studies suggest that elevated KYNA
may represent a pathophysiological condition analogous to that seen in schizophrenic patients.295 Because
of the activity of pyridoxal-5-phosphate in this pathway
(discussed above), these effects may mediate the clinical
uses of vitamin B6 in treatment of neurological disorders. Even transient deficits of B6 may cause significant
shifts in brain physiology.296–297
Quinolinic acid (QUIN) provides a critical link between the immune system and the brain. Stimulation of
the inflammatory response causes release of interferongamma (IFN-γ) by macrophages. QUIN interacts with
NMDA receptors of glutamatergic neurons that respond
to pain and other peripheral signals. This biochemical event is the origin of the typical pain symptoms of
viral infections. If they are overstimulated, the neurons
can degenerate with permanent loss of brain function,
known as glutamate excitotoxicity.298 Their loss is associated with the effects of stroke and with the end stages
of HIV infection. Studies have shown that QUIN has a
role in the etiology of HIV-related neurologic dysfunction.299,300 QUIN is selectively elevated in spinal cords
of rats with experimental allergic encephalomyelitis,
where its neurotoxic effects are suspected to contribute
in the etiology of the disorder.265 Quinolinate toxicity
is also suspected as an etiologic factor in Alzheimer’s
disease. Immunohistochemical studies of brain sections
from patients with dementia revealed high quinolinic
acid due to up-regulated kynurenin pathway in the
hippocampus.301 Figure 6.16 illustrates the neuronal
release, binding and recycling of glutamate.
Toxicants can enhance sensitization of NMDA receptors, decreasing the threshold for QUIN-induced neuronal
loss. Rats exposed to methyl mercury at gestational day
8 show significant increases of brain QUIN at day 21,
suggesting that kynurenin pathway alterations may mediate mercury effects on brain development.302 The widespread exposure to phthalates in plastic products has also

Since stress is an important part of depression,
studies have measured both urinary HVA and 5-HIAA
and found them to have strong positive correlation with
depression.285 Because of the prevalence of enterochromaffin cells in the transitional gut, there is considerable
capacity of serotonin output in response to stress.286, 287
Various lines of evidence from animal studies
suggest gastrointestinal microbial origins for elevated
5-HIAA. In animal studies, microbes or microbial
toxins increase serotonin and 5-HIAA. When animal
feed is contaminated with yeast (Fusarium) mycotoxins,
serotonin and 5-HIAA are elevateld in the brain, along
with lowering of brain concentrations of tryptophan.288
Intraperitoneal injection of bacterial cell wall lipopolysaccaride increases dopamine catabolites, 5-HIAA, and
tryptophan in all brain regions.289 Cattle grazed on
fungal-infected fescue have high pituitary levels of 5HIAA.290 Guinea pigs and kittens exposed to Escherichia
coli endotoxins have elevated levels of 5-HIAA.291 This
evidence might explain why elevated neurotransmitter
turnover is frequently found with elevated dysbiosis
markers.

COOH

COOH

Quinolinic
Acid (Figure 6.14) has
The hepatic kynurenin
pathway
been discussed under “Xanthurenate” with regard to
evaluating vitamin B6 status. There are two other organic acid products of that pathway for which elevated
levels in urine can have quite a different meaning. The
kynurenin pathway in interferon-gamma-stimulated
macrophages, astrocytes, and microglial cells operates
as a mechanism of defense against intracellular pathogens and as a mediator of stress response signals to the
brain (Figure 6.15).292 Depending on the timing and

been shown to have potential for enhancing quinolinate
production by inhibition of an alternative tryptophan
pathway in rats.303
A useful outcome of the conversion of tryptophan
to QUIN is the ultimate production of nicotinic acid to
supply its cofactor form, NAD. This step requires the
enzyme quinolinic acid phosphoribosyl transferase for
the linkage of the adenosyl moiety of NAD. The transferase has low activity in the brain, thus giving rise to

Tryptophan, Kynurenin, Steroids
OH

Tryptophan

N

NH-CHO

ma

mi

e

NH2
O
C-CH2-C-COOH
H

N

K
mo ynu
noo ren
xyg in
ena
B2
se
B3

NH2

NH2
O
C-CH2-C-COOH
H

NH2

nur
eni
nas
e
B6

OH

Ky

3-Hydroxykynurenin

COOH
HOCH

HOOC
N

HOOC

O

C

C
OH

COOH

NH2

Fe2+
OH

3-Hydroxyanthranilate

NH2

2-Amino-3-carboxymuconate
semialdehyde

Mg2+
N

OH

COOH

## Xanthurenate

B6

Kynurenin

COOH

OH

B6

das

N-Formykynurenin

For

COOH

H
INF-γ
NF-κB

Kynurenate

K
tra ynure
nsa nin
min
ase

N
H

NADPH
NH3 Tryp
t
dio ophan
xyg -2
Ind
ena ,3se
Dio oleam
xyg ine
Heme O
NH2
ena
se
C-CH -C-COOH

K
tra ynure
nsa nin
min
ase

COOH

increased QUIN as an unprocessed intermediate. In the
liver QUIN may be largely processed to NAD.
Vaccination with measles virus induces INF-γ
stimulation of the gate keeper enzyme, indoleamine2,3-dioxygenase (IDO), for viral clearance.304-306 IDO
catalyzes the initial oxidation of tryptophan to start the
conversion to QUIN (Figure 6.14). IDO is stimulated by
glucocorticoid hormones, whereas estrogens oppose this
effect, reducing the rate of kynurenin pathway activity

Quinolinate

Nicotinate

2-Amino-3-carboxymuconate
decarboxylase (ACMSD)
HOOC

Polyunsaturated
fatty acids

N

Picolinate

Figure 6.14 — The Kynurenin Pathway
Entry of tryptophan into the kynurenin pathway is governed by tryptophan-2,3-dioxygenase that is subject to regulation by
tryptophan, NADPH, kynurenin and steroid hormones. When all enzymes are properly formed and cofactor status is good, the
pathway leads to either quinolinate or nicotinate, depending on tissue location as shown in Figure 6.15. The critical point for
vitamin B6 functional assessment is the pyridoxal-5-phosphate requiring kynureninase step. Cofactor insufficiency to sustain
this enzyme activity causes diversion of 3-hydroxykynurenin to alternative pathways leading to production of xanthurenate
and kynurenate. Omega-3 polyunsaturated fatty acids suppress transcription of ACMSD, decreasing picolinate production.

Tryptophan-2,3
-dioxygenase

Kynurenate

NADPH

3-Hydroxyanthranilate
Kynureninase

B6

L-Tryptophan

L-Tryptophan
3-Hydroxykynurenate

A

Tryptophan-2,3
-dioxygenase
Urinary
Kynurenate
## Xanthurenate
Kynurenate

NADPHQuinolinate

3-Hydroxyanthranilate

Nicotinic Acid

B6

Kynureninase

Hepatic and CNS kynurenin pathway products

A

3-Hydroxykynurenate
(A) In the liver the kynurenine pathway processes excess tryptophan to form nicotinic acid,
sparing dietary intake requirements for vitamin B3.
Urinary
Quinolinate
## Xanthurenate
(B) Immune and neuronal cells use the kynurenin pathway to produce quinolinic
acid as way of
Kynurenate
modulating brain activity. Their output of quinolinic acid (and, secondarily, kynurenic
acid) interacts
with NMDA receptors of glutamatergic neurons in the hippocampus and other regions of the brain to
Acid
increase activity by agonizing response to glutamic acidNicotinic
and glycine.

Hepatic and CNS kynurenin pathway products

(A) In the liver the kynurenine pathway processes excess tryptophan to form nicotinic acid,
sparing dietary intake requirements for vitamin
B3.
Inflammation
(B) Immune and neuronal cells use the kynurenin pathway to produce quinolinic acid as way of
modulating brain activity. Their output of quinolinic acid (and, secondarily, kynurenic acid) interacts
with NMDA receptors of glutamatergic neurons IFN-γ
in the hippocampus and other regions of the brain to
increase activity by agonizing response to glutamic acid and glycine.

B

Mg++ Na , Ca

Inflammation
GTP
GTP
Cyclohydrolase-1

L-TRP
IDO
L-KYN

KYNA

Neopterin IFN-γ

L-Glutamate
QUIN
Macrophage/Microglia
Astroglia/Neurons/Meninges
+

GTP
GTP
Cyclohydrolase-1

L-TRP
IDO

Mg++ Na , Ca

++

L-Tryptophan
L-KYNL-TRP
L-KYNKYNA
L-Kynurenate

Urinary
Quinolinate
Kynurenate
Neopterin
NMDA Receptor

B

IFN-γ
Dihydroneopterin
Triphosphate

Intermediates

NMDA Receptor

Na+ , Ca++

IFN-γ

++

+

L-Glutamate

IDO
Intermediates
KYNA

QUINGTP

Dihydroneopterin
Triphosphate

Indoleamine dioxygenase
Kynurenic acid

Neopterin

Guanosine triphosphate

Macrophage/Microglia
Astroglia/Neurons/Meninges

Na+ , Ca++

Figure 6.15 — Hepatic and CNS Kynurenin Pathway Products

L-Tryptophan
(A) In the liver the kynurenine pathway processes excess tryptophan to form nicotinic acid, sparing dietary intake L-TRP
L-KYN
requirements for vitamin B3. (B) Immune and neuronal cells use the kynurenin pathway to produce quinolinic acid as
way of L-Kynurenate
IDO
Indoleamine dioxyg
modulating brain activity. Their output of quinolinic acid (and, secondarily, kynurenic acid)Urinary
interacts with NMDA receptors
of glutamatergic neurons in the hippocampus and other regions of the brain to increaseQuinolinate
activity by agonizing response
KYNAto
Kynurenic acid
glutamic acid and glycine.
GTP
Guanosine triphosp
Kynurenate
Neopterin

interferon-α, may influence the magnitude and duration
of response of the macrophage kynurenin pathway.309
Since the gut is frequently a source of chronic inflammatory signal induction via INF-γ, there is reason to
suspect that QUIN elevation may indicate both inflammatory bowel conditions and neuronal degeneration.
Within the brain, the hippocampus is an area rich in
NMDA receptors, and it is very sensitive to the neurotoxic effects of QUIN. Because modulation of glutamatergic activity affects firing patterns of dopaminergic
neurons, there is potential for QUIN excursions to
disrupt the primary learning system.295 These responses
suggest that QUIN elevation following episodes such as

Glutamate

Presynaptic
Nerve Terminal
EAAC1
SN1
Glutamine
GLNase SN2

and sparing tryptophan. One net result of estrogen’s
action is increased plasma tryptophan concentration
compared with the estrogen unstimulated state.178
The glucocorticoid effect is apparently reversed with
chronic exposure, since repeated administration of
hydrocortisone causes decreased QUIN in rat brain.307
Further differentiation of kynurenin pathway activity
in macrophages and microglial cells is at least partly
achieved through variation of responses to nitric oxide.
In IFN-γ-primed macrophages, nitric oxide negatively
modulates the expression of IDO activity, whereas no
such response is found in microglial cells.308 Cytokines
other than INF-γ, especially tumor necrosis factor-α and

to CSF
Glutamine

GS

Glutamate

GLT-1
GLAST

NH3
Capillary

EAAC1

Astrocyte

Glutamate

NMDA

KA

AMPA

Postsynaptic
Neuron

Quinolinate

Figure 6.16 — Quinolinate Impact on Glutamatergic Neurons
This figure was first presented as part of the discussion of glutamate and glutamine in Chapter 4, “Amino Acids.” The
stimulation by quinolinate is added here to draw attention to the conjunction of factors that contribute to the overall clinical
outcome in a patient with both inflammatory and amino acid regulatory issues. The inflammation will agonize NMDA
glutamatergic receptors via quinolinate while fluctuations in neuronal glutamate will produce varying symptoms of hyperexcitability. The familiar scenario of a viral infection that produces generalized pain and hyper-sensitization to light is one
reference point regarding the type of symptoms experienced by patients when these metabolic disorders are present. NMDA,
AMPA and KA are synaptic glutamate receptors. EAAC1 and GLT-1 and GLAST are high affinity glutamate transporters.
SN1/SN2 is a glutamine transporter system and GS is astrocyte glutamine synthetase.

HOOC
N

Picolinate

quinolinic acids away from the excitotoxin and toward
the neuroprotectant, has anticonvulsant and neuroprotective properties.316 The laughing gas nitrous oxide is
such a powerful NMDA antagonist that it has potential
neurotoxic effects that are managed by coadministration
of GABAergic-inhibiting drugs.317 Magnesium effectively
competes for NMDA receptors to prevent calcium entry
into the neuron. Thus, magnesium sulfate infusion
can be an effective and inexpensive way to reduce the
morbidity and mortality associated with acute glutamate
toxicity in conditions like aneurysmal subarachnoid
hemorrhage.318 A similar protective effect of magnesium is found in protecting against death due to birth
asphyxia.319 Otherwise, the alternatives for offsetting
QUIN toxic effects are opioid drugs.320

Picolinic Acid route just prior to
Figure 6.15 shows an alternative
QUIN formation in the kynurenin pathway that leads to
the formation of picolinate instead of nicotinate in hepatic tissue. Dietary protein and fatty acids modulate the
enzyme a-amino-b-carboxymuconate-e-semialdehyde
decarboxylase (ACMSD) that controls this branch point.
High-protein diets induce large increases in ACMSD
activity through a mechanism unrelated to increased
tryptophan in the diets.321 Thus high-protein intake
shifts the processing of tryptophan away from nicotinate
production to picolinate. Polyunsaturated fatty acids,
on the other hand, divert flow through the kynurenin
pathway from picolinate to quinolinate by inhibiting
ACMSD.322 Diets high in omega-3 PUFAs have the largest effects, suppressing transcription of the ACMSD gene
and decreasing picolinate production.323 The PUFA-mediated suppression of ACMSD resulted in increased flow
of tryptophan into QUIN and the raising of serum QUIN
concentrations by approximately two-fold.

viral infections is a metabolic event with potential for
precipitating brain developmental disruption of the type
seen in regressive autism.
Because of the tight, positive association between
QUIN and IFN-γ, immune stimulation and increased
QUIN production may also be a key feature in the progression of events that lead to chronic fatigue syndrome.
An immunological dysfunction in patients with chronic
fatigue syndrome has been demonstrated by decreased
monocyte response to IFN-γ.310 In one set of patients
with chronic fatigue syndrome, CD4 T lymphocytes
have decreased IFN-γ production.311 However, during
acute and convalescent parvovirus B19 infection, circulating IFN-γ is associated with prolonged and chronic
fatigue.312 Elevated QUIN may be an indication of the
immune-mediated form of chronic fatigue. A patient
with particularly low INF-γ-stimulated QUIN production is shown in Case Illustration 6.6.
KYNA, a biochemical precursor to QUIN, is frequently found to be simultaneously elevated by inflammatory responses. KYNA production via the kynurenin
pathway is characteristically altered in relapsing-onset
multiple sclerosis.313 Patients in remission or not
progressing for at least 2 months have lower rates of
CSF KYNA formation.313 Early work showed that the
gateway enzyme for the hepatic kynurenin pathway,
tryptophan-2,3-dioxygenase, is highly inducible by corticosteroids, and urinary kynurenin excretion increases
in direct proportion to activity of this enzyme in the
liver.314 Patients with diseases like rheumatoid arthritis
that are characterized by chronic corticosteroid stimulation or those under hydrocortisone therapy may show
patterns of elevated kynurenate with normal or low
quinolinate.
Refer to Case Illustration 6.6

Because QUIN is a powerful agonist of the NMDA
receptors, and KYNA antagonized this effect, the relative
amounts of the two metabolites should relate to the
potential for neuronal degeneration. In inflammatory
diseases, the ratio of QUIN/KYNA is frequently found
elevated, so that neurotoxicity must be suspected.315
Efforts have been intensified to develop kynurenic
acid analogues as neuroprotectants for the treatment of
stroke and neurodegenerative disease. Any agent that
can change the balance of synthesis of kynurenic and

Notes:

Oxidative Damage and
Antioxidant Markers
Cell Proliferation
p-Hydroxyphenyllactate (HPLA)
HOOC

OH

p-Hydroxyphenyllactate
(HPLA) is a metabolite of
p-Hydroxyphenylacetic Acid
tyrosine. Elevated HPLA is associated with tumor growth
and leukemia.328 HPLA is also a marker of hepatic encephalopathy in patients with hepatic cirrhosis,329 and
urinary levels may be elevated in some inborn errors of
metabolism.330, 331 The parasite Trypanosoma cruzi has
been shown to secrete HPLA when grown in culture, but
no evidence has been presented to demonstrate elevated
levels in human urine due to T. cruzi infection.332
As early as 1975, studies in mice established the
blastomogenic activity of HPLA. Twice weekly 1.5 mg
doses induced leukemias, adenomas, hepatomas, tumors
of the vascular tissue, and benign and malignant tumors
and precancerous conditions of the urinary bladder.333
The methyl ester methyl-p-hydroxyphenyllactate
(MeHPLA) is an important cell growth-inhibiting agent.
Tumor cells contain esterase activities that hydrolyze
the compound to the free acid HPLA. Thus, the effects
of elevated HPLA may be due to depletion of MeHPLA.
MeHPLA binds strongly to nuclear sites, blocks estradiol
stimulation of uterine growth, and inhibits growth of
human breast cancer cells.334 HPLA, on the other hand,
binds more weakly to the same nuclear site and does
not block uterotropic responses to estradiol or inhibit
growth of breast cancer cells. Thus, HPLA is an important regulator of normal and malignant cell growth, and
it may mediate the cancer-promoting effects of estrogen.
MeHPLA is deficient in a variety of rat and mouse mammary tumors and human breast cancer preparations, and
this deficiency correlates with the loss of regulatory control.334 Other estradiol-potentiating effects are mediated
by toxins such as pertussis335 and cholera toxin.336 These
effects are worsened by high HPLA because of the loss
of regulatory control when MeHPLA is depleted. The

Picolinate is a potent activator of inflammatory
chemokines.324 Picolinate and QUIN are thought to act
in a concerted way to regulate leukocyte recruitment and
distribution into damaged tissues during inflammatory
responses.325 Anti-Candida activity of neutrophils is
augmented by adding 2 mM picolinate to the culture
medium, especially in the presence of INF-γ.326 Mouse
macrophage ability to restrict the growth of Mycobacterium avium was augmented by coadministration of picolinate and INF-γ. The bacterial cells showed acquisition
of metabolic changes typical of apoptosis. Similar results
were found for antifungal activity when macrophages
were pretreated with picolinate.327 One possible mechanistic link between picolinate and macrophage activity is
its ability to up-regulate inducible nitric oxide synthase
in activated cells.308
We may conclude that low-protein diets and high
intake of omega-3 fatty acids tend to divert tryptophan
degradation from picolinate to nicotinate production in
the liver. Independent mechanisms regulate macrophage
picolinate formation in order to modulate responses to
infectious agents.
Since quinolinate is a normal physiological regulator of immune and neuronal responses, one might ask
whether quinolinate could be too low. This question has
not been addressed in current literature. From what we
know about the origin of quinolinate, a patient with an
undetectable level might be suspected of low immune
response to normal inflammatory signals that would
produce interferon-γ. A case where this situation may be
present is discussed in Case Illustration 6.6. Such scenarios emphasize the tissue differentiation of kynurenin
pathway responses. The pathway intermediates that reflect vitamin B6 status originate from hepatic kynurenin
pathway flux, whereas accumulation of quinolinate is a
phenomenon of cytokine-stimulated neurons and immune cells. The case shows how information from fatty
acid testing can provide insight about potential origins
and treatments in such cases.
Notes:

DNA Oxidative Damage

8-Hydroxy-2'-deoxyguanosine (8-OHdG)
N

NH
N

NH2

O

N

HO

O

HO

OH

When inflammatory markers like quinolinate or
8- Hydroxy-2'-deoxyguanosine
metabolic enhancers like
p-hydroxyphenyllactate are
elevated, there is a need to know the overall impact of
increased production of reactive oxygen species (ROS).138
Sustained inflammatory responses and increased cell
proliferation rates cause increased production of reactive
oxygen species.340 When local antioxidant protection
fails to keep reactive oxygen species in check, there is
increased threat of clinical consequences from damage
to cell membranes, enzymes or structural proteins, and
DNA or RNA. 8-Hydroxy-2'-deoxyguanosine (8-OHdG)
is a product of oxidative damage to DNA.341 8-OHdG is
formed in a pro-mutagenic DNA lesion due to reaction
of oxygen radicals with guanosine groups in DNA. It
is recognized as a useful marker in estimating DNA
damage induced by oxidative stress. Oxidative DNA
damage is common in various forms of chronic liver
disease, suggesting a link between chronic inflammation
and hepatocarcinogenesis.341 The uniform increases of
8-OHdG with the stages of Parkinson’s disease led to

suggesting its use for evaluating the progression of this
disease.342 Elevations of 8-OHdG have been reported
in diabetic nephropathy343 and chronic obstructive
pulmonary disease.344 Case Illustration 6.7 shows
actual laboratory results in a patient with COPD. In
studies published in 2006, human conditions where
oxygen radical damage has been assessed by measuring
urinary 8-OHdG include ultraviolet protection
of skin,345, 346 bladder cancers,347 hemodialysis,348
cardiomyopathy,349 insomnia,350 environmental toxin
exposures,351 diabetes,352 effects of cigarette smoke,353
arsenic poisoning,354 and depression.355 The potential
for genotoxicity from sidestream cigarette smoke
was also demonstrated by finding increased 8OHdG
production.356 Most studies measure 8-OHdG in urine.
Leukocyte 8-OHdG was found to be lower in lifelong
smokers, indicating the inappropriateness of this
specimen for assessing oxidative stress.357
The antioxidant protection in young children
was evaluated by urinary 8-OHdG.358 Formation of
8-OHdG is sufficiently sensitive to reveal even mild
chronic effects of ROS. The association of cancer with
chronic psychological stress and perceived overwork
may be via the formation of 8-OHdG.359 Increases in
8-OHdG with cigarette smoking is associated with aging
and enhancement of oxidative damage in human lung
tissues.360 8-OHdG levels rise with age in adults with
mild hypercholesterolemia and/or mild hypertension.361
Lower levels of antioxidants may predispose to
oxidative stress, which is manifested by higher levels of
8-OHdG. Levels of 8-OHdG were significantly higher
in atherosclerotic patients, and vitamin C levels were
significantly lower. This oxidative stress may promote and
worsen atherosclerosis.362 Exposure to organochlorines
does not result in elevated 8-OHdG, indicating that the
genotropic effects of this compound are exerted through
mechanisms other than ROS formation.363 Moderate
alcohol consumption seems to have the overall effect of
reducing DNA damage in some individuals as shown by
the decrease in 8-OHdG levels.364

cell proliferative stimulation of hepatic encephalopathy
is manifested as elevated urinary p-hydroxyphenyllactate.329 This effect may be mediated by HPLA inhibition
of brain Na+, K+-dependent ATPase.337
Elevated levels of HPLA result in a dramatic
decrease of ascorbic acid concentration in the liver,
adrenal glands, and blood.338 High doses of ascorbic acid
(100 mg/kg body weight daily) were shown to arrest or
significantly inhibit the excretion of HPLA in patients
with hemoblastoses and nephroblastoma.339 Thus,
high urinary HPLA signals an increased tissue growth
response that may be associated with neoplastic disease
or increased growth of normal tissue. The dramatic
responses to ascorbic acid suggest its involvement in
mediating this level of cell growth. Tissue saturating
levels of vitamin C should be considered in patients with
elevated HPLA.

Refer to Case Illustration 6.7

Diabetics tend to have higher urinary 8-OHdG
excretion than healthy controls and the levels are
related to the severity of tubulointerstitial lesions.
Oxidative stress may contribute to the progression

of tubulointerstitial injury in patients with diabetic
nephropathy.365 In a study of the analytical performance
of 8-OHdG measurements, no significant difference
between the mean group levels of 8-OHdG/creatinine in
spot urine and in 24-hour urine was observed.366 Thus,
a first morning urine specimen is adequate for 8-OHdG
measurements.

Tyrosine
Tyrosine
transaminase

B6

p-Hydroxyphenylpyruvate

Homogentisate (HGA)
p-Hydroxyphenylpyruvate
hydroxylase

HO
COOH

Ascorbate
Fe+2

Homogentisate

OH

Fe+2

Homogentisate-1,
2-dioxygenase

Toxic
benzoquinone
acetate

Fumarate + Acetoacetate

Figure 6.17 — Homogentisate Formation in

Catabolism of Tyrosine

The catabolism of tyrosine requires the genetically
susceptible enzyme homogentisate-1,2-dioxygenase.
Deficiency of this enzyme produces alkaptonuria with
characteristically high urinary levels of homogentisate,
and generation of toxic consequences by direct binding
to connective tissue and DNA oxidation due to the
alternative product, benzoquinone acetate.

The liver must provide a mechanism for clearing
postprandial tyrosine that exceeds utilization demands.
This pathway starts with tyrosine participating in the vitamin B6-dependent hepatic transamination system that
converts amino acids to their keto analogues. Tyrosine,
thus, is converted to p-hydroxyphenylpyruvate, and a
subsequent vitamin C-dependent oxidation produces
homogentisic acid (HGA) (Figure 6.17). The third
reaction is an oxidation step catalyzed by homogentisate-1,2-dioxygenase, assisted by iron. This enzyme is
deficient in people with the condition called alkaptonuria (AKU), and results in an elevated HGA. AKU was
first recognized from the characteristic symptom of urine
turning from straw colored to black, along with dark
blue color development in ears and eyes.18-20 The pigmentation, called ochronosis, arises from homogentisate
polymerization.21 Arthritis and nephrolithiasis are common clinical features in alkaptonuric patients.
Because the only observable signs of HGA deposition are pigmentation in connective tissues and
arthropathy that worsens with age, AKU was initially
considered to be an inborn metabolic disease with few
clinical consequences.22 However, more recent discoveries of the insidious metabolic effects of HGA have
changed the outlook for AKU patients. Excess HGA
is now known to produce oxidative effects on human
hemoglobin,23 to add significant risk of coronary heart
disease,24 and to produce oxidative damage to DNA24
with potentially mutagenic effects. Thus, elevated HGA
is not a harmless metabolite, but one that should be
managed at the earliest possible date of detection. AKU
is managed by restriction of tyrosine loading using a
low-protein diet, the success of which is monitored by
a lowering of urinary HGA.25 In addition, high doses of

Homogentisic Acid

Binding to
connective
tissue
ascorbic acid lower the binding of HGA to connective
tissue, lessening one of the clinical consequences of the
disorder.26 High levels of HGA also result in oxidation
to the alternative metabolite, benzoquinone acetic acid
that is a likely cause of the toxic consequences of the
disorder. DNA oxidative damage with increased excretion of 8-hydroxy-2'-deoxyguanosine has been observed
with HGA elevation.27 Treatment of AKU neonates with
high doses of ascorbic acid has been shown to reduce
the production of benzoquinone acetic acid.28 Combination protein-tyrosine restriction and high-dose ascorbic
acid can effectively lower urinary homogentisate and
relieve the joint pain reported by adults with the disorder.29, 30 Drugs that inhibit the enzymes of the pathway
can successfully lower HGA excretion, but may produce
elevations of plasma tyrosine with unknown long-term
side effects.19, 31
Quantitative clinical laboratory testing for urinary
homogentisate is challenging because the compound can

degrade rapidly during transport. For neonatal qualitative detection of alkaptonuria, the specimen should
be tested within two hours of collection or frozen and
shipped on dry ice and kept frozen until tested. Quantitative testing for lower levels to detect subtle metabolic
imbalances is even more susceptible to inaccuracy from
degradation. Even under frozen conditions homogentisate degrades so readily that accuracy of measurement
may be compromised unless the specimen arrives at the
laboratory frozen less than 2 days after collection.

Xylene
P450
2-Methylbenzoate
Glycine

2-Methylhippurate
Figure 6.18 — Metabolism of Xylene

Detoxification Markers

2-Methylhippurate
H
N

COOH

Xylene exposure

O

3- and 4-methyl isomers as well. With properly chosen
techniques, all of the isomers may be measured, allowing
detection of exposures to multiple xylene mixtures.367, 368
Xylene is a very common solvent found in paint
thinners and building products, fuel and exhaust fumes,
and industrial degreasers and solvents. Spray-painting workers show elevated methylhippurate, indicating
recent exposure to xylene.369 Both spot urine specimens
collected at the end of the work day and 24-hour urine
specimens showed high correlation with time-averaged paint-worker exposures.370 Patient counseling
in avoidance is indicated. Worker habits of smoking
and drinking in combination were found to suppress
the conversion of xylene to methylhippurates.371 The
importance of screening of methylhippurates in human
urine for evaluating occupational exposure is indicated
by the appearance of special analytical methods for their
measurement, such as micellar electrokinetic capillary
chromatography and LC/MS-MS.17, 372

Chapter 8, “Detoxification,” is devoted to the
subject of evaluating patient detoxification status or
biotransformation capacities. The compounds discussed
in detail here will be reintroduced there in relationship
to tests other than profiling of urinary organic acids.
The organic acids of this group serve as biomarkers of
distinct parts of the detoxification system, providing
insight about both exogenous toxin accumulation and
endogenous detoxification responses.

The highly water-insoluble xylene molecule is oxidized to
2-methylbenzoate by hepatic P450 cytochrome systems
(Phase I of detoxification) and then conjugated with
glycine by
glycine6.19
conjugase
(Phase II of
of detoxification)
to
Figure
Metabolism
Xylene
form 2-methylhippurate that appears in urine.

CH3

OH

2-Methylhippurate
2-Methylhippurate
is a by-product of the detoxification of the common solvent xylene, which is first
oxidized via hepatic P450 oxidase enzymes to 2-methylbenzoate. This organic acid is then conjugated with
glycine to form the peptide product, 2-methylhippurate
(Figure 6.18). The conjugation reaction requires formation of an acyl ester with coenzyme A. The potential for
enhancing clearance by assuring adequacy of the substrate (glycine) and the essential precursor of coenzyme
A (pantothenic acid) is discussed in more detail below
under “Benzoate and Hippurate.” Although the 2-methyl
isomer is the most abundant in most xylene preparations, the common solvent grade of xylene contains

Notes:

Ammonemia
NH4 + CO2 = 2ATP
Ammonia

Orotate
O

H3N-C-O-PO3=
=

NH
HN

COOH

O
Carbamoyl phosphate

O

Orotate
Urea
Figure 6.19 — Orotate and Ammonia

When the capacity of the major ammonia clearance
Figure
6.20
and
Ammonia
system, the
hepatic
andOrotate
renal urea
cycle,
is exceeded, the
optional conversion of carbamoyl phosphate to orotate
increases to clear the toxic ammonia.

above 10 g/d in adults can result in elevation of urinary
orotate due to increased ammonia generated from hepatic
oxidative deamination reactions.385 Although high-protein
diets might be suspected of contributing to ammonemia,
studies in rats have shown that, in these animals, highprotein intake induces sufficient glutamate synthesis in
perivenous hepatocytes to assist with the increased ammonia production.386 To the extent that a patient with high
urinary orotate is able to mount such responses, they may
tolerate high-protein diets. However, genetic polymorphic
effects predict that such ability may not be found in all
patients.

Orotic
Details of how ammonia
is Acid
cleared by the action
of the urea cycle were presented in detail in Chapter 4,
“Amino Acids,” where the urea cycle was diagrammed in
Figure 4.9. When there is insufficient capacity for detoxifying ammonia via the urea cycle, carbamoyl phosphate
leaves the mitochondria and stimulates the synthesis of
orotic acid (orotate)373 (Figure 6.19). Increased orotate
production is a sensitive indicator of arginine deficiency.374 Symptoms that develop following arginine deprivation can largely be accounted for by a decreased efficiency of ammonia detoxification and reduced formation
of nitric oxide. The reader may refer to the section “The
Urea Cycle and Nitrogen Management” in Chapter 4 for
discussion of the common symptoms of ammonemia.
Mild or late onset forms of inborn errors of urea-cycle
enzyme defects, such as ornithine transcarbamylase
(OTC) deficiency, may also lead to increased orotate and
ammonia levels.375, 376 Increased orotate biosynthesis is
observed with increasing ammonia concentrations in rat,
mouse and human liver. Orotate production is reduced
by in vitro arginine supplementation due to stimulation
of urea cycle activity.121,377 Hyperammonemic attacks and
urinary orotate excretion were both decreased significantly following arginine supplementation in patients
with late-onset ornithine transcarbamylase deficiency.374
Magnesium deficiency can also have adverse effects on
urea cycle enzymes378 and can be a cause of reversible
renal failure.379 In addition, orotate requires magnesium
for its metabolism. Although a normal level in a urinary
organic acid panel may not necessarily indicate magnesium sufficiency, high levels should alert one to a significant possibility of intracellular magnesium insufficiency,
especially in patients with kidney failure.380, 381
Intestinal bacterial overgrowth should always be
suspected in cases of chronic ammonemia. Although
cases of overgrowth severe enough to produce cirrhosis or coma are rare,382-384 patients with mild, transient
ammonemia may be detected on routine urinary orotate
assessment. Oral glutamine supplementation at levels
Hepatic Phase I and II Activity
Glucarate
OH

OH

COOH
HOOC
OH

OH

Various aspects of major detoxification pathways are
Acid 8, “Toxicants and
discussed in more detail inGlucaric
Chapter
Detoxification.” Glucaric acid (glucarate) is a by-product
of the predominant liver hepatic phase I detoxification reactions involving cytochrome P450 oxidation
of glucose to glucuronic acid, the substrate for phase
II conjugation reactions. Hepatic output of glucarate
is accurately reflected by urinary levels, and glucarate

Table 6.10 — Classes of Compounds Cleared by Glucuronidation401

Class

Examples

Polycyclic aromatic hydrocarbons

Benzo(a)pyrene, benzanthracene, naphthalene

Various nitrosamines

Cured meats, tobacco products, rubber products, pesticides

Fungal toxins

Aflatoxin

Steroid hormones

Estrogen, testosterone

Heterocyclic amines

Well-done, fried, or barbequed meats

Pharmaceutical drugs

Aspirin, lorazepam, digoxin, morphine

Vitamins

Vitamins A, D, E and K

may lead to oxidative stress, high levels of P450 activity,
and reduced capacity for phase II conjugation reactions.
Patients suffering from toxic burdens may experience a
wide range of symptoms, among them fatigue, headaches, muscle pain, mood disorders and poor exercise
tolerance. Researchers have reported that many chronic
fatigue syndrome patients have disordered liver detoxification ability and show signs of increased toxic
exposure.399
Hepatic phase II conjugation reactions convert fatsoluble substances to water-soluble forms for elimination. The major phase II pathways generate mercaptan
(glutathione), methyl, sulfate, glycine, and glucuronide
conjugates. Markers for all of these pathways may be
found in a profile of organic acids in urine. Assessment
of the metabolic status of these major detoxification processes assists in understanding the body’s capacity to detoxify foreign substances, and thereby prevent long-term
damage from their continued exposure. Measurement of
glucarate in urine serves as a specific biomarker for glucuronidation.400 Elevations in urinary glucarate specifically suggest exposure to pesticides, herbicides, fungicides,
petrochemicals, alcohol, and drugs.
The ability of the laboratory to measure glucarate is
determined by the type of sample preparation chosen.
Glucarate is extremely water soluble and does not move
into the organic solvent layer when methods requiring
solvent extraction are used. Newer methods utilizing
LC-MS/MS technology may report glucarate because no
solvent extractions are performed.

excretion is an indicator of overall hepatic detoxification
demand.387
The clinical significance of endogenous glucarate
production should not be confused with the cancerprotective role of oral supplementation with glucarate
salts, which decreases the enterohepatic circulation of
carcinogens.388 β-Glucuronidase produced by intestinal
bacteria can increase the enterohepatic circulation of
carcinogens.389 Oral d-glucarate is converted into the
potent β-glucuronidase inhibitor d-glucaro-1,4-lactone
under the influence of stomach acid. Urinary glucarate is
influenced by oral glucarate supplementation (usually as
calcium d-glucarate), because most absorbed glucarate is
cleared in urine.390
The liver produces glucuronate for use in phase II
conjugation reactions.391, 392 The best-known example
is glucuronate conjugation of the hemoglobin degradation product bilirubin as a final preparation for urinary
excretion. A great variety of drugs, food components
and products of gut microbial metabolism are prepared
for excretion by glucuronidation (Table 6.10). The
by-product glucarate can become elevated as an indication of enzyme induction due to such potentially toxic
exposures that induce greater rates of glucose oxidation
to glucuronic acid.393-395 Metabolic challenges that result
in stimulation of hepatic P450 activity tend to produce
increased excretion of glucarate. Urinary d-glucarate,
for example, is elevated during rifampicin/streptomycin
treatment396 and in pesticide-exposed groups.397 Both of
these exposures induce mixed function oxidase activity.
Glucarate measurements have been advanced as useful
biomarkers to xenobiotic exposure, being particularly
useful as a screening tool for xenobiotic exposure in
reproductive epidemiology.398
Long-term exposure to environmental pollutants
and continued toxic load to the detoxifying systems

Notes:

Glutathione Status
	α-Hydroxybutyrate (2-Hydroxybutyrate)
OH
H 3C

COOH

to load reducing equivalents (-H) onto NAD. Alcohol
consumption and insulin-stimulated glucose uptake
raise this ratio. See Chapter 9, “Oxidative Stress and
Aging,” for further discussion of the novel concept of
reductive stress.
Smoking, poor diet, and lack of exercise significantly inhibit the activity of AHBD, suggesting that urinary
elevation of AHB may be related to these factors.408 High
AHB is also found during phases of increased lymphocyte destruction in infectious diseases such as measles.409
Elevated AHB is found in birth asphyxia and in the
inherited metabolic diseases such as “cerebral” lactic
acidosis, glutaric aciduria type II, dihydrolipoyl dehydrogenase (E3) deficiency, and propionic acidemia.405
All of the conditions that have been associated with
increased AHB excretion may be related to increased
rates of hepatic glutathione synthesis from methionine
(Figure 6.20).
Elevated AHB, thus, shows increased flow through
the transsulfuration pathway as required during times of
increased demand for glutathione for meeting oxidative
stress or for detoxification functions. Other signs, such
as urinary pyroglutamate and sulfate, discussed below,
must be assessed to determine a patient’s ability to

a-Hydroxybutyrate
α-Hydroxybutyrate
(AHB) was mentioned briefly in
Chapter 4, “Amino Acids,” in the discussion of threonine
catabolism. It was pointed out that the contribution
of the threonine pathway constitutes a fairly constant
background amount of AHB because threonine intake
is small compared with most other amino acids, and
the alternative pathway of oxidation of the precursor
α-ketobutyrate to propionate is favored over reduction
to AHB under most conditions.402 Although there is little
direct evidence to date, the dominant source of urinary
AHB seems to be the conversion of cystathionine to
cysteine (see Chapter 4, “Amino Acids,” Figures 4.13
and 4.20). The activity of this pathway is highly variable, changing in response to demands for protection
against oxidative stress. As oxidative stress increases, the
flow of homocysteine shifts away from transmethylation
to methionine toward transsulfuration to cystathionine
in order to increase the flux of cysteine into glutathione synthesis.403 Thus, AHB production can be directly
Methionine
related to the rate of hepatic glutathione synthesis. This
reciprocal regulation of homocysteine flux is illustrated
in Figure 4.20.
Homocysteine
Serine
Myocardial tissue has high activities of the enzyme
α-hydroxybutyrate dehydrogenase (AHBD), which
catalyzes oxidation of AHB. The activity of AHBD on the
Cystathionine
second day after a myocardial infarction is a marker for
α-Ketobutyrate
estimates of infarct size and a measure of reperfusion
NADH
effectiveness.404 The intense energy demand of cardiac
Cysteine
NAD+
muscle is likely the reason for such high concentrations
α-Hydroxybutyrate
of AHBD in that tissue, because AHB strongly inhibits
mitochondrial energy metabolism as measured by CO2
Glutathione
production.405 Studies on rat liver mitochondria show
strong responses of enzyme activities that maintain a
Figure 6.20 — Alpha-hydroxybutyrate Formation
From Glutathione Biosynthesis
high NADPH/NADP+ ratio needed to recycle glutathione
As
the
rate

hepatic
and From
small intestinal
cysteine
Figure
6.21
Alpha-hydroxybutyrate
Formation
Glutathione
Biosynthesis
to the reduced state. Elevation of this ratio has been
formation
for
glutathione
synthesis
increases,
the byproposed as the explanation of high AHB excretion in
product α-hydroxybutyrate can be passed into urine at
extreme situations such as heavy alcohol consumphigher concentrations. When the conversion is limited by
tion.407 Any conditions that result in high activity of
availability of methionine (and homocysteine) the lower
+
rate of glutathione production can be reflected by falling
carbohydrate oxidation can raise the NADH/NAD ratio,
α-hydroxybutyrate in urine.
because the extramitochondrial oxidative pathways tend

sustain this flow. It is also possible to find some patients
in late stages of chronic glutathione and methionine
depletion who have such low capacity to generate the
transsulfuration flow that their AHB is normal. These
patients generally show low plasma methionine and taurine. Three scenarios of glutathione markers are shown
in Case Illustration 6.8.

Pyroglutamate (5-Oxoproline)
COOH
NH

Pyroglutamate is created
in the
γ-glutamyl cycle
Pyroglutamic
Acid
(GGC), a pathway that is highly active in renal tubules
and anywhere there is a high demand for glutathione
(Figure 6.21). When cytosolic glutamate is abundant,
the GGC functions without forming γ-glutamyl amino
acid bonds to achieve net glutathione synthesis. The
amino acid reabsorbing function of the GGC may be
unique to renal tissue. When the γ-glutamyl peptide
bonds are broken, instead of releasing glutamate, the
reaction produces the cyclic pyroglutamate that must be
opened by 5-oxoprolinase to regenerate glutamate. In
healthy individuals, a very modest amount of pyroglutamate is spilled in the urine because the rate of pyroglutamate conversion to glutamate for glutathione reformation keeps pace with the rate of γ-glutamyl amino
acid formation.410 The enzyme that initiates the cycle,
γ-glutamyl transpeptidase (GGT) is very abundant in hepatocytes, and this fact has led to the use of serum GGT
activity as a primary differential diagnostic tool for liver
disease because damage to hepatocytes causes release of
the enzyme into blood.411, 412 Although liver pathology is
indicated when serum GGT is elevated, other signs appear in cases of GGT deficiency.
Gene defects are known to cause deficiency of GGT.
Cell regulation by leukotriene production from polyunsaturated fatty acids is affected in individuals with GGT
deficiency because cysteinyl-leukotriene C4 (LTC[4])
fails to be cleaved to LTD(4), producing a total lack of
LTD(4).413 Growth failure, shortened life spans, and
infertility are found in mice with genetic GGT deficiency.414 The enzyme 5-oxoprolinase that converts the
ring form to the open-chain glutamate form may also be
defective. Hereditary 5-oxoprolinase deficiency can produce profound pyroglutamic aciduria. Developmental

O

delay has been reported in cases of human of 5-oxoprolinase deficiency.415, 416 Glutathione synthase deficiency is
the most common genetic defect seen in the GGC pathway.417 The autosomal recessive form of this defect in the
γ-glutamyl cycle causes recurrent kidney stones, whereas
the homozygous expression results in vomiting, diarrhea, and abdominal pain.418, 419 Defects in the enzyme
that accomplishes the final reaction for reformation of
glutathione produce quite different clinical outcomes.
Extreme pyroglutamic aciduria (also known as 5-oxoprolinuria) is found in patients with a polymorphism
in glutathione synthase characterized by metabolic
acidemia, hemolytic anemia, and central nervous system
damage.420 The enzymatic defect causes decreased
levels of cellular glutathione that greatly stimulates the
synthesis of γ-glutamylcysteine that cannot be utilized
because the defective enzyme drives the final glutathione
reforming step. Cysteine is released for further protein
and peptide synthesis along with pyroglutamate that
simply spills into the urine. Enzyme polymorphisms
can often be mild enough to escape detection until late
in life, if at all. Complaints of malaise and anorexia by
a 48-year-old man were idiopathic until organic acid
profiles revealed the cause of recurrent high anion gap
as consistent pyroglutamic aciduria, indicating a genetic
alteration in the γ-glutamyl cycle.421 Other cases of mild
impairment may become noticed only when drugs like
acetaminophen place stress on hepatic glutathione pools
and pyroglutamic aciduria causes elevated anion gap.422
As glutathione fails to be recovered in the
γ-glutamyl pathway, a concurrent reduction in total
body sulfate may be found (see below). Studies showing
an age-related decline in expression of glutathione synthase in rat liver suggests that this problem may be more
prevalent in older patients.423 Preformed glutathione or
Notes:

Burn patients excrete higher than normal amounts
of pyroglutamate, whereas their blood levels of glutathione are lowered and their rate of glycine synthesis
is decreased.429 The possibility that glutathione reformation by glutathione synthase can be limited by the
supply of glycine has been demonstrated in several
ways. Dietary glycine restricts glutathione formation
on the order of the effect produced by limiting sulfur
amino acid availability.430 Urinary pyroglutamic aciduria
has been proposed as a marker for glycine deficiency.431
During dietary protein restriction, glutathione synthesis
is limited. If glycine conjugation demand concurrently
is increased in healthy human subjects by methionine
loading, then pyroglutamate excretion increases because
of lowered availability of glycine. Under these conditions
urinary pyroglutamate is positively related to urinary
sulfate in a linear manner over the entire sulfate concentration range.432 These results indicate the diversion of

supplemental NAC may be used along with antioxidant
supplementation to build glutathione levels.424-426 Additionally, as shown in Figure 6.21, ATP (as Mg++-ATP)
is required in three steps. If any compromise in energy
production occurs, an increase in pyroglutamate could
theoretically be noted. Alternatively, drugs that require
glutathione conjugation can cause failure to sustain
glutathione adequacy. This effect has been reported in
acetaminophen toxicity.427 Elevated pyroglutamate following such normal drug use indicates a mild polymorphism that is revealed only under increased detoxification stress. In mammary tissue the γ-glutamyl cycle
may serve as a signaling pathway where pyroglutamate
stimulates amino acid metabolism. As usually is found
in studies of antioxidant systems, the over-use of NAC
and other glutathione inducers can cause adverse metabolic stress, so monitoring of progress with laboratory
evaluation is warranted.428

Cys-Gly

GSH Synthase

ATP

Glycine
Peptidase

γ-Glutamyl amino acids

γ-Glutamylcysteine
ADP + Pl

Cysteine

γ-Glutamyl
cyclotransferase

γ-Glutamylcysteine
synthetase

Amino acids in blood

ADP + Pl

γ-Glutamyl
transpeptidase

Amino acids in renal filtrate

Glutathione
(GSH)

Kidney

GLUTATHIONE
UTILIZATION

Pyroglutamate

Glutamate
Pyroglutaminase

ATP

GLUTATHIONE
RECOVERY

Urine
ATP

ADP + Pl

Figure 6.21 — The γ-Glutamyl Cycle
Rather than the usual alpha carboxyl peptide linkage, the gamma linkage of the glutamyl residue in glutathione is very
unique among peptide structures in human tissue. One consequence is to make oral glutathione persist in the presence of
pancreatic enzymes that degrade other peptides and proteins. Another is to make γ-linked amino acids unsusceptible to
proteolytic attack and therefore to allow their safe transport. The γ-glutamyl cycle steps that link glutamate, cysteine and
glycine serve to achieve net synthesis of glutathione, especially in the liver. In the kidney, γ-glutamyl transpeptidase generates
γ-glutamyl amino acids for transport from glomerular filtrate back into blood in the tubules of the kidney. The transport
process results in degradation of the glutathione peptide that must be reformed to sustain body glutathione levels. Restricted
mitochondrial ATP generation or low levels of available cysteine or glycine are factors that prevent the efficient reformation
steps, leading to elevated urinary pyroglutamate.

laboratory. Relative frequencies of moderate-to-severe
occurrences of elevated pyroglutamate are apparent from
inspection of the figure. N-acetylcysteine (NAC) is an
effective oral agent for rebuilding total body glutathione,
and oral taurine spares sulfur amino acids while providing an effective antioxidant.

Urinary Pyroglutamate
Pyroglutamate (µg/mg creatinine)
Reference
Limit
Sulfate
O
1534

1461

1388

1315

1242

1169

1096
1023
O
−
O

−

Case

Figure 6.22 — Distribution of Pyroglutamate Results

O

Sulfate is the ionic form of an inorganic rather than
Sulfate
organic acid. It may be included on panels of urinary
organic acids because of the important information it
provides about sulfur metabolism. For example, the
protein synthesis disruption of zinc deficiency causes
decreased incorporation of cystine into proteins with
concurrent large increases in urinary sulfate and taurine
from cysteine degradation.435 The rise in sulfate parallels
the depth of zinc deficiency, indicating that, if other
sulfate sources are normalized, urinary sulfate can be a
metabolic marker of the severity of zinc deficiency.
The sulfation pathway is used in phase II liver
detoxification for biotransformation of many drugs,
steroid hormones, phenolic compounds, and others.
The addition of a sulfate group increases water
solubility of hydrophobic compounds in preparation
for their excretion in urine (see Chapter 8, “Toxicants
and Detoxification”). The ratio of urinary sulfate to
creatinine has been used to assess total body reserve of
sulfur-containing compounds (especially glutathione)
used in phase II pathways.436 When the ratio of sulfate
to creatinine is low, these stores need replenishment.
Glutathione administration with oral N-acetylcysteine,
taurine, and salts of sulfate are used in combinations
to replenish sulfur pathways and restore the hepatic
supply of inorganic sulfate.437

methionine-derived cysteine from glutathione to sulfur
synthesis as glycine limitation worsens. See Chapter 4,
“Amino Acids,” for more in-depth discussion of sulfur
amino acid relationships.
Small amounts of pyroglutamate are always present in overnight urine because it is produced as an
intermediate in a cycle used in the active transport of
amino acids in renal tubules.433 Since the appearance of
a micromole of pyroglutamate in urine is accompanied
by the recovery of a micromole of amino acids into the
renal blood supply, we might think of the situation as
one where glutathione is wasted in order to prevent
massive essential amino acid loss. Up to one-third of
the glutathione circulating in blood may be used in this
amino acid recovery process.
Since pyroglutamate may be formed by heating
of foods that contain high amounts of glutamic acid,
urinary pyroglutamate may have dietary origins. Foods
high in glutamic acid include artificial diets where
glutamate is used as a flavor enhancer and high-protein foods, such as meats and eggs and dairy products.
This effect is of particular concern in neonatal diagnosis where normal infants consuming breast milk are
compared with those on formulas that are heated.434
Reference ranges established on large out-patient
adult populations will reflect normal intake of dietary
pyroglutamate.
Figure 6.22 shows results for urinary pyroglutamate in 1,500 sequential cases submitted to a clinical

The cutoff of 80 µg/mg creatinine is indicated by the
shaded bar. A large number of individuals have some
degree of wasting of glutathione and some individuals
are in a state of severe depletion, which can effect
detoxification and protection against free radical damage.

S

Refer to Case Illustration 6.8

Severe depletion of organic sulfur sources will
cause simultaneous high pyroglutamate and low sulfate
excretion. High pyroglutamate with normal sulfate indicates inadequate organic sulfur sources for production
of cysteine required for glutathione synthesis. Only

Intestinal
Dysbiosis Markers

The abnormal overgrowth of microflora in the
small and large intestine is sometimes referred to as “gut
dysbiosis” in order to distinguish this clinical condition
from that of infection. Dysbiosis has been related to a
wide variety of symptoms due to pathogenic toxins produced by the populations of microflora. Many high molecular weight products such as cholera toxin can exert
toxic consequences directly in the intestinal cells. Small
molecular weight products can appear in urine, revealing metabolic activities of the microbes that inhabit the
mucosal layer and lumen of the gut (Figure 6.23). The
compounds have a wide range of relative toxicities, with
cresol near the upper end and hippurate and benzoate at
the lower end.
Among the factors that lead to dysbiosis, importance of mealtime habits should not be overlooked
because of the power to restore intestinal health by
allowing normal stomach emptying rate and adequate
flow of gastric and pancreaticobiliary fluids. A much
more extensive discussion of tests that may be used for
evaluating digestive and microbial status of the gastro-

organic sulfur in the form of compounds such as
N-acetylcysteine or methionine along with adequate
glycine will restore normal glutathione levels. Normal urinary pyroglutamate with low sulfate levels can
occur in individuals with impaired sulfate activation.
In these cases, rapid replenishment of hepatic sulfate
may be accomplished with either sulfur donors like
N-acetylcysteine or inorganic sulfate such as sodium
sulfate.436 On the other hand, a well-nourished patient
under temporary metabolic stress of detoxification from,
for example, use of acetaminophen, may have elevated
α-hydroxybutyrate, signaling the increased rate of hepatic glutathione synthesis, but have no need for amino
acid or glutathione therapy due to a normal sulfate level.
An individual with limited ability to produce glutathione
may show the glycine depletion sign of high pyroglutamate and low sulfate. This patient is a candidate
for glutathione administration along with glycine and
N-acetylcysteine or methionine, and their taurine status
should be monitored, since depletion of other sulfurcontaining compounds is likely. Urinary sulfate has also
been shown to reflect intake of sulfiting agents widely
used as food additives.438

Dietary
Polyphenols

Bacteria

COMPOUND APPEARING
IN URINE
• Benzoate & Hippurate
• Phenylacetate
• Phenylpropionate

Bacteria &
Giardia

• o-, m-, & p-Cresol
• p-Hydroxybenzoate
• p-Hydroxyphenylpropionate

Clostridia Sp.

• 3,4-Dihydroxyphenylpropionate

• p-Hydroxyphenylacetate

Sugars

Bacteria

• Tricarballylate
• D-Lactate

Yeast &
Fungi

• D-Arabinitol

Figure 6.23 — Origins of Urinary Dysbiosis Markers
Undigested dietary polyphenols are the predominant substrate for growth of most intestinal microbes. Each species has
adapted a metabolic preference that sustains its growth while producing compounds that suppress the growth of competing
species. Certain species of bacteria and most yeast prefer carbohydrate substrates that are limited in most individuals by rapid
uptake in the upper small intestine. Restricted uptake found in small bowel syndrome or genetic carbohydrate absorptive
defects enhance the potential for overgrowth of the carbohydrate-preferring species.

description of dietary polyphenols and their microbial
products is provided to allow clinicians to develop a clear
picture of how abnormalities of the compounds should
be interpreted.
Dietary polyphenols, amino acids, and sugars that
are not transported from the gut lumen into enterocytes
can be used by gut microbes for growth.439 A summary
of some important dietary polyphenol structures and
dietary sources is shown in Figure 6.24. The wide range
of polyphenol food sources means the great majority
of patients will have sufficient intake for overgrowth of
bacterial microbes to be revealed. Only a small fraction
of dietary polyphenols are converted into products that
appear in the urine of healthy individuals. For example,
the total output of metabolic products from chlorogenic

intestinal tract is found in Chapter 7, “Gastrointestinal
Function,” where the urinary organic acid biomarkers of
overgrowth are included in a more general context.
Since the writing of the previous version of this
book, a great deal of new information has emerged
regarding urinary microbial products. Markers of yeast
growth have required total reevaluation as described
below under “Products of Fungi.” Much more information has been reported about the unique overgrowth
scenario revealed by high urinary d-lactate. The origin of
phenyl compounds has been greatly clarified by studies on microbial conversions of dietary polyphenols.
The phenyl compound emphasis from early reports of
human conditions of microbial overgrowth places great
importance on this area. Therefore, a more detailed

R1
OH
O

HO
R1

O

HO

O

Parsley
Celery,
Peppermint

Flavonols
R1
H
OH

Quercetin

Cranberries,
Onion,
Peppers,
Tomatoes
Kaempferol Broccoli
Isohamnetin Parsley

O

OH

H
OCH3

R1

OH

Gallate

OH

OH

OH
OH

R2

O

HO

R1
OH

Catechin

OR2

Anthocyanidins
Grapes
Plums

H

H
H

OH

Catechin

R1
OH

Oranges,
Lemons
Grapefruit

O+

HO

OH

Catechin

Hesperetin

OH

OH

HO

Flavonones
R2
H

O

OH

R1
OH
OH
O

OH

Naringenin

Apigenin
Luteolin

O

Flavones

R3

R2

OH

OH

R2

OH

O

HO

R1

Cyanidin
Malvadin

Cherries,
Raspberries,
Blueberries

Anthocyanidins

R1
OH

R2
H

OCH3 OCH3

Epicatechins

OH

Epicatechins
Epicatechins Chocolate,
Apples,
Blackberries
EGC*
Black tea
EGCG**
Green tea

R1
H

R2
H

OH
OH

H
Gallate

* Epigallocatechin (EGC)
** Epigallocatechin-3-gallate (EGCG)

Figure 6.24 — Dietary Polyphenolic Compounds That Serve As Substrates for Intestinal Bacterial Metabolism
The six classes of compounds shown represent the great majority of dietary polyphenols. The tables show members of each
class and common dietary sources. The designations of substituent groups (R) are also shown in the tables. Microbes in the
human gut metabolize these compounds, releasing the aromatic organic acids discussed in this section.

Table 6.11 — Chronological Summary of Microbial Substrate

and Urinary Product Reports

Substrate and Protocol Sketch

Urinary Products*

Identify products in human urine after administration of caffeic acid.409

m-Hydroxyhippurate +++

1964

Adding 50 mg catechin to rats on low catechin diet caused appearance of
urinary products that fell with administration of antibiotics.410

m-Hydroxyhippurate +++
m-Hydroxyphenylpropionate +++

1968

Caffeic acid (chlorogenic acid) challenge in rats and rabbits.411

p-Hydroxyphenylpropionate

1969

Anaerobic culture of entire rat intestinal content
with and without added catechins.412

p-Hydroxyphenylpropionate
m-Hydroxyphenylpropionate
δ-(3,4-Dihydroxyphenyl)-g-valerolactone

1970

Caffeic acid (chlorogenic acid) challenge in
conventional and germ-free rats.414

m-Hydroxyphenylpropionate
(complete absence in germ-free rats)

1971

Bacterial metabolite excretion in a patient with cystic fibrosis
and severely impaired amino acid absorption.413

p-Hydroxyphenylacetate
p-Hydroxybenzoate

Deuterated tyrosine metabolites found in in vivo and in culture medium
after 1 week of human fecal specimen anaerobic incubation.415

Phenol
p-Cresol
p-Hydroxybenzoate
p-Hydroxyhippurate
p-Hydroxyphenylacetate
p-Hydroxymandelate
p-Hydroxyphenyllactate

Products of normal rat cecal content action on
catechins in anaerobic batch culture.416

1986

1976

Year
1957

m-Hydroxyphenylpropionate +++
p-Hydroxyphenylpropionate +++
Benzoate ++
m-Hydroxyphenylacetate ++
Phenylacetate ++
p-Hydroxymandelate +
p-Hydroxyphenylglycol +
o-Hydroxyphenylacetate +
Homovanillate
Hydroxyphenylacetate
p-Hydroxyphenylacetate
p-Hydroxyphenyllactate
m-Hydroxyphenylhydracrylate
4-Hydroxy-3-methoxyphenylglycol

Urinary products from germ-free rats on standard chow
before and after fecal bacterial introduction.13

1994

Phenylacetate
o-, m-, and p-Hydroxybenzoate
p-Hydroxyphenylacetate
Phenylpropionate
o-, m-, and p-Hydroxyphenylpropionate
3,4-Dihydroxyphenylpropionate
p-Hydroxyphenyllactate

Urinary metabolites from oral administration
of Ginkgo biloba to humans.417

Hippurate
p-Hydroxybenzoate
p-Hydroxyhippurate
3-Methoxy-4-hydroxybenzoate
3-Methoxy-4-hydroxyhippurate
3,4-Dihydroxybenzoate

2000

Metabolites produced by human colonic microflora grown in culture on
C14-labeled proanthrocyanidin-enriched chow under anoxic conditions.418

Phenylacetate +++
Phenylpropionate +++
p-Hydrophenylacetate +
m-Hydroxyphenylacetate++
m-Hydroxyphenylpropionate +++
m-Hydroxyphenylvalerate ++

2000

Urinary products from consumption of brewed
black tea by human subjects.419

Hippurate +++

1997

Table 6.11 continued on following page..

Table 6.11 continued from previous page...
Urinary Products*

Comparison of rat urinary products on control
diet and after addition of wine extract.420

3,4-Dihydroxyphenylacetate +++
3,4-Dihydroxyphenylpropionate +++
p-Coumarate ++
Caffeate ++
Ferulate ++
o-Hydroxyhippurate ++
Hippurate ++
o-Hydroxybenzoate +
p-Hydroxybenzoate +
o-Hydroxyphenylacetate +
Vanillate +
p-Hydroxyhippurate
Phenylacetate

2003

Comparison of urinary products from humans on a polyphenolfree diet and after addition of 80 g chocolate /d, supplying 439 mg
proanthocyanidins and 137 mg catechin.406

Vanillate ++
Ferulate +
m-Hydroxybenzoate ++
3,4-Dihydroxyphenylacetate +
m-Hydroxyphenylacetate ++
m-Hydroxyphenylpropionate +
p-Hydroxybenzoate
p-Hydroxyhippurate
3,4-Dihydroxyphenylpropionate
Phenylacetate Hippurate --

2004

Changes in human subject excretion with introduction of grape seed
extract supplement that supplies 1000 mg of polyphenols.421

2005

Randomized, crossover design used for 17 humans to detect urinary
effects of two days dosing with 6 g green tea, 6 g black tea.422

m-Hydroxyphenylpropionate ++
m-Hydroxyphenylacetate ++
p-O-Methylgallate +
p-Hydroxyphenylacetate
Hippurate ++

2002

Substrate and Protocol Sketch

Year

* Compounds in bolder blue color showed significant increases as a result of the challenge described in the column labeled “Protocol Sketch.” Relative rankings of
the response magnitudes are shown as high (+++) to low (+). Compounds showing no significant urinary response are in black and those with negative response
are in bolder red color. For these compounds, the intervention suppressed either bacterial or host tissue reactions required for their production. Compounds from
studies that identified but did not quantitate the products are also shown in black.

acid, one of the most abundant dietary polyphenols,
has been reported to be less than 58% of ingested
amounts.440 Thus, a significant degree of variability in
urinary products among individuals may be ascribed
to varying rates of intestinal microbial growth. Differences in gut microbial action explains why some people
who consume soy protein produce significant amounts
of equol, whereas others do not.441 However, patients
under treatment with medical foods or total parenteral
nutrition may not be candidates for urinary phenolic
bacterial product assessment because of inadequate
polyphenol intake to allow microbial metabolic product formation. Since these patients are at risk of being
malnourished, there is potential for eventual interpretation of low fecal phenolics442 or urinary polyphenol
products443 as assessments of polyphenol inadequacy.
The other microbial products derived from non-phenolic
sources discussed below are not dependent on polyphenol intake. Table 6.11 summarizes many of the studies

reporting evidence that supports the microbial origin
of human urinary metabolites, and the foods or components that contribute to the wide variety of patterns
appearing for individual patients.
Many bacteria that inhabit the human gut have
highly adaptable metabolic responses to the food
sources provided by their environment.444 Scientist are
beginning to think of the 2 to 3 pounds of microbial
mass as an organ with vast metabolic potential that
expands human adaptability and that is required for
human health.445 Microbial catabolic pathways generally stop short of full oxidation of substrates to carbon
dioxide and water to yield organic acids and other
classes of compounds that can be absorbed from the gut
and excreted in urine. Early in vitro work demonstrated
various metabolic potentials for specific bacteria.446450
Measuring products formed by ruminants when
dietary intake of specific compounds was varied yielded
information about rumen bacteria. The proximity of the

range of products that might be measured increases and
connections with specific microbial overgrowth consequences are understood, the time may come when either
single or multiple timed urine collections will be able
to more accurately show the status and clinical consequences of intestinal dysbiosis. Recent combinations
of HPLC-MS and nuclear magnetic resonance-based
metabolomic studies have revealed great differences
between individuals, whereas single patients show quite
stable patterns across all types of molecules, including
microbial products.456, 457

Bacterial and Protozoal
Phenolic Products

By acting on various dietary or endogenous substrates, bacteria or parasites can generate metabolic
products that are absorbed and excreted in urine with
or without further modification in the liver and kidney.
Dietary polyphenols have been shown to be one of the
dominant substrates for yielding phenolic compounds,
whereas dietary simple sugars lead to generation of others. Some studies that have contributed to our knowledge of these products are summarized in Table 6.11.
Although there are numerous polyphenolic chemical
structures contained in foods, it appears that a relatively
small number of phenolic products are formed.443 This
feature of the system means that variations in specific
foods consumed from one patient to the next may have
only small effects on the potential for generating phenolic products. The greater factor is the type and activity of
the microbes that are present.
The anatomical region of the gut that is most likely
to yield bacterial metabolites is the middle or transitional
gut, including the terminal ileum and the ascending
colon because the passing of chyme to the lower ileum
corresponds to the lag phase for the onset of logarithmic
growth rates characteristic of most bacteria.458 It is during this most intense growth phase when the microbial
counts rise from 105 to 1011/g that metabolic products are
most actively produced. Thus, by measuring their products in urine, information principally about the mid- or
transitional-gut microbial mass is obtained. These microbial populations that may produce toxic metabolites may
be detected more accurately by their urinary markers
than by attempting to detect the organisms directly
through stool specimens. See Chapter 7, “Gastrointestinal
Function,” for further discussion of microbial populations in the gut and stool testing interpretation.

rumen to the oxygen content of swallowed air means
that organisms thriving there are generally aerobic and
microaerophilic, in contrast to the highly anaerobic environment below the stomach.451-454 This ruminal stage
of microbial activity is most closely approximated in the
human jejunum. Absorbed bacterial metabolic products
may undergo further metabolism in host tissues, mainly
liver and kidney. For example, urinary benzoic acid
was found in ruminant urine as the result of hepatic
action on the phenylpropionate, a principal product of
microbial metabolism of dietary cinnamic acid.452 These
data explain the failure of phenylpropionate to appear in
appreciable quantities in urine of most patients. Normal
hepatic oxidase activity converts any absorbed phenylpropionate into benzoate (and hippurate). The specific
compounds that are excreted by a given individual
depend on the available substrates and the species of organism present.443, 455 Some of the compounds discussed
in this section are exclusively produced by such intestinal microbial metabolism, whereas others may have
small contributions from human metabolic pathways.
Benzoate is a common dietary component. Nevertheless,
since benzoate is also potentially produced by intestinal bacteria, elevation of benzoate and hippurate can
add strength to conclusions when a general pattern of
elevated bacterial products is found.
High predictive values of urinary markers have
been established for some conditions. In one study of
360 acutely ill infants and children, small bowel disease
and bacterial overgrowth syndrome was predicted with
no false-negative results, and only 2% false-positive
results from urinary p-hydroxyphenylacetate.433 Three
of the patients who tested positive for this compound
were diagnosed with Giardia lamblia infection, giving
evidence of the potential for revealing certain types of
protozoal overgrowth.
The extent to which future work on urinary microbial markers may allow more detailed prediction of
pathogenic intestinal microbe growth needing specific
interventions is difficult to predict. As knowledge of the
Notes:

Benzoate
COOH

Hippurate

Benzoic Acid
O

Benzoate was one ofHippurate
the compounds first found
to be elevated in urine from patients with intestinal
bacterial overgrowth of various origins. Many patients
with intestinal bacterial overgrowth resulting from cystic
fibrosis or unclassified enteritis, celiac disease or shortbowel syndrome were found to have elevated benzoate
along with various degrees of elevated phenylacetate,
p-hydroxybenzoate, and p-hydroxyphenylacetate, as
described below.473 These products were thought to
be derived from unabsorbed phenylalanine or tyrosine
from dietary protein.473 Later reports have demonstrated
that bacterial catabolism of dietary polyphenols may be
the predominant origin of benzoate, which is normally
conjugated with glycine in the liver to form hippurate.13
Dietary polyphenols generally persist into the lower
small intestine because they are resistant to degradation
by digestive fluids474.
Coffee, fruits and vegetables are sources of benefiCH3
O
cial chlorogenic acid, over 57% of which is recovered
in
N 440
urine as organic acids, mainly benzoate andNhippurate.

HO

H
N

O

See Figure 6.25 for differentiation of caffeic acid from
caffeine that is also present in coffee and tea, but is not
a polyphenolic compound and does not yield any of the
compounds currently measured as intestinal microbial
products in urine. Quinic acid, a tetrahydroxybenzoic
acid compound found in tea, coffee, fruits, and vegetables is also largely metabolized to benzoic acid by
intestinal bacteria and excreted as hippurate.475 When
humans were changed from a low-polyphenol diet to
one including 6 g of green tea or black tea solids, they
started excreting more hippurate.472 The conversion of
catechin from tea is thought to involve bacterial release
of 3-phenylpropionate with subsequent absorption and
hepatic oxidation to benzoate and conjugation to yield
hippurate (Figure 6.26). Consumption of 6 g of green
tea solids by healthy male volunteers produced an approximate doubling of urinary hippurate from 1.9 to
4.0 mmol/24 h.472 A change of 2 mmol/24 h corresponds
to approximately 120 µg/mg creatinine, a small effect
compared with a typical abnormal cutoff of 800 µg/mg
creatinine. Similar results from ingestion of brewed
black tea had been reported before the tea extract study
was done.469 In addition, other studies found that the
measured levels of phenolic compounds from green tea
CH3
O of antibacterial agent to a
are lowered by administration
human subject, confirming
the
microbial
contribution to
N
N
the appearance of urinary products.
N
N
Ofood component.
Benzoic acid is also
a common
CH
It is used as a preservative in packaged
foods such as
Caffeine
pickles and lunch meats, and
it occurs naturally in
cranberries and other fruits.477 This should be taken into
OH
HOOC
account when interpreting
elevated hippurate
levels in
urine. Whether the source is dietary intake or jejunal

N

N

OH

O

Caffeic Acid

CH3
CH3

Caffeine

O

N
N

OH
O
O

N

N

HO

OH

HOOC

HO

O

O

OH

OH

CH3

OH

Caffeine

Caffeic Acid

OH
Chlorogenic Acid

OH

HO
FigureHOOC
6.25 — Differentiation
Caffeic Acid and Chlorogenic Acid
OHof Caffeine,
O
O
Although teas and coffee may contain all three comounds,
caffeine and caffeic acid have quite different chemical structures
OH is distinctly different from that of the other two
and the metabolism of caffeine by intestinal bacteria and human enzymes
HO
OH
O
compounds. Caffeine is a methylated
purine, while
caffeic acid is a phenolic organic acid. Chlorogenic acid, the ester of
Acid
OH
caffeic acid andCaffeic
quinic
acid is a major polyphenolic
compound in coffee. Intestinal microbial enzymes hydrolyze the ester
OH
bond, releasing
caffeic acid.
OH
HO

Chlorogenic Acid

O
O

HO

O

OH

LARGE BOWEL
OH

OH
OH

HO

OH

O

HO

OH

OH
O

OH

O

OH

OH

OH

Catechin

1-(3',4'-dihydroxyphenyl)-3-(2',-4',6'trihydroxyphenyl)-propan-2-ol

(-)-5-(3',4'-dihydroxyphenyl)γ-valerolacetone

Absorption
LIVER
Oxidation
HO

HO

HOOC−CH2−NH−C

O

Benzoic acid

Phenylpropionic acid

Hippuric acid

O

O

Figure 6.26 — Bacterial and Human Enzymatic Conversion of Catechin to Hippurate

Catechin from dietary green or black tea consumption is converted to 3-phenylpropionate by intestinal bacteria and the
absorbed 3-phenylpropionate is oxidized to benzoate and conjugated to hippurate by human intestinal and hepatic enzymes.
Higher rates of bacterial conversion causes elevation of urinary hippurate. Abnomally high hippurate is consistent with normal
polyphenol intake and abnormally high growth rates of those bacteria that can carry out this conversion.

Phenylacetate
COOH

bacterial metabolism, benzoate should be rapidly converted to hippurate by conjugation with glycine. Glycine
and pantothenic acid can be limiting factors in this process. Availability of glycine is easily limited as discussed
above (“Pyroglutamate”) and in Chapter 4, “Amino
Acids.” Elevated benzoate is a confirmatory marker for
inadequacy of glycine or pantothenic acid for conjugation reactions.478,479 Abnormalities of urinary benzoate
and hippurate may reveal clinically significant detoxification or dysbiosis issues. High benzoate indicates poor
detoxification via phase II glycine conjugation. Interpretations of other scenarios are collected in Table 6.12,
and Case Illustration 6.9 show scenarios of abnormal
benzoate and hippurate.
Refer to Case Illustration 6.9

The organic solvent, toluene, is detoxified by
oxidation to benzoic acid and excretion as hippurate.480
Although some reports have associated hippurate excretion with exposure to toluene, the relationship is weak
because of the multiple other sources of hippurate described here. Short-term toluene exposure produces no
significant changes in hippurate excretion.480
Phenylpropionate

Phenylacetic Acid
COOH

Phenylpropionic Acid
Intestinal bacterial action on
dietary polyphenols
causes the appearance of phenylacetate (PAA) in urine.
Excretion of PAA is markedly increased after the gastrointestinal tracts of germ-free rats are inoculated with
fecal microorganisms, indicating its microbial origin.13
Significant PAA has been found in human fecal water, indicating that absorption from the gut is only partial and
having potential implications for involvement in colonic
function.442 For individuals with normal, healthy intestinal function, phenylacetate should not appear at more

The similar compound that has two –CH2– groups
instead of one, phenylpropionate (PPA), is also produced
by anaerobic gut flora.494 PPA does not normally appear
in human urine, however, because it is metabolized by
mitochondrial medium-chain acyl-CoA-dehydrogenase
(MCAD).495 The glycine conjugate of PPA, 3-phenylpropionylglycine, has been proposed as a marker for diagnosing asymptomatic MCAD-deficient individuals who
do not sufficiently carry out the oxidative step.496 This
human genetic polymorphism test is unique in being
dependent on the production of PPA by gut flora such as
Peptostreptococcus anaerobis. A rare case of elevated unconjugated PPA is shown in Case Illustration 6.10 where
both asymptomatic MCAD deficiency and glycine conjugation deficiency is indicated. Because of the intestinal
bacterial requirement, the question of which organisms
may be required has been addressed in one study. Of
the 67 bacterial and 5 yeast isolates that were examined,
only the 3 isolates of Clostridium sporogenes and one of
Clostridium difficile produced PPA.497 These researchers
went on to investigate the effects of antibiotics on PPA
production by analysis of stool cultures to produce the
findings of Table 6.13. They conclude that use of PPA to
screen for asymptomatic MCAD deficiency must be done
with caution.

than background concentrations in urine. However,
phenylacetate is a trace product of endogenous phenylalanine catabolism that can accumulate in the phenylalaninemic state found in PKU.481 Although PAA shows
little toxic effect on brain glutamatergic activity,482 it has
significant effects on hepatic flux of glutamate and α-ketoglutarate,483 indicating that PAA may mediate some of
the toxic consequences of PKU. These findings are cause
for concern over chronic elevation of PAA due to bacterial metabolism in the gut. Urinary PAA is the product of
unidentified, specific strains of bacteria, marking a state
of bacterial overgrowth when it is elevated in urine.
A large body of literature has addressed quite a
different role of PAA in cancer treatment.484-492 PAA has
been found to modulate early estrogen-mediated events
in breast cancer,484 cell cycle events in prostate cancer,485
and regression of primary brain tumors.488 When these
effects are considered with knowledge of its intestinal
bacterial origin, a symbiotic relationship of novel proportion is suggested. Though little attention has been
directed to the subject, it is possible that normal flow of
PAA into blood from the gut is protective against neoplastic events similar to the protective effect of colonic
butyrate formation.493 There is potential clinical utility
for definition of low reference limits for PAA, and there
is high likelihood that future research will reveal other
such symbiotic relationships involving products of normal intestinal microbial metabolism.

Refer to Case Illustration 6.10

Table 6.12 — Interpretation of Patterns for Urinary Benzoate and Hippurate Abnormalities

Low

High

Low

High

Hippurate

Other Bacterial Markers

Interpretation

No elevations

Low intake of benzoate and precursors, plus normal or low
dietary polyphenol conversion by intestinal microbes

Multiple elevations

Low intake of benzoate and precursors with intestinal
microbial overgrowth of species that do not
metabolize dietary polyphenols (very rare)

No elevations

Glycine conjugation deficit (possibly genetic polymorphic phenotype
if hippurate is very low); dietary benzoate or precursor intake

Multiple elevations

Glycine conjugation deficit; presume benzoate is at least partially
from intestinal microbial action on dietary polyphenols

No elevations

Normal hippurate production via active glycine
conjugation; No indication of microbial overgrowth

Multiple elevations

Normal hippurate production via active glycine conjugation;
Presume hippurate is at least partially derived from
intestinal microbial action on dietary polyphenols

No elevations

Very high dietary benzoate or precursor intake
with partial conversion to hippurate

Multiple elevations

Very high benzoate load, some, or all, of which is contributed
by intestinal microbial action on dietary polyphenols

Benzoate

Low

Low

High

High

Table 6.13 — Antibiotic Activity Against Clostridia That Produce Phenylpropionate407

Intravenous

Oral

No effect

Inhibition

No effect

Inhibition

Cefazolin
Cefuroxime
Ampicillin sodium
Chloramphenicol
Gentamicin

Ticarcillin with clavulonate
Oxacillin

Amoxicillin alone
Amoxicillin with clavulonate

Metronidazole
Clindamycin

Cresol
OH

H3C

but newer synthetic compounds such as AST120 may
be more effective.500 Cresol excretion was found to be
lowered by administration of prebiotic substrate (oligofructose-enriched inulin) along with Lactobacillus casei,
Shirota and Bifidobacterium breve to human subjects.501
Strains of Escherichia coli can produce p-hydroxybenzoate from glucose.502 Other studies showing
intestinal microbial production of p-hydroxybenzoate
are summarized in Table 6.11. Esters of p-hydroxybenzoate, called parabens, have antibacterial activity503 and
they are part of the mechanism for establishing bacterial
dominance in intestinal populations. This phenomenon
is discussed further in Chapter 7, “Gastrointestinal
Function.”

Hydroxybenzoate p-Cresol

COOH

p-Hydroxybenzoic Acid

Hydroxyphenylacetate
COOH

Dietary polyphenols or tyrosine residues from
dietary proteins are the parent compounds from which
urinary p-cresol, p-hydroxybenzoate, and p-hydroxyphenylacetate are formed (Figure 6.27).454 Cresol has a
chemical structure very similar to phenol and is highly
toxic. Cresol excretion is not affected by dietary protein
intake, suggesting that the bacteria responsible reside in
the lower portions of the small intestine where amino
acids from dietary protein rarely penetrate. These bacteria apparently produce cresol from intestinal secretions
as well as from dietary sources.498 Mammalian tissues
have negligible metabolic activity toward absorbed cresol according to studies in sheep, where 95% of cresol
infused into the rumen appears in urine.454 Production
of cresol in humans may be dependent on small intestinal populations of aerobic or microaerophilic bacteria
because, in sheep, its production is almost exclusively
confined to the rumen.453
A large majority of adult celiac disease patients were
found to excrete unusually high amounts of p-cresol.499
Due to the loss of renal function, uremic patients accumulate cresol, which may contribute to toxic effects.
The resultant increase in serum cresol can be prevented
by the use of non-absorbed oral sorbents, demonstrating
that the origin of the p-cresol is the bowel. Finely powdered, activated charcoal is a generally available sorbent,

OH
OH

No other species has a digestive tract exactly like
humans. The one that
has the closest resemblance is
o-Hydroxyphenylacetic Acid
swine. Studies in newly weaned pigs have revealed
specific microbes that carry out tyrosine degradation
(Figure 6.27).504 Both the transamination to form phydroxyphenylacetate (HPA) and the decarboxylation
to p-cresol are carried out by Clostridium difficile. Since
Proteus vulgaris can do only the first of these steps, HPA
will increase in urine if P. vulgaris is the predominant organism. When P. vulgaris is accompanied by overgrowth
of a newly identified strain of Lactobacillus, however,
p-cresol will be the major product to accumulate. The
lactobacillus was not given species identification, but the
characteristics eliminate the species listed in the legend
of Figure 6.27. Such studies illustrate the potential for
more specific bacterial identifications based on patterns

Tyrosine

0.35
0.30

P. vulgaris
C. dificile

mg/L

0.25

p-Hydroxyphenylacetate

0.20
0.15
0.10

C. difficile
Unidentified species
of Lactobacillus

0.05
p-Cresol
Delphinidine-3-glucoside
p-Coumaric acid
3-Hydroxyphenylacetate

Figure 6.27 — Cresol from Bacterial

Metabolism of Tyrosine

Figure 6.28 — Timed Appearance of Black Currant

Unassimilated dietary tyrosine is metabolised by P. vulgaris
and C. difficile to p-hydroxyphenylacetate. This product
can be further metabolised to p-cresol by C. difficile and by
a Lactobacillus species other than acidophilus, leichmannii,
delbrueckii, plantarum, brevis, minutus or fermentum.504
Exact microbial origins of compounds found in urine are
difficult to establish.

Ingestion of 330 ml of black currant juice after 2 days of
low polyphenol diet resulted in the appearance of small
concentrations of unaltered anthocyanidin glycosides
and numerous products of their bacterial metabolism.
Hippurates (not shown) and unchanged parent
compounds like delphinidin-3-glucoside appear at peak
concentraions within one hour, showing how that they
have been delivered to absorptive regions of the gut.
Others like p-coumaric acid show second peaks at about
six hours, and still others like p-hydroxyphenylacetate
have peaks at 10 and 24 hours. The longer times of
appearance indicate activity in lower regions of the gut
where different microbes dominate.

of products appearing in urine. To achieve more detailed
assignments of origin, however, urine collections may
need to be timed following intake of specific sources. As
shown in Figure 6.28, a bolus of black currant juice can
cause the appearance of different products as it passes
from one region of the gut to the next.
p-Hydroxyphenylacetic aciduria has been found
useful in detecting small bowel disease associated with
Giardia lamblia infestation, ileal resection with blind
loop, and other diseases of the small intestine associated
with anaerobic bacterial overgrowth. 433 Use of antibiotics that act primarily against aerobic bacteria (such as
neomycin) can encourage the growth of protozoa and
anaerobic bacteria that then produce greater amounts
of these compounds.505 A clostridial species isolated
from swine feces carries out the further metabolism of
p-hydroxyphenylacetate to p-cresol.504
Patients with cystic fibrosis or other conditions
that severely impair amino acid absorption can demonstrate the potential for intestinal bacterial conversion of
phenylalanine and tyrosine to phenyl compounds that
appear in urine. These patients tend to excrete very high
levels of phenylacetate and p-hydroxyphenylacetate.463
However, since tyrosine released from dietary protein is
rapidly absorbed in most individuals; conversion of tyrosine to p-hydroxyphenylacetate may be a rarely observed
sign of dysbiosis in humans. However, the other isomers, o- and m-hydroxyphenylacetate, may be derived

Juice Metabolites In Human Urine

from dietary polyphenols that are unaffected by digestive
enzymes and they are normally abundant dietary components. Of the three isomers, the most likely bacterial
dysbiosis marker is m-hydroxyphenylacetate, which
appears when bacteria are introduced to germ-free rats
and increases markedly when humans are fed catechin
and proanthocyanidins-rich chocolate, as shown in
Table 6.11 (see row “2003”). In experiments conducted
with a human anaerobic fecal fermentation device,
quercetin was found to be metabolized within 2 hours
to 3,4-dihydroxyphenylacetate, which, over the next 8
hours, was converted to m-hydroxyphenylacetate.506
Notes:

COOH

p-Hydroxyphenylpropionic Acid

The o- (or 2) and m- (or 3)-hydroxyphenylpropionates can reveal specific types of intestinal bacterial
activity. When germ-free rats are given feed that is
contaminated with feces from standard rats, they begin
to excrete m-hydroxyphenylpropionate (m-HPPA).13
Subsequent studies showed that m-HPPA is absent
from the urine of germ-free rats, whereas it is the
principal product that appears from conventional rats
when caffeic acid is introduced.464 Increased excretion
of m-HPPA was found in healthy human volunteers
who consumed 1,000 mg of polyphenols as grape seed
extract (Figure 6.30).471 Low levels of urinary m-HPPA,
therefore, can indicate low intake of caffeic acid and the
proanthocyanidins found in grapes and other foods.
High levels of m-HPPA, on the other hand, may indicate
increased intestinal bacterial metabolism of dietary catechins and caffeic acid. m-HPPA systematically increases
in rat urine when catechin is added to their chow, and
its excretion in urine drops from around 200 µg/24 h to
At Diagnosis

After Treatment
Septicemia

Lactose Intolerance

Low Immunoglobulin

Giardia Iamblia

Ileo-colic Intussusception

Jejunal Web

Figure 6.29 — p-Hydroxyphenylacetate

Response to Treatment

The dramatic lowering of HPA after treatments commensurate
with six different clinical presentations demonstrates the
removal of bacterial overgrowth in every case, even when the
cause varied from lactose intolerance to Giardiasis.

Hydroxyphenylpropionate

HO

HPA is elevated in a wide variety of conditions
involving direct intestinal pathology or digestive organ
failure (Figure 6.29), which have obvious potential for
dysbiosis. Although treatments vary greatly depending
on the nature of the disorder, the lowering of elevated
urinary HPA reveals a normalized intestinal bacterial
population.473 Some microbial compounds are absorbed
and enter the detoxification pathways of the liver to be
excreted as modified products that can serve as indicators of gastrointestinal activities. For example, bacterial
amines are converted to piperidine, a sensitive biochemical index of gastrointestinal flora changes in celiac
disease.507 Other compounds appear due to genetic traits
that affect how bacterial products are metabolized. The
anaerobic bacterial product, 3-phenylpropionate mentioned previously, for example, is normally converted to
common hippuric acid, but is excreted as 3-phenylpropionylglycine in individuals with a relatively common
inborn error of fatty acid oxidation.497 Some compounds
excreted in these instances are not organic acids, so they
must be analyzed in separate assays to enhance the interpretation of origins for microbial compounds in urine.

10 µg/24 h after administration of a combination sulfathiozole + auromycin antibiotic.460 A close inspection of
the data from the chlorogenic acid study reveals a wide
range of individual variation in responses, as shown
in Figure 6.32. Such responses could be attributed to
variation in intestinal bacterial conversion potential from
the normal rates exhibited by most people.
Unlike the other two positional isomers, p (or 4)hydroxyphenylpropionate (p-HPPA) is produced in
human cells by tyrosine transamination. The further
conversion of p-HPPA to common energy pathway
intermediates is inhibited in genetic disorders that produce elevated tyrosine and p-HPPA in blood and urine.
Tyrosine transaminase is deficient in type II tyrosinemia
that may be controlled with a low phenylalanine and
tyrosine diet.508 The removal of p-HPPA is under the
control of the enzyme p-hydroxyphenylpyruvate dioxygenase that is deficient in type III genetic tyrosinemia.509
The reaction also requires participation of ascorbic acid.
Type III tyrosinemia has been studied in a mouse model
system to elucidate the nature of the genetic disorder.510
A nucleotide substitution has been identified that generates a termination codon resulting in failure to express
the gene in mice.511

12,000
A
mg/L
8,000
6,000
4,000
B
time (hrs.)
2,000

mg/L
Week 0
Week 6
Response to Grape Seed Extract
time (hrs.)
mg/L

D

time (hrs.)
mg/L

In vitro bacterial growth experiments indicate that,
in the gut, p-HPPA is metabolized by bacteria but not by
protozoa. Bacterial action converts p-HPPA into p-hydroxybenzoate, p-hydroxyphenylacetate, phenylpropionate, phenyllactate, and phenylpyruvate.512
When p-HPPA is elevated without concurrent
elevation of tyrosine, then the possibility of intestinal
clostridial production from dietary tyrosine should be
considered. Under in vitro conditions, where l-tyrosine
is supplied as a growth substrate, p-HPPA is a major
product of Clostridium sporogenes, Clostridium botulinum A, C. botulinum B and Clostridium caloritolerians.513
Such growth conditions also result in the appearance of
even greater concentrations of phenylpropionate, but
insignificant amounts of phenylacetate, phenyllactate,
p-hydroxyphenylacetate, and indole. Human fecal bacteria grown with the polyphenol naringin as a substrate
show predominant production of phenylpropionate or
p-HPPA as shown in Figure 6.31. These results help to
explain the varied patterns of urinary products that appear with individual patients.
C

Each line represents one individual. Although the
average response is an approximate doubling of
m-hydroxyphenylpropionate (m-HPPA) excretion, four
individuals show negative response while three others
show several fold increase. These data suggest large intraindividual differences in microbial populations that are
capable of releasing m-HPPA from ingested polyphenols.

Figure 6.30 — Individual Subject Variation in

m-HPPA Excretion (ug/24hr)

10,000
time (hrs.)
Naringin
p-Hydroxyphenylpropionate

Naringenin
Phenylpropionate

Figure 6.31 — Individual Patterns of

Naringin Degradation

Graphs A, B, C and D are from four individuals. Fecal
specimens were inoculated on growth media containing
added naringin. After 10 hours, subjects may be defined
as predominant producers of both phenylpropionates
(A and B), p-hydroxyphenylpropionate (C), or neither
phenylpropionate (D). The differences are due to
variations in dominant bacterial types. These products are
from growth in culture, so no effects of host metabolism
are seen.443

A

mg/L

mg/L
B

D

time (hrs.)

C

time (hrs.)

mg/L

mg/L

time (hrs.)
time (hrs.)

Caffeic acid
m-Hydrophenylpropionic acid

Chlorogenic acid
3,4-Dihydroxyphenylpropionic acid
Figure 6.32 — Individual Differences in Microbial Product Formation From Chlorogenic Acid

Graphs A, B, C and D are from four individual, healthy fecal donors. Individual fecal slurries were introduced into growth
media containing the polyphenol chlorogenic acid. Compounds plotted are chlorogenic acid and its degradation products,
caffeic acid, 3,4-dihydroxyphenylpropionic acid, and m-hydroxyphenylpropionic acid. Subject A has the slowest rate of
chlorogenic acid (the dietary component) removal and least appearance of 3,4-DHPP, while subjects C and D have very active
rates of 3,4-DHPP production.443

Abnormal appearance of the o- or m- isomers indicates the more common bacterial overgrowth utilizing
dietary polyphenols, whereas high p-hydroxyphenylacetate may be due to type III tyrosinemia or bacterial
conversion of unabsorbed tyrosine. Patients with the
genetic trait will present with characteristic signs of type
III tyrosinemia, whereas those with chronic maldigestion
of protein will generally show gastrointestinal signs.
Notes:
3,4-Dihydroxyphenylpropionate
COOH

HO
OH

Several clostridia are known to cause human
disease, for example, Clostridium difficile-associated
3,4-Dihydroxyphenylpropionic Acid
enteric disease epidemics514 and Clostridium perfringensassociated food borne infectious illness outbreaks
from eating cooked beef.515 However, many species of
the genus Clostridium make up a major portion of the
bacterial population in the normal human gut, with
Clostridium coccoides frequently found as the most

A
B

mg/L

mg/L
time (hrs.)
2000
D

1000

mg/L

1500

1000

mg/L
time (hrs.)

C

1500
time (hrs.)
time (hrs.)
Caffeic acid
m-Hydrophenylpropionic acid

Chlorogenic acid
3,4-Dihydroxyphenylpropionic acid

Figure 6.33 — Individual Fecal Bacterial Activity at Different Chlorogenic Acid Concentrations

The fecal slurry from a single individual was incubated at (A) 125 mg/l, (B) 500 mg/l, (C) 1500 mg/l and (D) 2000 mg/l
concentrations of chlorogenic acid. Curves are shown for concentrations of chlorogenic acid and its degradation products,
caffeic acid, 3,4-dihydroxyphenylpropionic acid, and m-hydroxyphenylpropionic acid. The conversion of caffeic acid to
3,4-DHPP is highly dependent on concentration, with much greater accumulation of 3,4-DHPP at high chlorogenic acid
concentrations. These data may simulate the effect of more vigorous bacterial activity at the same concentration.443

abundant species.516 The importance of clostridia to
urinary product formation is both their abundance and
their metabolic diversity.
The full designation of the compound discussed
here is 3-(3,4-dihydroxyphenyl)-propionic acid, which
we shorten to 3,4-dihydroxyphenylpropionic acid and
abbreviate as 3,4-DHPP. The appearance of 3,4-DHPP is
highly variable from one individual to the next as shown
in Figures 6.32 to 6.33.
Numerous reports have been received of patients
with Clostridium overgrowth confirmed by stool culture, where elevated levels of 3,4-DHPP have fallen to
baseline with Flagyl, but were unaffected by nystatin.596
Although other organisms may produce 3,4-DHPP,
clostridia is the most commonly encountered genera
among those susceptible to Flagyl. In vitro studies have

confirmed the production of 3,4-DHPP from dietary
quinolines by various species of clostridia.518, 519 Rats
excrete 3,4-DHPP when they are fed the naturally
occurring flavonoid hesperetin.520 Depending on the
species, clostridia excrete various other organic acids
as the end products of aromatic amino acid metabolism.513 Cytotoxic quinoid metabolites that require
glutathione conjugation for removal may be formed
from 3,4-DHPP.521 Various compounds closely related to
3,4-DHPP are also produced by the genus Clostridium.513
In addition, 3,4-DHPP has been found as a product of
metabolism of quinoline by Pseudomonas stutzeri.522, 523
Intestinal 3,4-DHPP is degraded by an enzyme produced
by E. coli, thus helping to insure its survival in the presence of intestinal clostridial growth.524, 525

Bacterial Products
from Tryptophan
Indican
O-SO3=

HO

N

Indican

Bacteria in the upper bowel produce the enzymes
that catalyze the conversion of tryptophan to indole. Absorbed indole is converted in the liver to indoxyl, which
is then sulfated to allow for urinary excretion. Indoxyl
sulfate (also known as indican) can be measured colorimetrically by conversion to colored oxidation products
or directly by liquid chromatography with a UV absorption or mass spectrometric detector.
Because the upper bowel is sparsely populated
with bacteria, indican is present in urine at low levels
in health. An elevated level of urinary indican is an
indication of upper bowel bacterial overgrowth. Certain
patients, such as those with celiac disease may be at
greater risk.499 Bacterial overgrowth, utilizing urinary
indican, was demonstrated in 8 out of 12 patients following jejuno-ileal bypass surgery.526
Oral, unabsorbed antibiotics reduce indican excretion.527 Indican excretion is also reduced when the gut
is populated with strains of Lactobacillus at levels above
105 organisms/g.527 Lactobacillus salivarius, Lactobacillus
plantarum, and Lactobacillus casei were more effective
in achieving reduced indican than were two strains of
Lactobacillus acidophilus. In patients with cirrhosis of the
liver, tryptophan loading can produce neuropsychiatric
manifestations due to intestinal bacterial production of
tryptophan metabolites.528 The symptoms are reduced
by antibiotic therapy, demonstrating the bacterial origin
of the metabolites.
Indican testing can aid in differentiating pancreatic
insufficiency from biliary stasis as the cause of steatorrhea (fatty stools).529 Patients with steatorrhea due to
pancreatic insufficiency show a rise of indican from
low values to above normal when they are treated with
pancreatic enzyme extract.529 Urinary indican does not
rise in patients with steatorrhea not due to pancreatic
insufficiency, nor in the normal subjects who receive
pancreatic enzymes. This scenario demonstrates how
bacterial populations respond to increased concentrations of luminal amino acids. Large shifts in bacterial

populations induced by the artificial sweetener, saccharin, have also been demonstrated by changes in indican
excretion.530
No age adjustment for reference limits is necessary,
since excretion has been shown to be constant for young
and elderly control subjects.531 The test sensitivity may
be enhanced by oral loading of 5 g tryptophan.532 The
number of false-positives may be reduced by including elevations of other bacterial metabolites with that of
indican as criteria of abnormal bacterial colonization of
the small intestine.533
The interpretation of indican results is complicated
by impaired protein digestion, which increases the
tryptophan available for bacterial action. Even patients
with normal intestinal bacterial populations can show
increased postprandial indican excretion when they
fail to digest dietary protein. The relationship between
increased indican and incomplete digestion might be
utilized as a measure of protein digestive adequacy. Indican evaluation has been used to assess intestinal absorption of tryptophan in scleroderma.534 Increased urinary
indican has been shown to correlate with enteric protein
loss.535 Indican elevation has revealed that impaired
protein digestion and increased bacterial conversion of
tryptophan is a complication of cirrhosis of the liver.536
Some degree of malabsorption was found in 30% of an
elderly population by combinations of indican with the
Shilling and other tests.537
Products of Dietary Carbohydrate
d-Lactate
HOOC

OH

Nanomolar concentrations
of d-lactic acid may be
D-Lactic Acid
produced by human tissues,538 but it is a major metabolic product of several strains of bacteria that inhabit
the human gut.539 d-lactate is frequently detected in
patients with short-bowel syndrome (SBS) due to poor
dietary carbohydrate absorbtion because of impaired
absorptive regions in the upper small intestine. Many
genres of bacteria can convert simple sugars into dlactate. However, Lactobacillus acidophilus is uniquely
adapted to withstand the dramatically lowered intestinal
pH resulting from massive accumulation of luminal
d-lactate and other organic acids. Under conditions of

Table 6.14 — Neurologic Signs &

Symptoms in 29 Patients
With D-Lactic Acidosis508

Symptom

% of Patients
Slurred speech
Disorientation
Impaired motor coordination
Hostile, aggressive, abusive behavior
Inability to concentrate
Nystagmus
Delirium
Hallucinations

Irritability

Altered mental status ranging from
drowsiness to coma
Headache
Partial ptosis
Asterixis

Excessive hunger
Blurred vision

carbohydrate malabsorption, d-lactate is simultaneously
increased in blood and urine.540 Some d-lactate entering portal circulation can undergo hepatic conversion
to carbon dioxide, but this pathway has limited capacity. This limitation is in contrast to the extremely large
capacity for metabolism of the l-lactate isomer produced
in skeletal muscle and other tissues. With continued
increases in intestinal output, rising blood levels are
reflected in urinary output of d-lactate.541 When intestinal production rates exceed the capacity for clearance,
d-lactic acidosis is produced.542 Intestinal symptoms of
diarrhea are frequently present due to the disruption of
bowel flora.543, 544
d-Lactic acidosis due to overgrowth of Lactobacillus plantarum was reported in a child who developed an
unusual encephalopathic syndrome due to neurotoxic
effects of d-lactate.545 d-Lactic acidosis may be accompanied by any of the various neurological symptoms listed
in Table 6.14.540, 546, 547 Attacks are usually episodic, lasting from a few hours to several days. Direct toxic effects
of d-lactate in the brain are suspected.546, 548
Jejunoileostomy patients have the highest risk of
developing d-lactic acidosis and the accompanying
encephalopathy because they usually have some degree
of carbohydrate malabsorption.549,550 Procedures as mild
as stomach stapling may lead to d-lactic acidosis.542
Precipitating factors include use of antibiotics554 and
medium-chain triglycerides.555 Carbohydrate malabsorption associated with pancreatic insufficiency can also
induce d-lactic acidosis.556 Elevated levels of d-lactate
were found in blood samples of 13 out of 470 randomly
selected hospitalized patients.552 Studies in cattle have
confirmed that increases in d-lactate following overloading of grain in the diet corresponded to growth of
lactobacilli rather than coliform bacteria.553
The specificity and sensitivity of urinary d-lactate
has led to the test being proposed for routine diagnosis

of bacterial infections.551 d-Lactate has also been reported to be a marker for diagnosis of acute appendicitis,557
and for differentiating perforated from simple appendicitis.558 Whatever the origin, patients are managed with
antibiotics and probiotics,559 including Saccharomyces
boulardii.540
During acidotic episodes in patients with SBS,
24-hour urinary excretion of d-lactate may rise to levels
above 600 µg/mg creatinine, far higher than concurrent
l-lactate concentrations of around 24 µg/mg creatinine.547 d-Lactic acidosis has also been reported in a
patient with chronic pancreatitis and renal failure rather
than short-bowel syndrome.556 Compared to controls,
significant elevations of d-lactate were reported for

Notes:

Table 6.15 — d-Lactate Isomers Produced

by Individual Species
of Lactobacillus565

Producers of Only d(-)-Lactate
Lactobacillus delbrueckii subsp. delbrueckii
Lactobacillus delbrueckii subsp. lactis
Lactobacillus delbrueckii subsp. bulgaricus
Lactobacillus jensenii
Lactobacillus vitulinus
Producers of Racemate dl-Lactate
Lactobacillus acidophilus
Lactobacillus amyiovorus

Lactobacillus aviarius subsp. aviarius
Lactobacillus brevis

Lactobacillus buchnari
Lactobacillus crispatus

Lactobacillus curvanus

Lactobacillus formentum

Lactobacillus gasseri
Lactobacillus graminis

ischemic bowel, small bowel obstruction, and acute
abdomen, with a negative predictive value of 96% and a
positive predictive value of 70%.561
The phenomenon of d-lactic acidosis has been described as turning sugar into acid in the gastrointestinal
tract.562 d-Lactate is not the only organic acid produced
from simple carbohydrates, they are also turned into
p-hydroxybenzoate and tricarballylate but those compounds are never absorbed at rates that can produce the
systemic effects found with d-lactate. When d-lactate
is elevated, supplementation with d-lactate-producing
species of Lactobacillus is contraindicated, and steps to
reduce bacterial populations should be considered. Not
all species of Lactobacillus produce significant d-lactate,
as shown in Table 6.15. Once the carbohydrate excess
in the small intestine is controlled, a recommended
approach to managing recolonization with probiotic species is to supplement with species that do not produce
d-lactate.
Urinary d-lactate reference values of 5.9 and
13.7 µg/mg creatinine for adults and children less than
one year old, respectively, have been reported.546, 547,
Studies that have performed simultaneous plasma
and urine specimen collections show that urinary

Notes:

Lactobacillus hamsteri
Lactobacillus helviticus
Lactobacillus homohiochii
Lactobacillus pentosus
Lactobacillus plantarum
Lactobacillus reuteri
Lactobacillus sake
Producers of Only l(+)-Lactate
Lactobacillus agilis
Lactobacillus amylophilus
Lactobacillus animalis
Lactobacillus bavaricus
Lactobacillus casei
Lactobacillus mali
Lactobacillus maltaromicus
Lactobacillus murinus
Lactobacillus paracasei subsp. paracasei
Lactobacillus paracasei subsp. tolerans
Lactobacillus ruminis
Lactobacillus salivarius
Lactobacillus sharpeae
Lactobacillus rhamnosus

Products of Fungi (Yeast)

concentrations can frequently be 10-fold higher than
plasma.559 An advance in analytical sensitivity has
recently been achieved in which a single chiral chromatographic separation allows resolution and lowlevel accuracy for simultneous, quantitative analysis of
d- and l-lactate by tandem mass spectroscopy.564 Since
independent enzymatic methods frequently have varying calibration errors and efficiencies of recovery, the
simultaneous determination of both isomers allows more
accurate detection of patients predominantly excreting
the d-isomer. In summary, urinary d-lactate elevation
may predict bacterial overgrowth as a result of: carbohydrate malabsorption, ischemic bowel, certain types of
pancreatic insufficiency, acute appendicitis, and surgical
procedures that compromise upper gastrointestinal function. Diagnosis and treatment of d-lactic acidosis can
significantly improve patient outcomes.

d-Arabinitol
OH

HO
OH

pathogenic Candida species, in vitro as well as in vivo.
d-Arabinitol is a five-carbon sugar alcohol that can

COOH

COOH

Tricarballylate (tricarb) is produced by a strain
Tricarbalyllic Acid
of aerobic bacteria that quickly repopulates in the gut
of germ-free animals.566 As its name implies, tricarb
contains three carboxylic acid groups that are ionized
at physiological pH to give a small molecule with three
negative charges akin to the structure of the powerful
chelating agent EDTA. Magnesium is bound so tightly by
tricarb that magnesium deficiency results from overgrowth of tricarb-producing intestinal bacteria in ruminants.567 This condition, known as “grass tetany,” is also
accompanied by lower levels of calcium and zinc, all
of which can form divalent ion complexes with tricarb
(Figure 6.34).

O

C

O-

CH
C

O-

+ Mg+

be assayed by enzymatic analysis. It is important to
distinguish the sugar alcohol from the sugar d-arabinose
that is unrelated to any yeast or fungal condition
in humans. A single report of two autistic brothers
who were found to have significant concentrations of
arabinose in their urine has led to claims about possible
associations of yeast infections and autism,568 though
no further evidence in support of this association has
been reported. DA, on the other hand, has long been
known to be associated with candidiasis in a variety of
clinical situations.569-571 The enzymatic method using
d-arabinitol dehydrogenase is precise (mean intra-assay
coefficients of variation [CVs], 0.8%, and mean interassay CVs, 1.6%) and it shows excellent recovery of
added DA.572
Among pathogenic yeasts and fungi, Candida spp.
are of widest clinical concern, because of their transmission by direct invasion of the gastrointestinal and genitourinary tracts and their ability to rapidly overwhelm
immune responses in many hospitalized patients. Most
species of Candida grow best on carbohydrate substrates.
Activities of the enzymes aldose reductase and xylitol
dehydrogenase are induced in Candida tenuis when the
organism is grown on arabinose.573 The rate of DA appearance in the body equals the urinary excretion rate
and is directly proportional to the concentration ratio of
DA to creatinine in serum or urine.574
Measuring serum DA allows prompt diagnosis of
invasive candidiasis.575 Immunocompromised patients
with invasive candidiasis have elevated DA/creatine
ratios in urine. Positive DA results have been obtained
several days to weeks before positive blood cultures, and
the normalization of DA levels has been correlated with
therapeutic response in both humans and animals.576,577
Elevated DA to creatinine ratios were reported in 69, 36,

COOH

O

OH

d-Arabinitol (DA) is a Arbinitol
metabolite of most

Tricarballylate

CH2

OH

CH2

-O

C

O

Figure 6.34 — Tricarballylate-magnesium Complex

Actions to Consider for
Elevated Dysbiosis Markers

Tartarate, citramalate, and other compounds were
found at high concentrations in two brothers who had
conditions thought to be associated with intestinal yeast
overgrowth.568 However, no evidence has appeared, that
supports the contention that tartarate and citramalate are
products of intestinal yeast overgrowth. Furthermore,
the large dietary intake effects on urinary tartarate
were not controlled in the single previous study.583
d-Arabinitol is the only urinary biomarker of invasive
Candida sp. overgrowth that has reliable scientific
support.
Early studies on bacterial isolates showed that
various strains of coliform bacteria can decarboxylate
amino acids to their amine forms. Thus, Bacterium coli
decarboxylated arginine, lysine, ornithine, histidine,
and glutamic acids to agmatine, cadaverine, putrescene,
histamine, and γ-aminobutyric acids, respectively.446450
These data must be viewed with caution, however,
because they do not reveal the extent to which the
products may be further metabolized by other microbial species in the gut or by human tissues. The amino
acid product γ-aminobutyrate is discussed in Chapter 4,
There are multiple negative impacts on nutrient
status caused by intestinal dysbiosis. Lowered levels of
vitamins B1, B2 and B6, and the minerals magnesium and
zinc are found in patients with elevated nascent production of ethanol due to gut fermentation584 (Figure 6.35).
Therefore, evaluation of micronutrient status and selection of appropriate repletion dosages of nutrients is a
key to successful management of patients with significant dysbiosis.
Further discussion of stool microbial analysis
and other methods for GI function testing is found in
Chapter 7, “Gastrointestinal Function.” Although species
identification is not possible from the limited number
of urinary markers currently detected, and no antibiotic
sensitivity testing can be done, the information available is sufficient for clinical decisions about appropriate
interventions. The susceptibilities of various bacteria
known to reside in the upper jejunum to five antibiotics are shown in Table 6.16. Many bacteriostatic herbal
preparations and natural compounds inhibit growth of
bacteria and yeast. A summary of interventions commonly used is presented in Table 6.17. Additional
insight may be gained from studies of the antibiotic
sensitivities of organisms present in cases of small intestinal bacterial overgrowth syndrome. Since the specimen
Serum enzyme stimulation
or mineral concentration

Putative Yeast Markers and
Promising Bacterial Markers

“Amino Acids,” where no association with bacterial overgrowth in humans is mentioned because of the absence
of such observations in the scientific literature. Tyrosine
decarboxylation was found to be characteristic of seven
strains of Streptococcus faecalis that had no activity toward other amino acids.447

and 9% of patients with Candida sepsis, Candida colonization, and bacterial sepsis, respectively.578 In another
study, when patients were divided into categories of
superficial candidiasis, possible deep, invasive candidiasis, and definite, deep invasive candidiasis, all three
groups showed significant DA elevations.579 Another
group reported highly elevated, slightly elevated, and
normal DAl levels in 2, 2, and 3 patients, respectively,
with superficial Candida colonization.580 Yet a fourth independent group has reported the appearance of DA in
both disseminated and simple peripheral candidiasis.581
The somewhat more discriminating elevated urine darabinitol–l-arabinitol (DA/LA) ratio has been found to
be a sensitive diagnostic marker for invasive candidiasis
in infants treated in neonatal intensive care units. Eight
infants with mucocutaneous candidiasis were given
empiric antifungal treatment, but had negative cultures;
five of these had repeatedly elevated DA/LA ratios. Three
infants with suspected, and four with confirmed invasive
candidiasis experience normalized ratios during antifungal treatment.582 The ratio of d- to l-arabinitol in serum
reveals the presence of disseminated candidiasis in immunosuppressed patients.576

B1
B2
B6
Mg
Zn
Normals
Ethanol=8.4

Fermentors
Ethanol=640

Figure 6.35 — Nutrient Deficiency Due to

Gut Fermentation

Figure 6.29 Nutrient deficiency due to gut fermentation

Table 6.16 — Antibiotic Sensitivities of Upper Jejunal Bacterial Strains in

Small Intestinal Bacterial Overgrowth Syndrome532

Antibiotic Sensitivity (% of Susceptible Strains)
Amoxicillin

AmoxicillinClavulanic
Acid

Cephalothin

Erythromycin

Trimethoprimsulfamethoxazol
Streptococcus
E. coli
?

?

Staphylococcus
Micrococcus
Klebsiella
?
Nisseria
Proteus
?
Acinetobacter
?
Enterobacter
?
Anaerobic
Lactobacillus
?
Bacteroides
Clostridium
?
Veillonella
?
Fusobacterium
?
Peptostreptococcus
?

Microaerophilic

Prevalence
(%)

Bacteria

used for the data in Table 6.17 was taken in the upper
jejunum,585 the data represent only the proximal part of
the small bowel where microaerobic species are most
likely to persist. The more distal regions of the jejunum
and the entire ileum are less favorable for aerobes.
Since the microbial compounds that appear in urine
originate in the lumen of the gut, oral sorbents that bind
them and prevent their absorption can be used. This approach is especially helpful for those compounds of high
toxicity like cresol. The absorbent, AST-120 (3–7 g/d),
has been shown to effectively lower p-cresol accumulation in uremic patients.500,586 Uremic coma and bleeding
tendency is attributed to the accumulation of p-cresol,
and p-cresol is a co-carcinogen in the mouse skin test.
The fact that an oral sorbent lowers levels of cresol in
uremia demonstrates that the gut is a significant source
of the toxin. Activated charcoal may be used for this
purpose, but there is greater tendency for constipation
than with AST-120. The generally sound advice of using
a high-fiber diet rich in legumes and other whole foods
is an effective way of achieving lowered transit times
and less exposure to intestinal toxicants.587-589 Fiber
simultaneously encourages favorable colonic species that
degrade cellulose. Because of the increased microbial
metabolism, dietary fiber can increase intestinal shortchain fatty acids and lactate in urine.590
Fasting is an effective way to reduce microbial
populations in the gut.591 If the resident microbes do
not receive a relatively constant infusion of substrate
for growth, such as carbohydrates or amino acids, they
die. A discussion of the various clinical ramifications
Notes:

of fasting is beyond the scope of this book. Although
many patients may be candidates for fasting,592 the vast
majority are reluctant to apply the discipline required to
properly execute severe food restriction.
Regular oral dosing with organisms favorable
to the human gut (probiotics) and use of substrates
that encourage their growth, such as dietary fiber
and fructo-oligosaccharide (pre-biotics) are generally
implemented to achieve long-term control of intestinal
microbes.593 When aggressive intervention is warranted,
use of amoxicillin-clavulanic acid is a suitable candidate,
because offending microaerophilic bacteria are very
susceptible to its antibacterial action, and the anaerobic
populations decline as well, possibly due to the more
oxygen-rich environment produced by declining populations of the oxygen-consuming species. The rising
oxygen content can have bactericidal effects on strictly
anaerobic species.

Table 6.17 — Intestinal Overgrowth

Interventions

Class of
Intervention

Examples

General

Encourage high fiber diet, remove mucosal
irritants such as allergenic or IgG-positive
foods, alcohol, and NSAIDs
Pharmaceutical: Amoxycillin/Clavulanic Acid

Antibacterial

Pharmaceutical: Nystatin
Anti-fungal

Natural: See natural antibacterials
L. acidophilus, L. sporogenes, Bifidobacteria sp.,
S. boulardii, soil organisms
Fructo-oligosaccharide (FOS), increase
use of raw and cooked vegetables

Mucosal
regeneration

Glutamine, pantothenic acid,
deglycyrrhizinated licorice, slippery elm,
oligopeptide preparations

Prebiotic

Pharmaceutical: Flagyl

Probiotic

Natural: See natural antibacterials plus oil of
oregano, undecylenic acid and caprylic acid

Anti-protozoal

Notes:

Natural: Goldenseal or other berberinecontaining herbs, citrus seed extract, garlic,
uva ursi, aloe vera, glycyrrhiza, olive leaf
extract, garlic

Case Illustrations
Case Illustration 6.1 —

Carnitine Insufficiency in Schizophrenia
lism makers, adipate and suberate are very high while the
marker derived largely from leucine catabolism is only in the
4th quintile, presumably because of the concurrent depleted
status of leucine exhibited in the amino acid data. v
(See also Chapter 4, Case Illustration 4.6, Essential Amino
Acid Support in Schizophrenia.)

Percentile Ranking by Quintile
1st

2nd

3rd

20%

40%

4th
60%

5th
80%

95%
Reference
Interval

Results
mcg/mg creatinine
10.6

H

10.5

H

3.4
5.5

<= 4.5
<= 5.8
<= 8.5

4.3

1.8

This data is from a woman who had her first psychotic episode at 21-years-old. She presented for this metabolic profile
twelve years later exhibiting a severe form of schizophrenia.
Her plasma amino acid profile shows very low lysine along
with low values for the branced chain amino acids (BCAA).
A urinary organic acid profile done at the same time showed
positive biochemical markers for carnitine insufficiency. The
results justify essential amino acid therapy
with a custom formula that enhances lysine
and BCAA levels. Initial use of carnitine can
NUTRIENT MARKERS
help to assure metabolic demand for energy
Fatty Acid Metabolism
production from fatty acid oxidation is met
(Carnitine & B2)
1 Adipate
while lysine status is enhanced gradually by
2 Suberate
twice daily dosing of free form amino acids.
3 Ethylmalonate
Note that the long chain fatty acid metabo-

Case Illustration 6.2 —

α-Ketoglutarate Dehydrogenase Deficiency139

Profound alpha-ketoglutaric aciduria was found in a
patient with progressive extrapyramidal tract disease. The
4½-year-old boy was referred for evaluation of chronic,
relentless and progressive loss of milestones. The neurological impairment was observed to be primarily motor with a

Urine organic acid excretion (mcg/mg creatinine)
Compound
Lactate
## β-Hydroxybutyrate
3,4 Dihydroxybutyrate
Glycolate
Adipate
Aconitate
Citrate
α-Ketoglutarate

α-Hydroxyglutarate
p-Hydroxyphenylacetate

Patient
Reference Limit
—
<2
<2
lesser degree of behavioral and cognitive delay. Development
had been normal until an infection at 1.5 years of age that
resulted in seizures 1 to 2 times daily that were treated with
valproic acid. His speech was normal, but he had difficulty
climbing up and down stairs and throwing a ball. Another

infection at age 3 resulted in spasticity of the lower, and then
the upper extremities, along with ataxic gait. Three months
later another upper respiratory infection with fever, diarrhea
and vomiting resulted in increased tremors in extremities,
difficulty swallowing and inability to walk.
His urinary organic acid profile is shown. The bold fonts
emphasize the profound cis-aconitate and α-ketoglutarate
elevations. Moderately elevated adipate, β-hydroxybutyrate,
and p-hydroxyphenylacetate are also found.
The activity of α-ketoglutarate dehydrogenase in fibroblasts was found to be ~27% of normal, revealing the major
metabolic lesion in this case. Normal response to thiamin
pyrophosphate was demonstrated, allowing elimination of
thiamin insufficiency as a reason for the low enzyme activity.
The absence of citrate elevation shows the responsiveness of
citrate synthase to the high concentrations of downstream
products, controlling even more severe accumulation of the
pathway intermediates.
After the patient was placed on thiamine 25 mg/kg/d,
biotin 80 mg/kg/d, L-carnitine 50 mg/kg/d, riboflavin
15 mg/kg/d, and the antipsychotic, thioridazine 15 mg/kg/d,
he was stabilized and discharged to a chronic care facility. v

Case Illustration 6.3 —

Apparent Succinate Dehydrogenase Deficiency

This report presents an unusual pattern of
Percentile Ranking by Quintile
95%
1st
2nd
3rd
4th
5th
very low isocitrate and very high succinate.
Reference
Interval
Results
80%
40%
60%
20%
ug/mg creatinine
The degree of succinate elevation (too high
4.1
<= 7.1
4 Pyruvate
4.5
H
to measure) is suggestive of an inborn error
10.7
1.4 - 41.4
5 Lactate
29.5
H
of metabolism. The low levels of precursors,
2.8
<= 12.8
6 ß-Hydroxybutyrate
1.8
cis-aconitate and isocitrate, as well as failing
Energy Production (Citric Acid Cycle)
(B comp., Q10, Amino acids, Mg)
to find low downstream products, fumarate
7 Citrate
127 - 1,550
and malate tend to be confusing. How76
8 Cis-Aconitate
L
29 - 122
ever, the citric acid cycle is not an isolated
9 Isocitrate
L
36 - 130
27.8
biochemical pathway. The intermediates may
10 a-Ketoglutarate
21.5
2.6 - 60.0
12.3
be drawn from multiple sources as shown
11 Succinate
>160.0
H
1.1 - 34.0
0.71
12 Fumarate
0.92
H
<= 1.40
in Figure 6.1. cis-Aconitase is inhibited by
2.3
13 Malate
2.0
<= 4.3
elevated succinate, limiting precursor formation and restricting the further accumulation
Succinate dehydrogenase deficiency is known to cause
of succinate. Note the elevations of pyruvate
encephalomyopathy in childhood and optic atrophy or
and lactate that have also been reported in cases of diagnosed
tumors in adulthood.148 Some variants respond to riboflavin
succinate dehydrogenase deficiency.
Of course we would expect rather profound clinical effects
and CoQ10. v
if succinate dehydrogenase is significantly impaired because
this enzyme is otherwise known as Complex II in the
electron transport system of the mitochondrial membrane.

Case Illustration 6.4 —

Signs of HMG-CoA Lyase Deficiency in Autism

The laboratory results shown below were found in a
3-year-old boy with autistic features. No supplementation of
coenzyme Q10 had been done to explain the slightly elevated
serum CoQ10.
Percentile Ranking by Quintile
1st

2nd
20%

Serum
Coenzyme Q10

1.57

Vitamin E

17.3
Vitamin A

0.78

ß-Carotene

Urine
H

0.68
ug/mg creatinine

Hydroxymethylglutarate

4th
60%

5th
80%

Results
ug/mg creatinine
3rd
40%

72.5

H

0.50

1.50

8.6

24.6

0.53

1.30

0.22

1.55

18.6

The urinary organic acid profile showed an extremely
elevated level of hydroxymethylglutarate (HMG), indicating
a potential deficiency of HMG-CoA lyase. The elevated HMG
can accelerate the biosynthetic pathway leading to CoQ10 and
cholesterol, although that pathway is tightly
controlled in most individuals. Serum
95%
cholesterol was found to be 164 mg/dL in
Reference
Interval
this 3-year-old.
This situation is in contrast to that
0.40 - 2.3
seen when statin drugs operate to inhibit
7.1 - 31.0
HMG-CoA reductase preventing the
0.41 - 1.5
conversion to mevalonate and cholesterol.
0.22 - 2.7
In that scenario, CoQ10 biosynthesis is also
inhibited producing lower serum levels. v
<= 27.2

Case Illustration 6.5 —

Specific Ketoisovaleric Aciduria as a Sign of Genetic Abnormality

This 10-year-old male has an extreme aversion to cold
environments and his urine was producing foam. A urinalysis showed greatly elevated total protein and moderately
elevated creatinine. His serum BUN and creatine was also
elevated. A urinary organic acid profile revealed severe
α-ketoisovaleric aciduria with 1st quintile α-ketoisocaproate
Percentile Ranking by Quintile
1st

2nd
20%

4th
60%

5th
80%

Results
μg/mg creatinine
a-Ketoisocaproate

<0.1
a-Keto-ß-Methylvalerate

0.3
## Xanthurenate

0.37
ß-Hydroxyisovalerate

1.7

0.60

H

0.39

2.47

1.6
0.70
9.0

a-Ketoisovalerate

Case Illustration 6.6 —

Undetectable Quinolinate

## B-Complex Vitamin Markers
(B1, B2, B3, B5, B6, Biotin)

3rd
40%

and α-keto-β-methylvalerate as shown in the inset. Such an
imbalance of the branced chain amino acids indicates factors
other than thiamin or general B-complex vitamin insufficiency that would affect all of them. Thus, the results support
a presumptive diagnosis of genetic polymorphism of the
isovaleryl-CoA dehydrogenase enzyme.
A low protein diet is indicated along with
supplementation
of carnitine and glycine.
95%
Reference
A trial of thiamin supplementation effect
Interval
on urinary α-ketoisovalerate will establish
whether the enzyme variant in this patient is
<= 0.94
<= 0.58
responsive to cofactor concentration. Plasma
<= 2.7
amino acids may be monitored to assess es<= 1.10
sential amino acid adequacy. v
<= 15.3

A 67-year-old woman who had exhibited
Percentile Ranking by Quintile
chronic signs of thyroid insufficiency with
95%
Ranges are for ages 13 and over.
1st
2nd
3rd
4th
5th
Reference
refractory responses to various administration
Interval
20%
40%
60%
80%
of thyroid hormone was tested for urinary orOrganic Acid Profile Results
mcg/mg creatinine
0.70
0.93 H
<= 1.10
ganic acids and plasma fatty acids. She exhibits Xanthurenate
1.5
Kynurenate
1.8 H
<= 2.5
orange coloration of the skin suggesting failure
10.2
<= 16.5
Quinolinate
<1
of β-carotene conversion to vitamin A which is
Plasma
Fatty Acid Profile Results
µM
stimulated by thyroxine. Testing confirmed an
9 - 276
elevated β-carotene along with low normal viEicosapentaenoic (20:5n3)
33 - 224
Dihomogamma Linolenic (20:3n6) 40 L
L
1.8 H
tamin A. Her urinary quinolinate was less than
269 - 1,170
Arachidonic (20:4n6)
366 L
the quantitative limit of detection (< 1.0 µ/mg
creatinine). This result is emphasized by the
elevation of xanthurenate and kynurenate,
first decile cutoff values. This pattern suggests that inflammetabolites produced in the hepatic kynurenin pathway.
matory cascade initiators may be insufficiently available to
Insufficiency of inflammatory cascade initiators such as the
maintain normal regulatory cytokine control. The thyroid
eicosanoid products of essential fatty acids could lead to poor
gland is responsive to eicosanoid signaling mechanisms via
cytokine stimulation of the neuronal kynurenin pathway
cyclooxygenase enzymes present in thyroid epithelial cells.594
activity (see Figure 6.15). The data has some support for
such a guess. This patient’s levels of polyunsaturated fatty
The laboratory data shown suggests that this patient is a
acids show an unusual pattern of mid-normal omega-3 levels
candidate for aggressive supplementation with vitamin B6
together with low levels of omega-6. The dominant omega-6,
and oils rich in gamma-linolenic acid which may assist in inseries 2 eicosanoid precursor, arachidonic acid, and the series
creasing DGLA and AA. A positive response in thyroid status
1 precursor, dihomogammalinolenic acid, are below their
would be supportive of the hypothesis. v

Case Illustration 6.7 —

Redox Stress in COPD

Oxidative Damage and Antioxidant Markers
This 72-year-old female has chronic
(Vitamin C and other antioxidants)
obstructive pulmonary disease, emphysema,
1.1
<= 2.0
27 p-Hydroxypenylacetate
3.5
H
severe fatigue, congestive heart failure and is
5.3
<= 7.6
28 8-Hydroxy-2-deoxyguanosine*
7.7
H
a former smoker. She has been on prescriptions of Mucinex, Actonel, Spiriva, Coreg
1.0
30 Orotate
2.4
H
<= 1.6
and Xanax The organic acid profile shows
7.0
31 Glucarate
12.2
H
<= 11.9
elevated HPLA and 8-OHdG, indicating
stimulation of cell division and oxidative
stress. Concurrent orotate elevation indicates
therapy with high antioxidant-content foods and suppledifficulty with meeting hepatic demands for ammonia
ments and arginine stimulation of urea cycle activity is
clearance through the urea cycle. The high glucarate signals
suggested by the data. v
stress on the hepatic glucuronidation pathway. Combination

Case Illustration 6.8 —

34 Sulfate
B

32 a-Hydroxybutyrate
33 Pyroglutamate
34 Sulfate

C

H
C

32 a-Hydroxybutyrate
33 Pyroglutamate
34 Sulfate

Notes:
3.5

H
H
0.5
H
L

3.5

32 a-Hydroxybutyrate
33 Pyroglutamate

B

A

A

demand (A), moderate threat of glutathione depletion needing glycine support (B) and chronic, severe glutathione deficiency where low sulfate suggests poor
total-body glutathione status and first
1.2
<= 2.2
quintile a-hydroxybutyrate indicates
< 95
inability to up-regulate glutathione
111 - 477
synthesis (C). Fasting plasma amino
acid profiles provide very helpful
1.2
additional information about these
<= 2.2
< 95
patients abilities to sustain methionine
111 - 477
and taurine sulfur-containing amino
acid levels. v

These three patterns represent the situation that might
be found in patients with mild, transient glutathione

Three Glutathione Demand Scenarios

1.2
<= 2.2
< 95
111 - 477

Case Illustration 6.9 —

Scenarios for Abnormal Benzoate and Hippurate
Percentile Ranking by Quintile
1st

< 0.1
Phenylpropionate

0.2
p-Hydroxybenzoate

0.9
p-Hydroxyphenylacetate
Indican
Tricarballylate

0.4
Benzoate

<1
Hippurate
Phenylacetate

< 0.1
Phenylpropionate

0.2
p-Hydroxybenzoate

0.2
p-Hydroxyphenylacetate
Indican
Tricarballylate

0.8
Benzoate

<1
Hippurate
Phenylacetate

< 0.1
Phenylpropionate
p-Hydroxybenzoate
2.5
0.11
2.1
1.0
1.6

2.5
H

0.11
2.1

H

1.8

H

p-Hydroxyphenylacetate
H
Indican
H
Tricarballylate

0.7
Benzoate

14.1

Hippurate
Phenylacetate

< 0.1
Phenylpropionate

2.0
p-Hydroxybenzoate

0.3
p-Hydroxyphenylacetate
Indican
Tricarballylate

0.4

<= 8.2
<= 786
<= 0.33
<= 9.7
<= 2.4
0.7
80%

95%
Reference
Interval

H
H

<= 30
<= 115
<= 3.6

Phenylacetate

60%

5th

4th

40%

Hippurate

3rd

H

D

3.9

C

Benzoate

B

20%

A

2nd

1.0
1.6

2.5
0.11
2.1
1.0
1.6

2.5
0.11
2.1
1.0
1.6

<= 8.2

<= 786

<= 0.33
<= 9.7
<= 2.4
<= 30
<= 115
<= 3.6

<= 8.2
<= 786
<= 0.33
<= 9.7
<= 2.4
<= 30
<= 115
<= 3.6

<= 8.2
<= 786
<= 0.33
<= 9.7
<= 2.4
<= 30
<= 115
<= 3.6

A- Detoxification Phase II glycine conjugation insufficiency without bacterial overgrowth—only benzoate high.
B- Normal glycine conjugation with absence of bacterial overgrowth—only hippurate high. Bacterial origin of the hippurate cannot
be ruled out, but dietary benzoate is the more common explanation.
C- Normal glycine conjugation with presence of bacterial overgrowth—hippurate plus other bacterial markers high.
D- Insufficient glycine conjugation with absence or restricted type of bacterial overgrowth—benzoate and hippurate high. The
more severe levels raise the probability that specific bacteria overgrowth is contributing benzoate and hippurate, even though
other products of polyphenol metabolism are not abnormal. v

Case Illustration 6.10 —

An Unusual Microbial Phenyl Compound Pattern

This 58-year-old woman has a pattern of
Percentile Ranking by Quintile
95%
multiple elevations for the phenyl bacterial
1st
2nd
3rd
4th
5th
Reference
Interval
20%
40%
60%
80%
products in her urinary organic acids pro2.5
<= 8.2
Benzoate
34.1 H
file. Phenylpropionate is greatly elevated,
<= 786
Hippurate
indicating lack of medium-chain acyl-CoA
0.11
<= 0.33
Phenylacetate
0.09
dehydrogenase. Even in the absence of
2.1
<= 9.7
Phenylpropionate
>32 H
this enzyme, however, glycine conjugation
1.0
<= 2.4
p-Hydroxybenzoate
6.5 H
enzymes should form the glycine conjugate,
<= 30
p-Hydroxyphenylacetate
60 H
3-phenylpropionyl glycine for elimination.
<= 115
Indican
1.6
<= 3.6
Tricarballylate
6.3 H
The pattern shows great elevation of benzo0.40
<=1.24
Dihydroxyphenylpropionate
2.55 H
ate and low normal hippurate that only
occurs when the glycine conjugation system
is severely compromised (by a second
genetic polymorphism in most cases). The
by Lactobacillus brevis or L. hilgardii during fermentation.599
data indicate the presence of dual genetic defects affecting
PEA is a neuromodulatory agent that induces dopamine reMCAD and glycine conjugase enzymes. Further complicating
lease. Combined dosing of mice with PEA (100 mg/kg, i.p.)
the picture is the unique absence of phenylacetate, indicating
and l-deprenyl (10 mg/kg, s.c.) produces stereotypic behavthat bacterial species with ability to produce this compound
ior, following which brain dopamine levels are reduced.600
are strongly suppressed.
Urinary PA was found to be low in unipolar depression601
Regarding phenylacetate: Although elevated urinary
and mania.602 In a separate study, patients with severe
phenylacetate (PA) may be ascribed to the presence of
depression (Hamilton Depression score of 17 or higher)
intestinal bacterial growth, a distinctly different indication
were shown to have lower plasma and urinary PA levels than
may be drawn from finding abnormally low levels. Since the
those with less severe scores.603 These studies provide a basis
section of the laboratory report shown here is presenting the
for the elevation of mood by supplemental phenylalanine.
group of bacterial markers, it does not have low limits for PA.
Raised PA excretion has also been proposed to explain the
Methods that are optimized to accurately measure PA in the
antidepressant effects of exercise.604 Thus, in addition to the
low physiological range can reveal cases of abnormally low
potential protective effects of PA against cancer as discussed
values.
in this chapter, the compound has further potential as a
Mammalian brain can convert phenylalanine to 2-phenylemarker that shows metabolic effects of PEA on mood and
thylamine (PEA)597, and PEA is degraded to phenylacetate in
behavior. In both instances, increased risk is indicated by
abnormally low urinary PA. v
the liver.598 Wine is a notable dietary source of PEA formed

Notes:

References

19.

Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of
alkaptonuria. N Engl J Med. 2002;347(26):2111-2121.

20.

Chuang D, Shih V. Disorders of branched chain amino acid and keto acid

Metabolic and Molecular Bases of Inherited Disease. Vol 2, 8th ed. New

metabolism. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic

York: Mcgraw-Hill; 2001.

and Molecular Bases of Inherited Disease. Vol 1. 7th ed. New York:

21.

Mcgraw-Hill; 1995:1239-1277.

alkaptonuria patient. Biochem Cell Biol. 1991;69(4):269-273.

C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases

22.

of Inherited Disease. Vol 1. 7th ed. New York: McGraw-Hill;1995:1387-

23.

Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy

human erythrocytic hemoglobin. Int J Hematol. 2000;72(3):318-324.

(increased K(m)): relevance to genetic disease and polymorphisms. Am J

24.

Clin Nutr. 2002;75(4):616-658.

syndrome. Cardiology. 1998;90(4):302-304.

Ozand PT, Gascon GG. Organic acidurias: a review. Part 2. J Child Neurol.

and healthy children. Clin Chem Lab Med. 2003;41(3):356-359.
26.

Scriver CR. The Metabolic and Molecular Bases of Inherited Disease. 8th

with experimental alcaptonuria. Nature. 1970;228(5273):770-771.

Tanake K, Hine D, West-Dull A, et al. Gas-chromatographic method of

27.

analysis for urinary organic acids. I. retention indices of 155 metabolically

16.

Scriver CR, Rosenberg LE. Amino Acid Metabolism and its Disorders.

Norwalk: Appleton-Century-Crofts; 1984.

Lord R, Bralley J. Organics in urine: assessment of gut dysbiosis, nutrient
deficiencies and toxemia. Nutr Pers. 1997;20(4):25-31.

11.

10.

Bralley J, Lord R. Urinary organic acids profiling for assessment of

nutrient deficiencies, gut dysbiosis and toxicity. In: Murray P, ed. Textbook

of Natural Medicine. Vol 29. Edinburgh: Churchill Livingstone; 1998:22912.

237.

1994;59(2):177-180.

1994;47(12):2294-2297.

Abnormalities in Amino Acid Metabolism in Clinical Medicine. Norwalk:
Duez P, Kumps A, Mardens Y. GC-MS profiling of urinary organic acids
evaluated as a quantitative method. Clin Chem. 1996;42(10):1609-1615.
16.

Newborn Screening Panel. J Pediatr. 2002;141(4):524-531.
17.

18.

Beltran-Valero de Bernabe D, Granadino B, Chiarelli I, et al. Mutation and
polymorphism analysis of the human homogentisate 1, 2-dioxygenase
gene in alkaptonuria patients. Am J Hum Genet. 1998;62(4):776-784.

von Kleist-Retzow JC, Schauseil-Zipf U, Michalk DV, et al. Mitochondrial
Physiol. 2003;88(1):155-166.

33.

Petersen KF, Dufour S, Befroy D, et al. Impaired mitochondrial activity in
the insulin-resistant offspring of patients with type 2 diabetes. N Engl J
Med. 2004;350(7):664-671.

34.

Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the
elderly: possible role in insulin resistance. Science. 2003;300(5622):11401142.

35.

von Kleist-Retzow JC, Cormier-Daire V, de Lonlay P, et al. A high rate
(20%-30%) of parental consanguinity in cytochrome-oxidase deficiency.
Am J Hum Genet. 1998;63(2):428-435.

36.

Matern D, Strauss AW, Hillman SL, et al. Diagnosis of mitochondrial
trifunctional protein deficiency in a blood spot from the newborn
screening card by tandem mass spectrometry and DNA analysis. Pediatr

zwitterionic organic acids using weak-anion exchange chromatography
Sci. 2006;848:303-310.

Suzuki Y, Oda K, Yoshikawa Y, et al. A novel therapeutic trial of

diseases--an expanding spectrum of disorders and affected genes. Exp

Bishop MJ, Crow BS, Kovalcik KD, et al. Quantification of urinary
with tandem MS detection. J Chromatogr B Analyt Technol Biomed Life

Mayatepek E, Kallas K, Anninos A, et al. Effects of ascorbic acid and low-

1999;44(2):79-84.
32.

Insinga RP, Laessig RH, Hoffman GL. Newborn screening with tandem
mass spectrometry: examining its cost-effectiveness in the Wisconsin

and radiographic abnormalities with protein restriction and ascorbic acid

homogentisic aciduria in a murine model of alkaptonuria. J Hum Genet.

Appleton-Century-Crofts; 1984:419-453.
15.

Morava E, Kosztolanyi G, Engelke UF, et al. Reversal of clinical symptoms

protein diet in alkaptonuria. Eur J Pediatr. 1998;157(10):867-868.
31.

Sweetman L. Qualitative and quantitative analysis of organic acids in
physiologic fluids for diagnosis of the organic acidurias. In: Nyhan W, ed.

effect in infancy. Pediatr Res. 1989;26(2):140-144.

in alkaptonuria. Ann Clin Biochem. 2003;40(Pt 1):108-111.
30.

Goodwin BL, Ruthven CR, Sandler M. Gut flora and the origin of
some urinary aromatic phenolic compounds. Biochem Pharmacol.

14.

29.

Ong CN, Lee BL, Shi CY, et al. Elevated levels of benzene-related
compounds in the urine of cigarette smokers. Int J Cancer.

13.

alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic

Nyhan W. Abnormalities in Amino Acid Metabolism in Clinical Medicine.

Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in

28.

Philadelphia: Saunders; 1973.
9.

Hiraku Y, Yamasaki M, Kawanishi S. Oxidative DNA damage induced by
homogentisic acid, a tyrosine metabolite. FEBS Lett. 1998;432(1-2):13-

important compounds. Clin Chem. 1980;26(13):1839-1846.
8.

Lustberg TJ, Schulman JD, Seegmiller JE. Decreased binding of 14Chomogentisic acid induced by ascorbic acid in connective tissue of rats

ed. New York: McGraw-Hill; 2001.
7.

Olah AV, Llyes I, Szoke A, et al. Urinary homogentisic acid in alkaptonuric

25.

1991;6(4):288-303.
6.

Vavuranakis M, Triantafillidi H, Stefanadis C, et al. Aortic stenosis and
coronary artery disease caused by alkaptonuria, a rare genetic metabolic

Ozand PT, Gascon GG. Organic acidurias: a review. Part 1. J Child Neurol.
1991;6(3):196-219.

5.

Yoneda Y, Akazawa M, Koizumi J, et al. Multi-effective properties of
homogentisic acid revealed in reactions with human hemoglobin and

stimulates variant enzymes with decreased coenzyme binding affinity

4.

Mannoni A, Selvi E, Lorenzini S, et al. Alkaptonuria, ochronosis, and
ochronotic arthropathy. Semin Arthritis Rheum. 2004;33(4):239-248.

1422.
3.

Menon IA, Persad SD, Haberman HF, et al. Characterization of
the pigment from homogentisic acid and urine and tissue from an

Sweetman L, Williams JC. Branched chain organic acidurias. In: Scriver

2.

La Du B. Alkaptonuria. In: Scriver C, Beaudet A, Sly W, Valle D, eds. The

1.

Res. 1999;46(1):45-49.
37.

Gillingham MB, Scott B, Elliott D, et al. Metabolic control during exercise
with and without medium-chain triglycerides (MCT) in children with
long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional
protein (TFP) deficiency. Mol Genet Metab. 2006;89:58-63.

56.

Labarthe F, Benoist JF, Brivet M, et al. Partial hypoparathyroidism
associated with mitochondrial trifunctional protein deficiency. Eur J

Zucker rats: indications for impaired oxidation of butyrate and hexanoate.

Pediatr. 2006;165(6):389-391.

Metabolism. 1990;39(10):1012-1020.
57.

Spiekerkoetter U, Bennett MJ, Ben-Zeev B, et al. Peripheral neuropathy,
episodic myoglobinuria, and respiratory failure in deficiency of the

with elevated butyryl- and isobutyryl-carnitine detected by tandem mass

mitochondrial trifunctional protein. Muscle Nerve. 2004;29(1):66-72.

spectrometry newborn screening. Pediatr Res. 2003;54(2):219-223.
58.

Spierkerkoetter U, Khuchua Z, Yue Z, et al. The early-onset phenotype
of mitochondrial trifunctional protein deficiency: a lethal disorder with

butyryl/isobutyrylcarnitine concentrations as marker of SCAD defect and

multiple tissue involvement. J Inherit Metab Dis. 2004;27(2):294-296.
41.

ethylmalonic encephalopathy. J Inherit Metab Dis. 2006;29(5):685.
59.

Curione M, Danese C, Viola F, et al. Carnitine deficiency in patients

60.

Cardiovasc Dis. 2005;15(4):279-283.
Paulson DJ. Carnitine deficiency-induced cardiomyopathy. Mol Cell

44.

dehydrogenase. Pediatr Res. 1996;39(6):1059-1066.
61.

Singh RB, Aslam M. L-carnitine administration in coronary artery disease

of enzymes involved in terminal oxidative metabolism in skeletal

Rizos I. Three-year survival of patients with heart failure caused by dilated

muscle mitochondria from a riboflavin-responsive, multiple acyl-CoA

cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2

dehydrogenase deficiency patient. Electrophoresis. 2006;27(5-6):11821198.
62.

Asai T, Okumura K, Takahashi R, et al. Combined therapy with
PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due
Feller AG, Rudman D. Role of carnitine in human nutrition. Journal of

2004;67(6):48-52.

van Maldegem BT, Duran M, Wanders RJ, et al. Clinical, biochemical,

65.

deficiency. JAMA. 2006;296(8):943-952.

and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase
49.

Rinaldo P, Welch RD, Previs SF, et al. Ethylmalonic/adipic aciduria: effects

dehydrogenase deficiency. J Pediatr. 1995;126(1):69-71.
68.

studies on the omega- and omega-1-oxidation of medium-chain (C6-C12)
51.

Pediatr. 1994;124(1):79-86.
70.

C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Bases of

treatable hepatomuscular disorder in two adult brothers. J Hepatol.

Inherited Disease. Vol 1. 8th ed. New York: Mcgraw-Hill; 2001.
71.

Amendt BA, Greene C, Sweetman L, et al. Short-chain acyl-coenzyme
A dehydrogenase deficiency. Clinical and biochemical studies in two

syndrome. Neurology. 1988;38(2):239-241.
73.

1994;16 Suppl:12-22.
55.

Schuler AM, Gower BA, Matern D, et al. Influence of dietary fatty acid

Wallace DC. Mitochondrial genetics: a paradigm for aging and
degenerative diseases? Science. 1992;256(5057):628-632.

74.

chain-length on metabolic tolerance in mouse models of inherited

Bates CJ. Liberation of 14CO2 from [14C]adipic acid and [14C]octanoic
acid by adult rats during riboflavin deficiency and its reversal. Br J Nutr.

defects in mitochondrial fatty acid beta-oxidation. Mol Genet Metab.
2004;83(4):322-329.

Trauner DA, Horvath E, Davis LE. Inhibition of fatty acid beta oxidation
by influenza B virus and salicylic acid in mice: implications for Reye’s

Ozand PT, Rashed M, Millington DS, et al. Ethylmalonic aciduria: an
organic acidemia with CNS involvement and vasculopathy. Brain Dev.

Scholte HR, Busch HF, Bakker HD, et al. Riboflavin-responsive complex I
deficiency. Biochim Biophys Acta. 1995;1271(1):75-83.

72.

patients. J Clin Invest. 1987;79(5):1303-1309.
54.

Roe C, Ding J. Mitochondrial Fatty Acid Oxidation Disorders. In: Scriver

Elias E, Gray RG, Poulton K, et al. Ethylmalonic adipic aciduria--a
1997;26(2):433-436.

53.

Burlina AB, Dionisi-Vici C, Bennett MJ, et al. A new syndrome with
ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. J

artifactual sources of urinary organic acids: a comprehensive table. Clin
52.

McTague JA, Forney R, Jr. Jamaican vomiting sickness in Toledo, Ohio.
Ann Emerg Med. 1994;23(5):1116-1118.

69.

Kumps A, Duez P, Mardens Y. Metabolic, nutritional, iatrogenic, and
Chem. 2002;48(5):708-717.

Dawson DB, Waber L, Hale DE, et al. Transient organic aciduria and
persistent lacticacidemia in a patient with short-chain acyl-coenzyme A

C10-dicarboxylic and C6-C10-omega-1-hydroxy monocarboxylic acids

fatty acids in human and rat liver. Pediatr Res. 1983;17(10):828-834.

Tein I, Haslam RH, Rhead WJ, et al. Short-chain acyl-CoA dehydrogenase
Neurology. 1999;52(2):366-372.

67.

Gregersen N, Mortensen PB, Kolvraa S. On the biologic origin of C6in human and rat with acyl-CoA dehydrogenation deficiencies: in vitro

Bok LA, Vreken P, Wijburg FA, et al. Short-chain Acyl-CoA dehydrogenase
deficiency: studies in a large family adding to the complexity of the

deficiency: a cause of ophthalmoplegia and multicore myopathy.

excretion of organic acids, acylcarnitines, and acylglycines. Pediatr Res.
50.

Suppl 3:S213-218.

disorder. Pediatrics. 2003;112(5):1152-1155.
66.

of oral medium-chain triglycerides, carnitine, and glycine on urinary
1991;30(3):216-221.

Gregersen N, Andresen BS, Bross P. Prevalent mutations in fatty acid
oxidation disorders: diagnostic considerations. Eur J Pediatr. 2000;159

1996;255(1):67-83.

64.

Fontaine M, Briand G, Ser N, et al. Metabolic studies in twin brothers
with 2-methylacetoacetyl-CoA thiolase deficiency. Clin Chim Acta.

48.

Bykov IL. [Effect of L-carnitine on metabolic disorders in rats with
experimental acyl-CoA dehydrogenase deficiency]. Eksp Klin Farmakol.

Nutrition. 1988;118(5):541-547.
47.

Liang WC, Tsai KB, Lai CL, et al. Riboflavin-responsive glutaric aciduria
type II with recurrent pancreatitis. Pediatr Neurol. 2004;31(3):218-221.

63.

to systemic carnitine deficiency. Cardiovasc Res. 2006;70(3):566-577.
46.

Gianazza E, Vergani L, Wait R, et al. Coordinated and reversible reduction

and cardiomyopathy. J Assoc Physicians India. 1998;46(9):801-805.

Pt 3):S120-123.
45.

Corydon MJ, Gregersen N, Lehnert W, et al. Ethylmalonic aciduria is
associated with an amino acid variant of short chain acyl-coenzyme A

Biochem. 1998;180(1-2):33-41.
43.

Gordon N. Acyl-CoA dehydrogenase deficiency: varieties with
neurological involvement. Dev Med Child Neurol. 2005;47(3):207-210.

with coeliac disease and idiopathic dilated cardiomyopathy. Nutr Metab
42.

Merinero B, Perez-Cerda C, Ruiz Sala P, et al. Persistent increase of plasma

40.

Koeberl DD, Young SP, Gregersen NS, et al. Rare disorders of metabolism

39.

McDevitt J, Wilson S, Her GR, et al. Urinary organic acid profiles in fatty

38.

1990;63(3):553-562.
75.

Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic
and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet.
2006;142(2):95-103.

76.

96.

Murray RK, Granner DK, Mayes PA, et al., eds. Harper’s Illustrated
Biochemistry. New York: Lange Medical Books/McGraw-Hill; 2003.

77.

axis is suppressed in cancer and its normalization promotes apoptosis and

Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial

inhibits cancer growth. Cancer Cell. 2007;11(1):37-51.
97.

encephalomyopathies. Short-term double-blind, crossover study. Eur
Neurol. 1997;37(4):212-218.
78.

2006;89(5):1390-1399.
98.

1996;40(2):309-318.

individuals with type 2 diabetes. Diabetes. 1997;46(11):1786-1791.
99.

stimulated glycogen synthesis is associated with activation of

Naito E, Ito M, Yokota I, et al. Thiamine-responsive lactic acidaemia: role

phosphatidylinositol 3-kinase and is independent of insulin receptor
tyrosine phosphorylation. Biochemistry. 1998;37(19):7006-7014.

Gries CL, Scott ML. The pathology of thiamin, riboflavin, pantothenic

100. Bardosi A, Creutzfeldt W, DiMauro S, et al. Myo-, neuro-, gastrointestinal

acid and niacin deficiencies in the chick. J Nutr. 1972;102(10):1269-

encephalopathy (MNGIE syndrome) due to partial deficiency of

1285.

cytochrome-c-oxidase. A new mitochondrial multisystem disorder. Acta

Munujos P, Coll-Canti J, Beleta J, et al. Brain pyruvate oxidation in

Neuropathol. 1987;74(3):248-258.

82.

101. Adams JH, Koeslag JH. Glycogen metabolism and post-exercise ketosis

experimental thiamin-deficiency encephalopathy. Clin Chim Acta.
1996;255(1):13-25.

in carbohydrate-restricted trained and untrained rats. Q J Exp Physiol.

Toyoshima M, Oka A, Egi Y, et al. Thiamine-responsive congenital lactic

1989;74(1):27-34.

83.

102. Pan JW, Rothman TL, Behar KL, et al. Human brain beta-hydroxybutyrate

acidosis: clinical and biochemical studies. Pediatr Neurol. 2005;33(2):98104.

and lactate increase in fasting-induced ketosis. J Cereb Blood Flow Metab.

84.

Rao GA, Riley DE, Larkin EC. Fatty liver caused by chronic alcohol

2000;20(10):1502-1507.

103. Massey LK, Roman-Smith H, Sutton RA. Effect of dietary oxalate and

ingestion is prevented by dietary supplementation with pyruvate or
glycerol. Lipids. 1984;19(8):583-588.

Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy,
treatment options. CNS Drugs. 2006;20(6):443-464.

lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of
87.

Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV

infected patients: a systematic review of published cases. Sex Transm
Infect. 2003;79(4):340-343.

Kruse JA. Review: metformin does not increase risk for lactic acidosis or

88.

increase lactate levels in type 2 diabetes. ACP J Club. 2004;141(1):7.
89.

Kwong SC, Brubacher J. Phenformin and lactic acidosis: a case report and
review. J Emerg Med. 1998;16(6):881-886.

Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic

90.

acidosis in human immunodeficiency virus-infected patients: report of 12
cases and review of the literature. Clin Infect Dis. 2002;34(6):838-846.
91.

Konrad T, Vicini P, Kusterer K, et al. alpha-Lipoic acid treatment decreases
serum lactate and pyruvate concentrations and improves glucose
effectiveness in lean and obese patients with type 2 diabetes. Diabetes
Care. 1999;22(2):280-287.

92.

Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogueinduced lactic acidosis [letter]. Lancet. 1998;352(9124):291-292.

93.

Santos JL, Fontanellas A, Moran MJ, et al. Nonsynergic effect of
ethanol and lead on heme metabolism in rats. Ecotoxicol Environ Saf.
1999;43(1):98-102.

94.

Bardosi A, Cruetzfeldt W, al. e. Lactate, hydroxybutyrate, and fumarate
elevation in an adult with defective cytochrome c oxidase. Acta
Neuropathol. 1987;74(3):248-258.

95.

kidney stones. J Am Diet Assoc. 1993;93(8):901-906.

104. Brinkley LJ, Gregory J, Pak CY. A further study of oxalate bioavailability in

review of the literature. Can Respir J. 2002;9(3):203-208.
86.
calcium on urinary oxalate and risk of formation of calcium oxalate

Prakash S, Mehta S. Lactic acidosis in asthma: report of two cases and

85.

Pandey SK, Anand-Srivastava MB, Srivastava AK. Vanadyl sulfate-

Neurol Sci. 1998;156(1):41-46.
of pyruvate dehydrogenase complex. Eur J Pediatr. 1998;157(8):648-652.
81.

Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of
supplemental chromium improve glucose and insulin variables in

Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial
encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J

80.

Liong MT, Shah NP. Effects of a Lactobacillus casei synbiotic on serum
lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci.

Walker V, Bennet L, Mills GA, et al. Effects of hypoxia on urinary
organic acid and hypoxanthine excretion in fetal sheep. Pediatr Res.

79.

Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel

foods. J Urol. 1990;144(1):94-96.

105. Al-Wahsh IA, Horner HT, Palmer RG, et al. Oxalate and phytate of soy
foods. J Agric Food Chem. 2005;53(14):5670-5674.
106. Allison MJ, Cook HM, Milne DB, et al. Oxalate degradation by
gastrointestinal bacteria from humans. J Nutr. 1986;116(3):455-460.
107. Mikami K, Akakura K, Takei K, et al. Association of absence of intestinal
oxalate degrading bacteria with urinary calcium oxalate stone formation.
Int J Urol. 2003;10(6):293-296.
108. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after
an oral course of lactic acid bacteria at high concentration. Kidney Int.
2001;60(3):1097-1105.
109. Hoppe B, von Unruh G, Laube N, et al. Oxalate degrading bacteria: new
treatment option for patients with primary and secondary hyperoxaluria?
Urol Res. 2005;33(5):372-375.
110. Goldfarb DS. Microorganisms and calcium oxalate stone disease. Nephron
Physiol. 2004;98(2):48-54.
111. Kodama T, Akakura K, Mikami K, et al. Detection and identification of
oxalate-degrading bacteria in human feces. Int J Urol. 2002;9(7):392-397.
112. van Woerden CS, Groothof JW, Wanders RJ, et al. [From gene to disease;
primary hyperoxaluria type I caused by mutations in the AGXT gene].
Ned Tijdschr Geneeskd. 2006;150(30):1669-1672.
113. Maldonado I, Prasad V, Reginato AJ. Oxalate crystal deposition disease.
Curr Rheumatol Rep. 2002;4(3):257-264.
114. McConnell N, Campbell S, Gillanders I, et al. Risk factors for developing
renal stones in inflammatory bowel disease. BJU Int. 2002;89(9):835-841.

Oshida Y, Iwao N, Ohsawa I, et al. Effect of insulin on intramuscular 3-

115. Williams CP, Child DF, Hudson PR, et al. Why oral calcium supplements

hydroxybutyrate levels in diabetic rats. Horm Metab Res. 1998;30(2):70-

may reduce renal stone disease: report of a clinical pilot study. J Clin

71.

Pathol. 2001;54(1):54-62.

135. Rotig A, de Lonlay P, Chretien D, et al. Aconitase and mitochondrial

116. Chen WC, Chen HY, Lu HF, et al. Association of the vitamin D receptor
gene start codon Fok I polymorphism with calcium oxalate stone disease.

iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet.

BJU Int. 2001;87(3):168-171.

1997;17(2):215-217.

117. Selvam R. Calcium oxalate stone disease: role of lipid peroxidation and

136. Andreeshcheva EM, Popova TN, Artyukhov VG, et al. Free radical

antioxidants. Urol Res. 2002;30(1):35-47.

oxidation and catalytic activity of aconitate hydratase in rat liver under

118. Matsumoto I, Kuhara T, Matsumoto M, et al. Urinary organic acid profile

normal conditions and during toxic hepatitis. Bull Exp Biol Med.
2004;137(4):352-354.

studies in a patient with cytochrome c oxidase deficiency. 39th ASMS

137. Bouton C, Chauveau MJ, Lazereg S, et al. Recycling of RNA binding iron

Conf. 1991; Nashville, TN.
119. Varalakshmi P, Sandhya S, Malarkodi KP. Evaluation of the effect of lipoic

regulatory protein 1 into an aconitase after nitric oxide removal depends
on mitochondrial ATP. J Biol Chem. 2002;277(34):31220-31227.

acid administered along with gentamicin in rats rendered bacteremic. Mol

138. Murakami K, Haneda M, Yoshino M. Prooxidant action of xanthurenic

Cell Biochem. 2003;248(1-2):35-40.
120. Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion.

acid and quinoline compounds: role of transition metals in the generation
of reactive oxygen species and enhanced formation of 8-hydroxy-2’-

Am J Physiol. 1987;253(4 Pt 2):F595-605.
121. Milner JA. Metabolic aberrations associated with arginine deficiency. J

deoxyguanosine in DNA. Biometals. 2006;19(4):429-435.
139. al Aqeel A, Rashed M, Ozand PT, et al. A new patient with alpha-

Nutr. 1985;115(4):516-523.
122. Prior RL, Zimber A, Visek WJ. Citric, orotic, and other organic

ketoglutaric aciduria and progressive extrapyramidal tract disease. Brain
Dev. 1994;16:33-37.

acids in rats injected with active or inactive urease. Am J Physiol.

140. Gascon GG, Ozand PT, Brismar J. Movement disorders in childhood

1975;228(3):828-833.
123. VanDervoort K, Wiesen J, Frank R, et al. Urolithiasis in pediatric patients:

organic acidurias. Clinical, neuroimaging, and biochemical correlations.
Brain Dev. 1994;16 Suppl:94-103.

a single center study of incidence, clinical presentation and outcome. J

141. Shaw Dea. Management of fatigue: a physiological approach. Am J Med

Urol. 2007;177(6):2300-2305.
124. Hoppe B, von Unruh GE, Blank G, et al. Absorptive hyperoxaluria leads to

Sci. 1962:243:758.

142. Hicks J. Treatment of fatigue in general practice: a double blind study.

an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am
J Kidney Dis. 2005;46(3):440-445.

Clin Med. 1964:85.

of a metabolic evaluation and response to medical therapy. J Urol.

ketoglutaric acid and sodium thiosulfate in cyanide poisoning. J Toxicol

2001;165(6 Pt 2):2328-2330.

126. Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of a low

animal protein, high fiber diet in the prevention of recurrent calcium
oxalate kidney stones. Am J Epidemiol. 1996;144(1):25-33.
and vitamin D. Urol Oncol. 2003;21(5):384-391.

127. Moyad MA. The potential benefits of dietary and/or supplemental calcium
128. Hunzinger C, Wozny W, Schwall GP, et al. Comparative profiling of the

mammalian mitochondrial proteome: multiple aconitase-2 isoforms

Clin Toxicol. 1995;33(6):721-724.

144. Tulsawani R, Bhattacharya R. Effect of alpha-ketoglutarate on cyanideinduced biochemical alterations in rat brain and liver. Biomed Environ Sci.
2006;19(1):61-66.

145. Kawaguchi A, Bloch K. Inhibition of glutamate dehydrogenase and
malate dehydrogenases by palmitoyl coenzyme A. J Biol Chem.
1976;251(5):1406-1412.
146. Pinard JM, Marsac C, Barkaoui E, et al. [Leigh syndrome and

including N-formylkynurenine modifications as part of a protein

leukodystrophy due to partial succinate dehydrogenase deficiency:

biomarker signature for reactive oxidative species. J Proteome Res.

regression with riboflavin]. Arch Pediatr. 1999;6(4):421-426.

2006;5(3):625-633.

129. Delaval E, Perichon M, Friguet B. Age-related impairment of

mitochondrial matrix aconitase and ATP-stimulated protease in rat liver
and heart. Eur J Biochem. 2004;271(22):4559-4564.
130. Juang HH. Modulation of iron on mitochondrial aconitase expression in
human prostatic carcinoma cells. Mol Cell Biochem. 2004;265(1-2):185194.
131. Bulteau AL, O’Neill HA, Kennedy MC, et al. Frataxin acts as an iron

147. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy
with coenzyme Q10 deficiency. Neurology. 1997;48(5):1238-1243.
148. Rustin P, Rotig A. Inborn errors of complex II--unusual human
mitochondrial diseases. Biochim Biophys Acta. 2002;1553(1-2):117-122.
149. Nowaczyk MJ, Lehotay DC, Platt BA, et al. Ethylmalonic and
methylsuccinic aciduria in ethylmalonic encephalopathy arise from
abnormal isoleucine metabolism. Metabolism. 1998;47(7):836-839.
150. Halperin ML, Schiller CM, Fritz IB. The inhibition by methylmalonic acid

chaperone protein to modulate mitochondrial aconitase activity. Science.

of malate transport by the dicarboxylate carrier in rat liver mitochondria.

2004;305(5681):242-245.

A possible explantation for hypoglycemia in methylmalonic aciduria. J

132. Ross KL, Eisenstein RS. Iron deficiency decreases mitochondrial aconitase
abundance and citrate concentration without affecting tricarboxylic acid
cycle capacity in rat liver. J Nutr. 2002;132(4):643-651.
133. Chen OS, Blemings KP, Schalinske KL, et al. Dietary iron intake rapidly
influences iron regulatory proteins, ferritin subunits and mitochondrial
aconitase in rat liver. J Nutr. 1998;128(3):525-535.
134. Schalinske KL, Chen OS, Eisenstein RS. Iron differentially stimulates
translation of mitochondrial aconitase and ferritin mRNAs in mammalian
143. Hume AS, Mozingo JR, McIntyre B, et al. Antidotal efficacy of alpha-

125. Tekin A, Tekgul S, Atsu N, et al. Cystine calculi in children: the results

Clin Invest. 1971;50(11):2276-2282.
151. Bavenholm PN, Kuhl J, Pigon J, et al. Insulin resistance in type 2 diabetes:
association with truncal obesity, impaired fitness, and atypical malonyl
coenzyme A regulation. J Clin Endocrinol Metab. 2003;88(1):82-87.
152. Deschauer M, Gizatullina Z, Schulze A, et al. Molecular and biochemical
investigations in fumarase deficiency. Mol Genet Metab. 2006;88(2):146152.
153. Bourgeron T, Chretien D, Poggi-Bach J, et al. Mutation of the fumarase

cells. Implications for iron regulatory proteins as regulators of

gene in two siblings with progressive encephalopathy and fumarase

mitochondrial citrate utilization. J Biol Chem. 1998;273(6):3740-3746.

deficiency. J Clin Invest. 1994;93(6):2514-2518.

154. Gellera C, Uziel G, Rimoldi M, et al. Fumarase deficiency is an autosomal

171. Kosters WW, Kirchgessner M. Effect of varying vitamin B6 intake of early-

recessive encephalopathy affecting both the mitochondrial and the

weaned piglets on urinary xanthurenic and kynurenic acid excretion,

cytosolic enzymes. Neurology. 1990;40(3 Pt 1):495-499.

serum transaminase activity and urea concentration. Int J Vitam Nutr Res.

155. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q

1976;46(3):373-380.
172. Knapp A. [Tryptophan loading and vitamin B6 deficiency. I.

levels in humans. Proc Natl Acad Sci U S A. 1990;87(22):8931-8934.
156. Mortensen SA, Vadhanavikit S, Muratsu K, et al. Coenzyme Q10: clinical

Excretion of xanthurenic acid, kynurenine, trigonelline amide, and
5-hydroxyindoleacetic acid in various diseases.]. Dtsch Gesundheitsw.

benefits with biochemical correlates suggesting a scientific breakthrough

1961;16:941-951.

in the management of chronic heart failure. Int J Tissue React.

173. Abbassy AS, Zeitoun MM, Abouiwfa MH. The state of vitamin B6

1990;12(3):155-162.
157. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in

deficiency as measured by urinary xanthurenic acid. J Trop Pediatr.
1959;5:45-50.

statin-related myopathy. Arch Neurol. 2005;62(11):1709-1712.

174. Takeuchi F, Tsubouchi R, Izuta S, et al. Kynurenine metabolism and

158. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase

xanthurenic acid formation in vitamin B6- deficient rat after tryptophan

inhibitors and the associated depletion of coenzyme Q10. A review of
animal and human publications. Biofactors. 2003;18(1-4):101-111.

injection. J Nutr Sci Vitaminol (Tokyo). 1989;35(2):111-122.

159. Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme

175. Matte JJ, Girard CL, Seve B. Effects of long-term parenteral administration

Q10 during statin therapy. Ann Pharmacother. 2006;40(2):290-294.

of vitamin B6 on B6 status and some aspects of the glucose and protein

160. Chuang DT, Ku LS, Cox RP. Thiamin-responsive maple-syrup-urine

metabolism of early-weaned piglets. Br J Nutr. 2001;85(1):11-21.
176. Sohier J, Bousquet B, Garnier JP, et al. [Photosensitivity and disturbances

disease: decreased affinity of the mutant branched-chain alpha-keto acid
dehydrogenase for alpha-ketoisovalerate and thiamin pyrophosphate. Proc

of tryptophan metabolism (kynurenin pathway) (author’s transl)]. Ann

Natl Acad Sci U S A. 1982;79(10):3300-3304.

Dermatol Venereol. 1979;106(5):491-494.

161. Chuang DT, Chuang JL, Wynn RM. Lessons from genetic disorders of

177. el-Zoghby SM, Abdel-Tawab GA, Girgis LH, et al. Functional capacity of
the tryptophan-niacin pathway in the premenarchial phase and in the

branched-chain amino acid metabolism. J Nutr. 2006;136(1 Suppl):243S249S.

menopausal age. Am J Clin Nutr. 1975;28(1):4-9.

and induction of oxidative stress in glial cells caused by the branchedchain alpha-keto acids accumulating in maple syrup urine disease.
163. Funchal C, Schuck PF, Santos AQ, et al. Creatine and antioxidant

women receiving hormone replacement therapy. Biochem Pharmacol.

treatment prevent the inhibition of creatine kinase activity and the

administration on tryptophan metabolism in rats and in menopausal

Neurochem Int. 2006;49:640-650.

178. Bender DA, Laing AE, Vale JA, et al. The effects of oestrogen

162. Funchal C, Latini A, Jacques-Silva MC, et al. Morphological alterations

morphological alterations of C6 glioma cells induced by the branched-

1983;32(5):843-848.

179. Moroni F, Russi P, Gallo-Mezo MA, et al. Modulation of quinolinic
and kynurenic acid content in the rat brain: effects of endotoxins and
nicotinylalanine. J Neurochem. 1991;57(5):1630-1635.
180. Bates CJ. Vitamin analysis. Ann Clin Biochem. 1997;34 ( Pt 6):599-626.

Mol Neurobiol. 2006;26(1):67-79.

181. Connick JH, Stone TW. The role of kynurenines in diabetes mellitus. Med

chain alpha-keto acids accumulating in maple syrup urine disease. Cell
164. Funchal C, Rosa AM, Wajner M, et al. Reduction of glutamate uptake

into cerebral cortex of developing rats by the branched-chain alphaketo acids accumulating in maple syrup urine disease. Neurochem Res.
2004;29(4):747-753.

165. Cupisti A, Langer K, Barsotti G. Plasma levels of branched chain keto

acids in nephrotic patients. Nephron. 1993;63(2):237.

166. Teplan V, Schuck O, Horackova M, et al. Effect of a keto acid-amino acid
supplement on the metabolism and renal elimination of branched-chain
amino acids in patients with chronic renal insufficiency on a low protein
diet. Wien Klin Wochenschr. 2000;112(20):876-881.
167. Zhao Y, Jaskiewicz J, Harris RA. Effects of clofibric acid on the activity
and activity state of the hepatic branched-chain 2-oxo acid dehydrogenase
complex. Biochem J. 1992;285(Pt 1):167-172.
168. Vockley J, Parimoo B, Tanaka K. Molecular characterization of four

Hypotheses. 1985;18(4):371-376.
182. Kotake Y, Ueda T, Mori T, et al. Abnormal tryptophan metabolism and
experimental diabetes by xanthurenic acid (XA). Acta Vitaminol Enzymol.
1975;29(1-6):236-239.
183. Ikeda S, Kotake Y. Urinary excretion of xanthurenic acid and zinc in
diabetes: (3). Occurrence of xanthurenic acid-Zn2+ complex in urine
of diabetic patients and of experimentally-diabetic rats. Ital J Biochem.
1986;35(4):232-241.
184. Hattori M, Kotake Y. Studies on the urinary excretion of xanthurenic acid
in diabetics. Acta Vitaminol Enzymol. 1984;6(3):221-228.
185. Gillmer MD, Mazibuko D. Pyridoxine treatment of chemical diabetes in
pregnancy. Am J Obstet Gynecol. 1979;133(5):499-502.
186. Bennink HJ, Schreurs WH. Improvement of oral glucose tolerance in
gestational diabetes by pyridoxine. Br Med J. 1975;3(5974):13-15.

different classes of mutations in the isovaleryl-CoA dehydrogenase gene

187. Guthrie H. Introductory Nutrition. 4th ed. St. Louis: Mosby; 1979.

responsible for isovaleric acidemia. Am J Hum Genet. 1991;49(1):147-

188. Mock N, Malik M, Stumbo P, et al. Increased urinary excretion of 3-

157.
169. Chiang EP, Selhub J, Bagley PJ, et al. Pyridoxine supplementation corrects
vitamin B6 deficiency but does not improve inflammation in patients with
rheumatoid arthritis. Arthritis Res Ther. 2005;7(6):R1404-1411.
170. Tada K, Yokoyama Y, Nakagawa H, et al. Vitamin B6 dependent
xanthurenic aciduria (the second report). Tohoku J Exp Med.
1968;95(2):107-114.

hydroxyisovaleric acid and decreased urinary excretion of biotin are
sensitive early indicators of decreased biotin status in experimental biotin
deficiency. Am J Clin Nutr. 1997;65:951-958.
189. Scholtissek J, Barth CA, Hagemeister H, et al. Biotin supply by large
bowel bacteria in minipigs: evidence from intracaecal avidin. Br J Nutr.
1990;64(3):715-720.
190. Nyhan WL. Inborn errors of biotin metabolism. Arch Dermatol.
1987;123(12):1696-1698a.

211. Roon-Djordjevic Bv, Cerfontain-van S. Urinary excretion of histidine

191. Bender D. Nutritional Biochemistry of the Vitamins. 2nd ed: Cambridge
University Press; 2003.

metabolites as an indication for folic acid and vitamin B 12 deficiency.

192. Dostalova L. Vitamin status during puerperium and lactation. Ann Nutr

Clin Chim Acta. 1972;41:55-65.
212. Armstrong P, Rae PW, Gray WM, et al. Nitrous oxide and

Metab. 1984;28(6):385-408.
193. Krause KH, Berlit P, Bonjour JP, et al. Vitamin status in patients on chronic

formiminoglutamic acid: excretion in surgical patients and anaesthetists.
Br J Anaesth. 1991;66(2):163-169.

anticonvulsant therapy. Int J Vitam Nutr Res. 1982;52(4):375-385.

213. Everman BW, Koblin DD. Aging, chronic administration of ethanol, and

194. Mock DM, Stadler DD, Stratton SL, et al. Biotin status assessed
longitudinally in pregnant women. J Nutr. 1997;127(5):710-716.

acute exposure to nitrous oxide: effects on vitamin B12 and folate status in

195. Dupuis L, Campeau E, Leclerc D, et al. Mechanism of biotin

rats. Mech Ageing Dev. 1992;62(3):229-243.
214. Hine RJ. Folic acid: Contemporary clinical perspective. Persp Appl Nutr.

responsiveness in biotin-responsive multiple carboxylase deficiency. Mol
Genet Metab. 1999;66(2):80-90.

1993;93(1):3-14.

196. Buenrostro JL, Kratzer FH. Effect of Lactobacillus inoculation and

215. Cooperman JM, Lopez R. The role of histidine in the anemia of folate

antibiotic feeding of chickens on availability of dietary biotin. Poult Sci.

deficiency. Exp Biol Med (Maywood). 2002;227(11):998-1000.
216. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease:

1983;62(10):2022-2029.
197. Riudor E, Vilaseca MA, Briones P, et al. Requirement of high biotin doses

evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.
217. Marin GH, Tentoni J, Cicchetti G. Megaloblastic anemia: rapid and

in a case of biotinidase deficiency. J Inherit Metab Dis. 1989;12(3):338339.

economical study. Sangre (Barc). 1997;42(3):235-238.

198. Perez B, Desviat LR, Rodriguez-Pombo P, et al. Propionic acidemia:

218. Shojania AM. Oral contraceptives: effect of folate and vitamin B12

identification of twenty-four novel mutations in Europe and North

metabolism. Can Med Assoc J. 1982;126(3):244-247.
219. Sellers TA, Kushi LH, Cerhan JR, et al. Dietary folate intake, alcohol, and

America. Mol Genet Metab. 2003;78(1):59-67.
199. Lucke T, Perez-Cerda C, Baumgartner M, et al. Propionic acidemia:

risk of breast cancer in a prospective study of postmenopausal women.
Epidemiology. 2001;12(4):420-428.

unusual course with late onset and fatal outcome. Metabolism.

220. Title LM, Cummings PM, Giddens K, et al. Effect of folic acid and

2004;53(6):809-810.
200. Siegel GJ. Basic Neurochemistry : Molecular, Cellular, and Medical Aspects.
7th ed. Amsterdam, Boston: Elsevier; 2006.

antioxidant vitamins on endothelial dysfunction in patients with coronary

221. Loria CM, Ingram DD, Feldman JJ, et al. Serum folate and cardiovascular

and their metabolic markers methylmalonic acid and total homocysteine

artery disease. J Am Coll Cardiol. 2000;36(3):758-765.

201. Mohammad MA, Molloy A, Scott J, et al. Plasma cobalamin and folate
among Egyptian children before and after nutritional supplementation

with the probiotic bacteria Lactobacillus acidophilus in yoghurt matrix.
Int J Food Sci Nutr. 2006;57(7-8):470-480.

202. Kwok T, Cheng G, Lai WK, et al. Use of fasting urinary methylmalonic
Nutrition. 2004;20(9):764-768.

acid to screen for metabolic vitamin B12 deficiency in older persons.

203. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of cobalamin
deficiency in the Framingham elderly population [see comments]. Am J
Clin Nutr. 1994;60(1):2-11.

204. Rule SA, Hooker M, Costello C, et al. Serum vitamin B12 and
1994;47(3):167-171.

transcobalamin levels in early HIV disease. Am J Hematol.

disease mortality among US men and women. Arch Intern Med.
2000;160(21):3258-3262.

222. Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast
cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res.
2001;61(19):7136-7141.
223. Sengelov H, Hansen OP, Simonsen L, et al. Inter-relationships between
single carbon units’ metabolism and resting energy expenditure in weightlosing patients with small cell lung cancer. Effects of methionine supply
and chemotherapy. Eur J Cancer. 1994;30A(11):1616-1620.
224. Stolzenberg-Solomon RZ, Pietinen P, Barrett MJ, et al. Dietary and other
methyl-group availability factors and pancreatic cancer risk in a cohort of
male smokers. Am J Epidemiol. 2001;153(7):680-687.
225. Bergmark C, Mansoor MA, Swedenborg J, et al. Hyperhomocysteinemia

205. Savage DG, Lindenbaum J. Neurological complications of acquired

in patients operated for lower extremity ischaemia below the age of 50--

cobalamin deficiency: clinical aspects. Baillieres Clin Haematol.

effect of smoking and extent of disease. Eur J Vasc Surg. 1993;7(4):391-

1995;8(3):657-678.
206. Henriquez H, el Din A, Ozand PT, et al. Emergency presentations of
patients with methylmalonic acidemia, propionic acidemia and branched
chain amino acidemia (MSUD). Brain Dev. 1994;16 Suppl:86-93.
207. Suormala T, Baumgartner MR, Coelho D, et al. The cblD defect causes
either isolated or combined deficiency of methylcobalamin and
adenosylcobalamin synthesis. J Biol Chem. 2004;279(41):42742-42749.
208. Roe CR, Struys E, Kok RM, et al. Methylmalonic semialdehyde
dehydrogenase deficiency: psychomotor delay and methylmalonic
aciduria without metabolic decompensation. Mol Genet Metab.
1998;65(1):35-43.
209. Bain MD, Jones M, Borriello SP, et al. Contribution of gut bacterial
metabolism to human metabolic disease. Lancet. 1988;1(8594):10781079.
210. Schuller E. Folic Acid Metabolism and the Figlu Test. Presse Med.
1965;73:1411-1414.
396.
226. Chowers Y, Sela BA, Holland R, et al. Increased levels of homocysteine
in patients with Crohn’s disease are related to folate levels. Am J
Gastroenterol. 2000;95(12):3498-3502.
227. Campbell BA. Megaloblastic anemia in pregnancy. Clin Obstet Gynecol.
1995;38(3):455-462.
228. Pearl PL, Hartka TR, Taylor J. Diagnosis and Treatment of
Neurotransmitter Disorders. Curr Treat Options Neurol. 2006;8(6):441450.
229. Goveas JS, Csernansky JG, Coccaro EF. Platelet serotonin content
correlates inversely with life history of aggression in personalitydisordered subjects. Psychiatry Res. 2004;126(1):23-32.
230. Sagud M, Mihaljevic-Peles A, Pivac N, et al. Platelet serotonin and serum
lipids in psychotic mania. J Affect Disord. 2006;97:247-251.

231. Koch CA, Lasho TL, Tefferi A. Platelet-rich plasma serotonin levels

249. Maas JW, Bowden CL, Miller AL, et al. Schizophrenia, psychosis, and

in chronic myeloproliferative disorders: evaluation of diagnostic use

cerebral spinal fluid homovanillic acid concentrations. Schizophr Bull.

and comparison with the neutrophil PRV-1 assay. Br J Haematol.

1997;23(1):147-154.
250. Sharma RP, Javaid JI, Davis JM, et al. Pretreatment plasma homovanillic

2004;127(1):34-39.
232. Platen P, Lebenstedt M, Schneider M, et al. Increased urinary excretion

acid in schizophrenia and schizoaffective disorder: the influence of
demographic variables and the inpatient drug-free period. Biol Psychiatry.

rates of serotonin and metabolites during bedrest. Acta Astronaut.

1998;44(6):488-492.

2005;56(9-12):801-808.

251. Yoshimura R, Ueda N, Shinkai K, et al. Plasma levels of homovanillic

233. Kotzailias N, Marker M, Jilma B. Early effects of paroxetine on serotonin
storage, plasma levels, and urinary excretion: a randomized, double-blind,

acid and the response to risperidone in first episode untreated acute

placebo-controlled trial. J Clin Psychopharmacol. 2004;24(5):536-539.

schizophrenia. Int Clin Psychopharmacol. 2003;18(2):107-111.

234. Sies CW, Florkowski CM, Sullivan M, et al. Urinary VMA, dopamine and

252. Prohaska JR, Brokate B. Dietary copper deficiency alters protein levels of

the likelihood of neuroblastoma: a preferred way of reporting laboratory

rat dopamine beta-monooxygenase and tyrosine monooxygenase. Exp Biol

results? Ann Clin Biochem. 2006;43(Pt 4):300-305.

Med (Maywood). 2001;226(3):199-207.

235. Jeffery J, Devendra D, Farrugia J, et al. Increased urinary dopamine

253. Prohaska JR, Brokate B. Copper deficiency alters rat dopamine beta-

excretion in association with bilateral carotid body tumours-- clinical,

monooxygenase mRNA and activity. J Nutr. 1999;129(12):2147-2153.

biochemical and genetic findings. Ann Clin Biochem. 2006;43(Pt 2):156-

254. Schoenemann HM, Failla ML, Rosebrough RW. Cardiac and splenic levels

160.

of norepinephrine and dopamine in copper deficient pigs and rats. Comp

236. Davidson M, Giordani AB, Mohs RC, et al. Control of exogenous factors

Biochem Physiol C. 1990;97(2):387-391.
255. Kekesi G, Joo G, Csullog E, et al. The antinociceptive effect of intrathecal

affecting plasma homovanillic acid concentration. Psychiatry Res.
1987;20(4):307-312.

kynurenic acid and its interaction with endomorphin-1 in rats. Eur J

237. Cohrs S, Guan Z, Pohlmann K, et al. Nocturnal urinary dopamine

Pharmacol. 2002;445(1-2):93-96.
256. Matsuo M, Tasaki R, Kodama H, et al. Screening for Menkes disease using

excretion is reduced in otherwise healthy subjects with periodic leg
movements in sleep. Neurosci Lett. 2004;360(3):161-164.

the urine HVA/VMA ratio. J Inherit Metab Dis. 2005;28(1):89-93.

238. Dantonello TM, Kuster E, Muhlbauer B. Urinary dopamine and renal

258. Weldin J, Jack R, Dugaw K, et al. Quercetin, an over-the-counter

239. Pestana M, Jardim H, Serrao P, et al. Reduced urinary excretion of

Blood Press Res. 1998;21(6):438-444.
dopamine and metabolites in chronic renal parenchymal disease. Kidney

240. Glover DA, Powers MB, Bergman L, et al. Urinary dopamine and turn bias
in traumatized women with and without PTSD symptoms. Behav Brain

241. Luippold G, Benohr P, Piesch C, et al. Urinary dopamine excretion in

healthy volunteers: effect of sodium diet and acute water load. Pflugers
Arch. 2000;440(1):28-33.

242. Orgacka H, Zbytniewski Z. Excretion of vanillic acid and homovanillic
acid and tissue distribution of catecholamines and their metabolites

in mice with various levels of pigmentation. Endokrynol Pol.
1991;42(3):471-479.

supplement, causes neuroblastoma-like elevation of plasma homovanillic
acid. Pediatr Dev Pathol. 2003;6(6):547-551.

259. Numata K, Kusui H, Kawakatsu H, et al. Increased urinary HVA levels in

Blood Press Res. 1998;21(1):59-65.

Res. 2003;144(1-2):137-141.
quercetin in the animal body. J Biol Chem. 1956;223(1):251-257.

handling of L-DOPA in fasted spontaneously hypertensive rats. Kidney

257. Booth AN, Deeds F, Jones FT, et al. The metabolic fate of rutin and

243. Braverman E, Pfeiffer C. Tyrosine: the antidepressant. The Healing
Nutrients Within: Facts, Findings, and New Research on Amino Acids.
New Canaan: Keats Publishing; 1987:44-58.

neuroblastoma screens related to diet, not tumor. Pediatr Hematol Oncol.
1997;14(6):569-576.
260. Yang H, Zheng Y, Liang Y. [Effects of aluminum on neurobehavioral
function and metabolism of monoamine neurotransmitter]. Zhonghua Yu
Fang Yi Xue Za Zhi. 1998;32(2):82-84.
261. Egorova AB, Uspenskaia Iu A, Kruglik OV, et al. [Disorder of the
serotoninergic regulation of bone marrow cell proliferation under the
action of a xenobiotic inducer of oxidative stress]. Eksp Klin Farmakol.
1998;61(4):34-37.
262. McCall RB. Evidence for a serotonergically mediated sympathoexcitatory
response to stimulation of medullary raphe nuclei. Brain Res.
1984;311(1):131-139.
263. Samathanam GK, White SR, Kalivas PW, et al. Effects of 5-

244. Mauron J. Tyrosine and hypertension. Bibl Nutr Dieta. 1986;38:209-218.

hydroxytryptophan on extracellular serotonin in the spinal cord of rats

245. Akimaru K, Shoji T, Fukunaga Y, et al. Amplification of N-myc gene and

with experimental allergic encephalomyelitis. Brain Res. 1991;559(1):37-

increase of urinary VMA and HVA in patients with neuroblastic tumors.
Nippon Ika Daigaku Zasshi. 1994;61(2):148-153.
246. Lucas K, Gula MJ, Knisely AS, et al. Catecholamine metabolites in
ganglioneuroma. Med Pediatr Oncol. 1994;22(4):240-243.
247. Parekh N, Venkatesh B, Cross D, et al. Cardiac troponin I predicts
myocardial dysfunction in aneurysmal subarachnoid hemorrhage [In
Process Citation]. J Am Coll Cardiol. 2000;36(4):1328-1335.
248. Fukuda M, Niwa S, Hiramatsu K, et al. Exaggerated responsivity of brain

43.
264. Krenger W, Honegger CG, Feurer C, et al. Changes of neurotransmitter
systems in chronic relapsing experimental allergic encephalomyelitis in rat
brain and spinal cord. J Neurochem. 1986;47(4):1247-1254.
265. Flanagan EM, Erickson JB, Viveros OH, et al. Neurotoxin quinolinic acid
is selectively elevated in spinal cords of rats with experimental allergic
encephalomyelitis. J Neurochem. 1995;64(3):1192-1196.
266. Scott CF Jr, Cashman N, Spitler LE. Experimental allergic

dopaminergic system activity in schizophrenia: a preliminary finding of

encephalitis; treatment with drugs which alter CNS serotonin levels. J

increased variance of plasma homovanillic acid level in a chronic patient.

Immunopharmacol. 1982;4(3):153-162.

Schizophr Res. 1996;20(1-2):241-244.

267. Norman T. The new antidepressants - mechanisms of action. Aust Prescr.
1999;22:106-108.

285. Mitani H, Shirayama Y, Yamada T, et al. Plasma levels of homovanillic

268. Langer C, Piper C, Vogt J, et al. Atrial fibrillation in carcinoid heart disease
: The role of Serotonin. A review of the literature. Clin Res Cardiol.

acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover

2006;96:114-118.

in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry.

269. Shibusawa N, Mori M. [Serotonin producing tumors (carcinoid tumors

2006;30:531-534.
286. Grundy D. Serotonin and sensory signalling from the gastrointestinal

and carcinoid syndrome)]. Nippon Rinsho. 2006;Suppl 3:324-327.
270. Varas MJ, Navarro MA, Rosell P, et al. [Urinary 5-HIAA stimulation test

lumen. J Physiol. 2006;575(Pt 1):1-2
287. Gershon MD. Review article: serotonin receptors and transporters -- roles

for the diagnosis of carcinoid syndrome caused by carcinoid tumors of the
middle intestine]. Rev Esp Enferm Apar Dig. 1986;70(4):311-315.

in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther.

271. Zuetenhorst JM, Bonfrer JM, Korse CM, et al. Carcinoid heart disease: the

2004;20 Suppl 7:3-14.

role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of

288. Swamy HV, Smith TK, MacDonald EJ. Effects of feeding blends of

atrial natriuretic peptide, transforming growth factor-beta and fibroblast

grains naturally contaminated with Fusarium mycotoxins on brain

growth factor. Cancer. 2003;97(7):1609-1615.

regional neurochemistry of starter pigs and broiler chickens. J Anim Sci.

272. Zuetenhorst JM, Korse CM, Bonfrer JM, et al. Daily cyclic changes in the

2004;82(7):2131-2139.
289. Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and

urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid
tumors. Clin Chem. 2004;50(9):1634-1639.

serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp

273. Stuerenburg HJ, Ganzer S, Muller-Thomsen T. 5-Hydroxyindoleacetic acid

Ther. 1992;261(3):964-969.
290. Porter JK, Stuedemann JA, Thompson FN, Jr., et al. Neuroendocrine

and homovanillic acid concentrations in cerebrospinal fluid in patients
with Alzheimer’s disease, depression and mild cognitive impairment.

measurements in steers grazed on endophyte-infected fescue. J Anim Sci.

Neuro Endocrinol Lett. 2004;25(6):435-437.

1990;68(10):3285-3292.

274. Shimomura T, Tanaka H, Takahashi K. Plasma serotonergic activation in

291. Hahn Z, Szekely M. Hypothalamic monoamine contents in endotoxin
fever of new-born guinea pigs and kittens. Neurosci Lett. 1979;11(3):279-

rats during the course of experimental allergic neuritis. Jpn J Psychiatry

282.

Neurol. 1990;44(3):637-640.

292. Rabinoff M. Short note: possible role of macrophage metabolic

275. Shah GM, Shah RG, Veillette H, et al. Biochemical assessment of niacin
deficiency among carcinoid cancer patients. The American Journal of

products including quinolinic acid and neopterin in the pathogenesis of
inflammatory brain diseases. Med Hypotheses. 1994;42(2):133-134.

276. Kema IP, Schellings AM, Meiborg G, et al. Influence of a serotonin- and

293. Ziegler DR, Herman JP. Local integration of glutamate signaling in the

dopamine-rich diet on platelet serotonin content and urinary excretion

Gastroenterology. 2005;100(10):2307-2314.

of biogenic amines and their metabolites. Clin Chem. 1992;38(9):1730-

hypothalamic paraventricular region: regulation of glucocorticoid stress
responses. Endocrinology. 2000;141(12):4801-4804.

294. Leonard BE, Myint A. Inflammation and depression: is there a causal

1736.
277. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary

excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985;42(4):639-

643.

278. Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2)

adrenoceptor and serotonin transporter polymorphisms with constipation
and somatic symptoms in functional gastrointestinal disorders. Gut.
2004;53(6):829-837.

279. Lincoln J, Crowe R, Kamm MA, et al. Serotonin and 5-

hydroxyindoleacetic acid are increased in the sigmoid colon in severe
idiopathic constipation. Gastroenterology. 1990;98(5 Pt 1):1219-1225.
280. Helander A, Beck O, Jones AW. Laboratory testing for recent
alcohol consumption: comparison of ethanol, methanol, and 5hydroxytryptophol. Clin Chem. 1996;42(4):618-624.
281. Apak S, Kazez A, Ozel SK, et al. Spot urine 5-hydroxyindoleacetic

connection with dementia? Neurotox Res. 2006;10(2):149-160.
295. Erhardt S, Engberg G. Increased phasic activity of dopaminergic neurones
in the rat ventral tegmental area following pharmacologically elevated
levels of endogenous kynurenic acid. Acta Physiol Scand. 2002;175(1):4553.
296. Pulkkinen MO, Salminen J, Virtanen S. Serum vitamin B6 in pure
pregnancy depression. Acta Obstet Gynecol Scand. 1978;57(5):471-472.
297. Shor-Posner G, Feaster D, Blaney NT, et al. Impact of vitamin B6 status
on psychological distress in a longitudinal study of HIV-1 infection. Int J
Psychiatry Med. 1994;24(3):209-222.
298. Molz S, Decker H, Dal-Cim T, et al. Glutamate-induced toxicity in
hippocampal slices involves apoptotic features and p38(MAPK) signaling.
Neurochem Res. 2007;Jul 7.
299. Brouwers P, Heyes MP, Moss HA, et al. Quinolinic acid in

acid levels in the early diagnosis of acute appendicitis. J Pediatr Surg.

the cerebrospinal fluid of children with symptomatic human

2005;40(9):1436-1439.

immunodeficiency virus type 1 disease: relationships to clinical status and

282. Ilkhanizadeh B, Owji AA, Tavangar SM, et al. Spot urine 5-hydroxy
indole acetic acid and acute appendicitis. Hepatogastroenterology.
2001;48(39):609-613.
283. Bonafe L, Thony B, Penzien JM, et al. Mutations in the sepiapterin
reductase gene cause a novel tetrahydrobiopterin-dependent monoamineneurotransmitter deficiency without hyperphenylalaninemia. Am J Hum
Genet. 2001;69(2):269-277.

therapeutic response. J Infect Dis. 1993;168(6):1380-1386.
300. Achim CL, Heyes MP, Wiley CA. Quantitation of human
immunodeficiency virus, immune activation factors, and quinolinic acid
in AIDS brains. J Clin Invest. 1993;91(6):2769-2775.
301. Guillemin GJ, Brew BJ, Noonan CE, et al. Indoleamine 2,3 dioxygenase
and quinolinic acid immunoreactivity in Alzheimer’s disease
hippocampus. Neuropathol Appl Neurobiol. 2005;31(4):395-404.

284. Brautigam C, Hyland K, Wevers R, et al. Clinical and laboratory findings

302. Zanoli P, Cannazza G, Baraldi M. Prenatal exposure to methyl mercury

in twins with neonatal epileptic encephalopathy mimicking aromatic

in rats: focus on changes in kynurenine pathway. Brain Res Bull.

L-amino acid decarboxylase deficiency. Neuropediatrics. 2002;33(3):113-

2001;55(2):235-238.

117.

321. Sanada H, Miyazaki M. Effect of high-protein diet on liver alpha-amino-

303. Fukuwatari T, Ohsaki S, Fukuoka S, et al. Phthalate esters enhance

beta-carboxymuconate-epsilon-semialdehyde decarboxylase in rats. J Nutr

quinolinate production by inhibiting alpha-amino-beta-carboxymuconateepsilon-semialdehyde decarboxylase (ACMSD), a key enzyme of the

Sci Vitaminol (Tokyo). 1984;30(2):113-123.
322. Egashira Y, Murotani G, Tanabe A, et al. Differential effects of dietary

tryptophan pathway. Toxicol Sci. 2004;81(2):302-308.
304. Obojes K, Andres O, Kim KS, et al. Indoleamine 2,3-dioxygenase

fatty acids on rat liver alpha-amino-beta-carboxymuconate-epsilonsemialdehyde decarboxylase activity and gene expression. Biochim

mediates cell type-specific anti-measles virus activity of gamma interferon.

Biophys Acta. 2004;1686(1-2):118-124.

J Virol. 2005;79(12):7768-7776.

323. Egashira Y, Sato M, Tanabe A, et al. Dietary linoleic acid suppresses gene

305. Ovsyannikova IG, Reid KC, Jacobson RM, et al. Cytokine production
patterns and antibody response to measles vaccine. Vaccine. 2003;21(25-

expression of rat liver alpha-amino-beta-carboxymuconate-epsilon-

26):3946-3953.

semialdehyde decarboxylase (ACMSD) and increases quinolinic acid in

306. Patterson CE, Lawrence DM, Echols LA, et al. Immune-mediated

serum. Adv Exp Med Biol. 2003;527:671-674.

protection from measles virus-induced central nervous system disease is

324. Bosco MC, Rapisarda A, Massazza S, et al. The tryptophan catabolite

noncytolytic and gamma interferon dependent. J Virol. 2002;76(9):4497-

picolinic acid selectively induces the chemokines macrophage

4506.

inflammatory protein-1 alpha and -1 beta in macrophages. J Immunol.

307. Connick J, Lombardi G, Beni M, et al. Decrease in rat cerebral quinolinic

2000;164(6):3283-3291.
325. Bosco MC, Rapisarda A, Reffo G, et al. Macrophage activating properties of

acid concentration following chronic hydrocortisone treatment. Neurosci
Lett. 1988;88(2):216-220.

the tryptophan catabolite picolinic acid. Adv Exp Med Biol. 2003;527:55-

308. Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, et al. Differential

65.

326. Abe S, Hu W, Ishibashi H, et al. Augmented inhibition of Candida

regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and
inflammatory mediators in IFN-gamma-activated murine macrophages

albicans growth by murine neutrophils in the presence of a tryptophan

and microglial cells. J Immunol. 1997;159(1):419-426.

metabolite, picolinic acid. J Infect Chemother. 2004;10(3):181-184.
327. Mucci A, Varesio L, Neglia R, et al. Antifungal activity of macrophages

macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J

engineered to produce IFNgamma: inducibility by picolinic acid. Med

309. Pemberton LA, Kerr SJ, Smythe G, et al. Quinolinic acid production by
Interferon Cytokine Res. 1997;17(10):589-595.

Microbiol Immunol (Berl). 2003;192(2):71-78.

328. Ishiwata K, Vaalburg W, Elsinga PH, et al. Metabolic studies with L-[1-

chronic fatigue syndrome. Scand J Immunol. 1991;33(3):319-327.

14C]tyrosine for the investigation of a kinetic model to measure protein

with chronic fatigue syndrome have decreased interferon-gamma

311. Visser J, Blauw B, Hinloopen B, et al. CD4 T lymphocytes from patients
production and increased sensitivity to dexamethasone. J Infect Dis.
1998;177(2):451-454.

312. Kerr JR, Barah F, Mattey DL, et al. Circulating tumour necrosis factor-

alpha and interferon-gamma are detectable during acute and convalescent
parvovirus B19 infection and are associated with prolonged and chronic

fatigue. J Gen Virol. 2001;82(Pt 12):3011-3019.

313. Rejdak K, Bartosik-Psujek H, Dobosz B, et al. Decreased level of kynurenic
acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients.
Neurosci Lett. 2002;331(1):63.

310. Gupta S, Vayuvegula B. A comprehensive immunological analysis in

314. Altman K, Greengard O. Correlation of kynurenine excretion with liver
tryptophan pyrrolase levels in disease and after hydrocortisone induction.
J Clin Invest. 1966;45(10):8.

315. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine
pathway metabolism in inflammatory and non-inflammatory neurological
disease. Brain. 1992;115(Pt 5):1249-1273.
316. Stone TW. Kynurenic acid antagonists and kynurenine pathway inhibitors.
Expert Opin Investig Drugs. 2001;10(4):633-645.
317. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, et al. Nitrous oxide
(laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin.
Nat Med. 1998;4(4):460-463.
318. Wong GK, Chan MT, Poon WS, et al. Magnesium therapy within 48 hours
of an aneurysmal subarachnoid hemorrhage: neuro-panacea. Neurol Res.
2006;28(4):431-435.
319. Gathwala G, Khera A, Singh I. Magnesium therapy in birth asphyxia.
Indian J Pediatr. 2006;73(3):209-212.

synthesis rates with PET. J Nucl Med. 1988;29(4):524-529.

329. Muting D, Wuzel H, Bucsis L, et al. Urinary p-hydroxyphenyllactic acid
as indicator of hepatic encephalopathy in patients with hepatic cirrhosis
[letter]. Lancet. 1985;2(8468):1365-1366.
330. Matsuo M, Saiki K, Tanabe J, et al. Citrullinaemia: an infantile form with
p-hydroxyphenylpyruvic and p-hydroxyphenyllactic acidurias. J Inherit
Metab Dis. 1987;10(3):276.
331. Mayatepek E, Seppel CK, Hoffmann GF. Increased urinary excretion
of dicarboxylic acids and 4-hydroxyphenyllactic acid in patients with
Zellweger syndrome. Eur J Pediatr. 1995;154(9):755-756.

332. Montemartini M, Santome JA, Cazzulo JJ, et al. Production of aromatic
alpha-hydroxyacids by epimastigotes of Trypanosoma cruzi, and its
possible role in NADH reoxidation. FEMS Microbiol Lett. 1994;118(12):89-92.
333. Rauschenbach MO, Zharova EI, Sergeeva TI, et al. Blastomogenic activity
of p-hydroxyphenyllactic acid in mice. Cancer Res. 1975;35(3):577-585.
334. Markaverich BM, Gregory RR, Alejandro MA, et al. Methyl phydroxyphenyllactate. An inhibitor of cell growth and proliferation and
an endogenous ligand for nuclear type-II binding sites. J Biol Chem.
1988;263(15):7203-7210.
335. Markaverich BM, Gregory RR, Alejandro M, et al. Methyl phydroxyphenyllactate and nuclear type II binding sites in malignant
cells: metabolic fate and mammary tumor growth. Cancer Res.
1990;50(5):1470-1478.
336. Sheffield LG, Kotolski LC. Epidermal growth factor modulates
cholera toxin induced mammary gland development. Endocr Res.
1993;19(4):259-271.

320. Shibuta S, Varathan S, Mashimo T. Ketamine and thiopental sodium:

337. Seda HW, Gove CD, Hughes RD, et al. Inhibition of partially purified

individual and combined neuroprotective effects on cortical cultures

rat brain Na+, K+-dependent ATPase by bile acids, phenolic acids and

exposed to NMDA or nitric oxide. Br J Anaesth. 2006;97(4):517-524.

endotoxin. Clin Sci (Lond). 1984;66(4):415-420.

356. Xi ZG, Chao FH, Yang DF, et al. 8-hydroxydeoxyguanosine as a biomarker

338. Levchuk AA, Faron RA, Khrustalev SA, et al. [Effect of the carcinogenic
tyrosine metabolite p-hydroxyphenyllactic acid on the ascorbic acid

of oxidative DNA damage induced by environmental tobacco side-stream

concentration in the organs and blood of mice]. Biull Eksp Biol Med.

smoke and its mechanism. Biomed Environ Sci. 2005;18(1):43-47.
357. van Zeeland AA, de Groot AJ, Hall J, et al. 8-Hydroxydeoxyguanosine

1986;102(10):462-463.
339. Baikova VN, Vares IM, Rybal’chenko VG, et al. [Congenital disorders of

in DNA from leukocytes of healthy adults: relationship with cigarette
smoking, environmental tobacco smoke, alcohol and coffee consumption.

tyrosine metabolism and their correction in children with tumors]. Vopr

Mutat Res. 1999;439(2):249-257.

Onkol. 1987;33(11):42-48.
340. Kaushik S, Kaur J. Effect of chronic cold stress on intestinal epithelial cell

358. Stewart RJ, Askew EW, McDonald CM, et al. Antioxidant status of young

proliferation and inflammation in rats. Stress. 2005;8(3):191-197.

children: response to an antioxidant supplement. J Am Diet Assoc.

341. Kitada T, Seki S, Iwai S, et al. In situ detection of oxidative DNA damage,

2002;102(11):1652-1657.
359. Irie M, Asami S, Nagata S, et al. Relationships between perceived

8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol.
2001;35(5):613-618.

workload, stress and oxidative DNA damage. Int Arch Occup Environ

342. Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine

Health. 2001;74(2):153-157.
360. Lee HC, Lim ML, Lu CY, et al. Concurrent increase of oxidative

levels as a biomarker for progression of Parkinson disease. Neurology.
2005;64(6):1081-1083.

DNA damage and lipid peroxidation together with mitochondrial

343. Xu GW, Yao QH, Weng QF, et al. Study of urinary 8-

DNA mutation in human lung tissues during aging--smoking
enhances oxidative stress on the aged tissues. Arch Biochem Biophys.

hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in

1999;362(2):309-316.

diabetic nephropathy patients. J Pharm Biomed Anal. 2004;36(1):101-

361. Kouda K, Nakamura H, Fan W, et al. The relationship of oxidative DNA

104.
344. Igishi T, Hitsuda Y, Kato K, et al. Elevated urinary 8-

damage marker 8-hydroxydeoxyguanosine and glycoxidative damage
marker pentosidine. Clin Biochem. 2001;34(3):247-250.

hydroxydeoxyguanosine, a biomarker of oxidative stress, and lack of

362. Gackowski D, Kruszewski M, Jawien A, et al. Further evidence that

association with antioxidant vitamins in chronic obstructive pulmonary

oxidative stress may be a risk factor responsible for the development of

disease. Respirology. 2003;8(4):455-460.
345. Toyokuni S, Yasui H, Date A, et al. Novel screening method for ultraviolet

hydroxy-2’-deoxyguanosine. Pathol Int. 2006;56(12):760-762.

2’-deoxyguanosine (8-OHdG) in cancerous and noncancerous breast

346. Orimo H, Tokura Y, Hino R, et al. Formation of 8-hydroxy-2’-

atherosclerosis. Free Radic Biol Med. 2001;31(4):542-547.

363. Charles MJ, Schell MJ, Willman E, et al. Organochlorines and 8-hydroxy-

protection: Combination of a human skin-equivalent model and 8-

deoxyguanosine in the DNA of cultured human keratinocytes by clinically
ultraviolet A. Cancer Sci. 2006;97(2):99-105.

used doses of narrowband and broadband ultraviolet B and psoralen plus
347. Wada T, Tanji N, Ozawa A, et al. Mitochondrial DNA mutations and

8-hydroxy-2’-deoxyguanosine Content in Japanese patients with urinary
bladder and renal cancers. Anticancer Res. 2006;26(5A):3403-3408.

348. Mastalerz-Migas A, Steciwko A, Pokorski M, et al. What influences the
level of oxidative stress as measured by 8-hydroxy-2’-deoxyguanosine in
patients on hemodialysis? J Physiol Pharmacol. 2006;57 Suppl 4:199-205.
349. Watanabe E, Matsuda N, Shiga T, et al. Significance of 8-hydroxy-2’-

deoxyguanosine levels in patients with idiopathic dilated cardiomyopathy.
J Card Fail. 2006;12(7):527-532.

350. Matsumoto Y, Ogawa Y, Yoshida R, et al. [Relationship between length of

caused by organochlorines affects breast cancer? Arch Environ Contam
Toxicol. 2001;41(3):386-395.

364. Yoshida R, Shioji I, Kishida A, et al. Moderate alcohol consumption
reduces urinary 8-hydroxydeoxyguanosine by inducing of uric acid. Ind
Health. 2001;39(4):322-329.
365. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage
and tubulointerstitial injury in diabetic nephropathy. Nephron.
2002;91(2):327-329.
366. Pilger A, Ivancsits S, Germadnik D, et al. Urinary excretion of 8-hydroxy2’-deoxyguanosine measured by high-performance liquid chromatography
with electrochemical detection. J Chromatogr B Analyt Technol Biomed
Life Sci. 2002;778(1-2):393-401.
367. Inoue O, Seiji K, Suzuki T, et al. Simultaneous determination of hippuric

sleep and oxidative stress marker, urinary 8-hydroxy-2’-deoxyguanosine].

acid, o-, m-, and p-methylhippuric acid, phenylglyoxylic acid, and

Nippon Eiseigaku Zasshi. 2006;61(3):357-365.

mandelic acid by HPLC. Bull Environ Contam Toxicol. 1991;47(2):204-

351. Pilger A, Rudiger HW. 8-Hydroxy-2’-deoxyguanosine as a marker of
oxidative DNA damage related to occupational and environmental
exposures. Int Arch Occup Environ Health. 2006;80(1):1-15.
352. Endo K, Miyashita Y, Sasaki H, et al. Probucol and atorvastatin decrease
urinary 8-hydroxy-2’-deoxyguanosine in patients with diabetes and
hypercholesterolemia. J Atheroscler Thromb. 2006;13(1):68-75.
353. Feng S, Roethig HJ, Liang Q, et al. Evaluation of urinary 1-hydroxypyrene,
S-phenylmercapturic acid, trans,trans-muconic acid, 3-methyladenine, 3ethyladenine, 8-hydroxy-2’-deoxyguanosine and thioethers as biomarkers
of exposure to cigarette smoke. Biomarkers. 2006;11(1):28-52.
354. Kubota R, Kunito T, Agusa T, et al. Urinary 8-hydroxy-2’-deoxyguanosine

210.
368. Tardif R, Brodeur J, Plaa GL. Simultaneous high-performance liquid
chromatographic analysis of hippuric acid and ortho-, meta-, and paramethylhippuric acids in urine. J Anal Toxicol. 1989;13(6):313-316.
369. Triebig G, Schaller KH, Weltle D. Neurotoxicity of solvent mixtures in
spray painters. I. Study design, workplace exposure, and questionnaire.
Int Arch Occup Environ Health. 1992;64(5):353-359.
370. Lundberg I, Sollenberg J. Correlation of xylene exposure and methyl
hippuric acid excretion in urine among paint industry workers. Scand J
Work Environ Health. 1986;12(2):149-153.
371. Inoue O, Seiji K, Kawai T, et al. Excretion of methylhippuric acids in urine

in inhabitants chronically exposed to arsenic in groundwater in

of workers exposed to a xylene mixture: comparison among three xylene

Cambodia. J Environ Monit. 2006;8(2):293-299.

isomers and toluene. Int Arch Occup Environ Health. 1993;64(7):533-539.

355. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2’deoxyguanosine in clinical depression. Psychosom Med. 2006;68(1):1-7.
tissue: do the data support the hypothesis that oxidative DNA damage

394. Hunter J, Maxwell JD, Stewart DA, et al. Urinary D-glucaric acid excretion

372. Lee KJ, Lee JJ, Moon DC. Application of micellar electrokinetic capillary
chromatography for monitoring of hippuric and methylhippuric acid in

and total liver content of cytochrome P-450 in guinea-pigs: relationship

human urine. Electrophoresis. 1994;15(1):98-102.

during enzyme induction and following inhibition of protein synthesis.

373. Visek WJ. Nitrogen-stimulated orotic acid synthesis and nucleotide

Biochem Pharmacol. 1973;22(6):743-747.
395. Sandle LN, Braganza JM. An evaluation of the low-pH enzymatic assay of

imbalance. Cancer Res. 1992;52(7 Suppl):2082s-2084s.
374. Nagasaka H, Yorifuji T, Murayama K, et al. Effects of arginine treatment

urinary D-glucaric acid, and its use as a marker of enzyme induction in
exocrine pancreatic disease [published erratum appears in Clin Chim Acta

on nutrition, growth and urea cycle function in seven Japanese boys

1990;188(3):279]. Clin Chim Acta. 1987;162(3):245-256.

with late-onset ornithine transcarbamylase deficiency. Eur J Pediatr.

396. Perry W, Jenkins MV. Note on the enzyme assay for urinary D-glucaric

2006;165(9):618-624.
375. Gilchrist JM, Coleman RA. Ornithine transcarbamylase deficiency: adult

acid and correlation with rifampicin-induced mixed function oxidase
activity. Int J Clin Pharmacol Ther Toxicol. 1986;24(11):609-613.

onset of severe symptoms. Ann Intern Med. 1987;106(4):556-558.

397. Edwards JW, Priestly BG. Effect of occupational exposure to aldrin on

376. Takanashi J, Kurihara A, Tomita M, et al. Distinctly abnormal brain

urinary D-glucaric acid, plasma dieldrin, and lymphocyte sister chromatid

metabolism in late-onset ornithine transcarbamylase deficiency. Neurology.
2002;59(2):210-214.

exchange. Int Arch Occup Environ Health. 1994;66(4):229-234.

377. Milner JA, Visek WJ. Orotate, citrate, and urea excretion in rats fed

398. Hogue CJ, Brewster MA. The potential of exposure biomarkers in
epidemiologic studies of reproductive health. Environ Health Perspect.

various levels of arginine. Proc Soc Exp Biol Med. 1974;147(3):754-759.
378. Lizarralde G, Mazzocco VE, Flink EB. Magnesium deficiency and urea

1991;90:261-269.
399. Bland J, Bralley J, Rigden S. Management of chronic fatigue symptoms

cycle enzymes in rat liver. Proc Soc Exp Biol Med. 1967;126(1):249-251.

by tailored nutritional intervention using a program designed to support

reversible renal failure. Lancet. 1973;1(7795):135-136.

hepatic detoxification. Paper presented at: HealthComm, Gig Harbor, WA;

380. Goksel BK, Torun D, Karaca S, et al. Is low blood magnesium level

1997.

400. Marsh CA. Biosynthesis of D-glucaric acid in mammals: a free-radical

associated with hemodialysis headache? Headache. 2006;46(1):40-45.
381. Klein CJ, Moser-Veillon PB, Schweitzer A, et al. Magnesium, calcium, zinc,

mechanism? Carbohydr Res. 1986;153(1):119-131.

401. Jakoby WB, Bend JR, Caldwell J. Metabolic Basis of Detoxication :
Metabolism of Functional Groups. New York: Academic Press; 1982.

and nitrogen loss in trauma patients during continuous renal replacement
therapy. JPEN J Parenter Enteral Nutr. 2002;26(2):77-92; discussion 92-

379. Whang R, Ryan MP, Aikawa JK. Magnesium deficiency: a cause of

402. Morkunaite S, Teplova VV, Saris NE. Mechanism of dihydrolipoate

93.

382. Adamek MU, Brass H, Karbach U. [A rare cause of hepatic coma]. Med
Klin (Munich). 2001;96(4):234-237.

383. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on
minimal hepatic encephalopathy in patients with cirrhosis. Hepatology.
2004;39(5):1441-1449.

384. Van Laethem JL, Gay F, Franck N, et al. Hyperammoniemic coma in a

patient with ureterosigmoidostomy and normal liver function. Dig Dis Sci.
1992;37(11):1754-1756.

385. Nelson J, Qureshi IA, Ghole VS, et al. Regulation of orotic acid
biosynthesis and excretion induced by oral glutamine administration in
mice. Biochem Med Metab Biol. 1993;49(3):338-350.

386. Boon L, Geerts WJ, Jonker A, et al. High protein diet induces pericentral
glutamate dehydrogenase and ornithine aminotransferase to provide
sufficient glutamate for pericentral detoxification of ammonia in rat liver
lobules. Histochem Cell Biol. 1999;111(6):445-452.
387. Anders M, Dekant W, eds. Conjugation-Dependent Carcinogenicity and

stimulation of the mitochondrial permeability transition: effect of different
respiratory substrates. IUBMB Life. 2000;49(3):211-216.

403. Banerjee R, Zou CG. Redox regulation and reaction mechanism of human
cystathionine-beta-synthase: a PLP-dependent hemesensor protein. Arch
Biochem Biophys. 2005;433(1):144-156.
404. Dissmann R, Linderer T, Schroder R. Estimation of enzymatic infarct
size: direct comparison of the marker enzymes creatine kinase and alphahydroxybutyrate dehydrogenase. Am Heart J. 1998;135(1):1-9.
405. Silva AR, Ruschel C, Helegda C, et al. Inhibition of in vitro CO2
production and lipid synthesis by 2-hydroxybutyric acid in rat brain. Braz
J Med Biol Res. 2001;34(5):627-631.
406. Bellomo G, Martino A, Richelmi P, et al. Pyridine-nucleotide oxidation,
Ca2+ cycling and membrane damage during tert-butyl hydroperoxide
metabolism by rat-liver mitochondria. Eur J Biochem. 1984;140(1):1-6.
407. Landaas S. The formation of 2-hydroxybutyric acid in experimental
animals. Clin Chim Acta. 1975;58(1):23-32.

Toxicity of Foreign Compounds. New York: Academic Press; 1994.

408. Imaki M, Kawabata K, Yoshida Y, et al. Evaluation of the effects of various

388. Hanausek M, Walaszek Z, Slaga TJ. Detoxifying cancer causing agents to

factors on the serum alpha hydroxybutyrate dehydrogenase activity in

prevent cancer. Integr Cancer Ther. 2003;2(2):139-144.
389. Kim DH, Jin YH. Intestinal bacterial beta-glucuronidase activity of patients
with colon cancer. Arch Pharm Res. 2001;24(6):564-567.

young females. Appl Human Sci. 1995;14(6):297-302.
409. Kano K, Ichimura T. Increased alpha-hydroxybutyrate dehydrogenase in
serum from children with measles. Clin Chem. 1992;38(5):624-627.

390. Walaszek Z, Szemraj J, Narog M, et al. Metabolism, uptake, and excretion

410. Chalmers RA, Lawson AM. Organic Acids in Man : Analytical Chemistry,

of a D-glucaric acid salt and its potential use in cancer prevention. Cancer

Biochemistry, and Diagnosis of the Organic Acidurias. London, New York:

Detect Prev. 1997;21(2):178-190.
391. Mulder GJ. Conjugation Reactions in Drug Metabolism : An Integrated
Approach : Substrates, Co-Substrates, Enzymes and Their Interactions In
Vivo and In Vitro. London, New York: Taylor & Francis; 1990.
392. Timbrell J. Principles of Biochemical Toxicology. 3rd ed. London, New
York: Taylor & Francis; 2000.
393. Hunter J, et al. Urinary D-glucaric acid excretion as a test for hepatic

Chapman and Hall; 1982.
411. Baral N, Pokhrel S, Lamsal M, et al. Utility of gamma-glutamyl
transpeptidase and mean corpuscular volume in alcoholic liver disease.
Southeast Asian J Trop Med Public Health. 2005;36(4):1007-1010.
412. Han GQ, Qin CY, Shu RH. The analysis of gamma-glutamyl
transpeptidase gene in different type liver tissues. World J Gastroenterol.
2003;9(2):276-280.

enzyme induction in man. Lancet. 1971;1:572-575.

431. Jackson AA, Badaloo AV, Forrester T, et al. Urinary excretion of 5-

413. Mayatepek E, Okun JG, Meissner T, et al. Synthesis and metabolism of
leukotrienes in gamma-glutamyl transpeptidase deficiency. J Lipid Res.

oxoproline (pyroglutamic aciduria) as an index of glycine insufficiency in

2004;45(5):900-904.

normal man. Br J Nutr. 1987;58(2):207-214.

414. Harding CO, Williams P, Wagner E, et al. Mice with genetic gamma-

432. Meakins TS, Persaud C, Jackson AA. Dietary supplementation with

glutamyl transpeptidase deficiency exhibit glutathionuria, severe

L-methionine impairs the utilization of urea-nitrogen and increases 5-L-

growth failure, reduced life spans, and infertility. J Biol Chem.

oxoprolinuria in normal women consuming a low protein diet. J Nutr.

1997;272(19):12560-12567.

1998;128(4):720-727.

415. Bernier FP, Snyder FF, McLeod DR. Deficiency of 5-oxoprolinase in an

433. Chalmers RA, Valman HB, Liberman MM. Measurement of 4-

8-year-old with developmental delay. J Inherit Metab Dis. 1996;19(3):367-

hydroxyphenylacetic aciduria as a screening test for small-bowel disease.

368.

Clin Chem. 1979;25(10):1791-1794.

416. Mayatepek E, Hoffmann GF, Larsson A, et al. 5-Oxoprolinase deficiency

434. Oberholzer VG, Wood CB, Palmer T, et al. Increased pyroglutamic acid

associated with severe psychomotor developmental delay, failure to thrive,

levels in patients on artificial diets. Clin Chim Acta. 1975;62(2):299-304.

microcephaly and microcytic anaemia. J Inherit Metab Dis. 1995;18(1):83-

435. Hsu JM, Anthony WL. Zinc deficiency and urinary excretion of taurine-

84.

35S and inorganic sulfate-35S following cystine-35S injecion in rats. J

417. Njalsson R, Norgren S. Physiological and pathological aspects of GSH

Nutr. 1970;100(10):1189-1195.
436. Levy G. Sulfate conjugation in drug metabolism: role of inorganic sulfate.

metabolism. Acta Paediatr. 2005;94(2):132-137.
418. Larsson A, Mattsson B, Wauters EA, et al. 5-oxoprolinuria due to

Fed Proc. 1986;45(8):2235-2240.
437. Gregus Z, White C, Howell S, et al. Effect of glutathione depletion on

hereditary 5-oxoprolinase deficiency in two brothers--a new inborn error
of the gamma-glutamyl cycle. Acta Paediatr Scand. 1981;70(3):301-308.

sulfate activation and sulfate ester formation in rats. Biochem Pharmacol.

419. Vina JR, Palacin M, Puertes IR, et al. Role of the gamma-glutamyl cycle in

1988;37(22):4307-4312.

438. Magee EA, Curno R, Edmond LM, et al. Contribution of dietary protein

the regulation of amino acid translocation. Am J Physiol. 1989;257(6 Pt
1):E916-922.

and inorganic sulfur to urinary sulfate: toward a biomarker of inorganic

420. Shi ZZ, Habib GM, Rhead WJ, et al. Mutations in the glutathione

sulfur intake. Am J Clin Nutr. 2004;80(1):137-142.

439. USDA Database for the Flavonoid Content of Selected Foods. Beltsville,

421. Tailor P, Raman T, Garganta CL, et al. Recurrent high anion gap metabolic
acidosis secondary to 5-oxoproline (pyroglutamic acid). Am J Kidney Dis.
422. Dempsey GA, Lyall HJ, Corke CF, et al. Pyroglutamic acidemia: a cause of

high anion gap metabolic acidosis. Crit Care Med. 2000;28(6):1803-1807.
423. Liu RM, Dickinson DA. Decreased synthetic capacity underlies the ageRedox Signal. 2003;5(5):529-536.

associated decline in glutathione content in Fisher 344 rats. Antioxid

424. Atkuri KR, Mantovani JJ, Herzenberg LA, et al. N-Acetylcysteine-a safe

antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol. 2007.
425. Rojas C, Cadenas S, Lopez-Torres M, et al. Increase in heart glutathione
redox ratio and total antioxidant capacity and decrease in lipid
peroxidation after vitamin E dietary supplementation in guinea pigs. Free

Radic Biol Med. 1996;21(7):907-915.

426. Janse van Rensburg C, Erasmus E, Loots DT, et al. Rosa roxburghii
supplementation in a controlled feeding study increases plasma
antioxidant capacity and glutathione redox state. Eur J Nutr.
2005;44(7):452-457.
427. Humphreys BD, Forman JP, Zandi-Nejad K, et al. Acetaminophen-induced
anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria)
acquired in hospital. Am J Kidney Dis. 2005;46(1):143-146.
428. Mukherjee TK, Mishra AK, Mukhopadhyay S, et al. High concentration
of antioxidants N-acetylcysteine and mitoquinone-Q induces intercellular
adhesion molecule 1 and oxidative stress by increasing intracellular
glutathione. J Immunol. 2007;178(3):1835-1844.
429. Yu YM, Ryan CM, Fei ZW, et al. Plasma L-5-oxoproline kinetics and whole
blood glutathione synthesis rates in severely burned adult humans. Am J
Physiol Endocrinol Metab. 2002;282(2):E247-258.
430. Metges CC, Yu YM, Cai W, et al. Oxoproline kinetics and oxoproline
urinary excretion during glycine- or sulfur amino acid-free diets in
humans. Am J Physiol Endocrinol Metab. 2000;278(5):E868-876.
440. Gonthier MP, Verny MA, Besson C, et al. Chlorogenic acid bioavailability

2005;46(1):E4-10.

Maryland: US Department of Agriculture; 2003.

synthetase gene cause 5-oxoprolinuria. Nat Genet. 1996;14(3):361-365.

largely depends on its metabolism by the gut microflora in rats. J Nutr.
2003;133(6):1853-1859.

441. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for
estrogen receptor beta, is the exclusive enantiomeric form of the soy
isoflavone metabolite produced by human intestinal bacterial flora. Am J
Clin Nutr. 2005;81(5):1072-1079.
442. Jenner AM, Rafter J, Halliwell B. Human fecal water content of phenolics:
the extent of colonic exposure to aromatic compounds. Free Radic Biol
Med. 2005;38(6):763-772.
443. Rechner AR, Smith MA, Kuhnle G, et al. Colonic metabolism of dietary
polyphenols: influence of structure on microbial fermentation products.
Free Radic Biol Med. 2004;36(2):212-225.

444. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the
human intestine. Science. 2005;307(5717):1915-1920.
445. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal
gut microbiome. Science. 2006;312(5778):1355-1359.
446. Gale EF. The oxidation of amines by bacteria. Biochem J. 1942;36(1-2):6475.
447. Gale EF. Production of amines by bacteria: The decarboxylation of
amino-acids by organisms of the groups Clostridium and Proteus With an
addendum by Brown, GL, MacIntosh, FC, and White, PB. Biochem J.
1941;35(1-2):66-80.
448. Gale EF. The production of amines by bacteria: The decarboxylation of
amino-acids by strains of Bacterium coli. Biochem J. 1940;34(3):392-413.
449. Gale EF. The production of amines by bacteria: The production of
putrescine from l(+)-arginine by Bacterium coli in symbiosis with
Streptococcus faecalis. Biochem J. 1940;34(6):853-857.
450. Gale EF. The production of amines by bacteria: The production of
tyramine by Streptococcus faecalis. Biochem J. 1940;34(6):846-852.

470. Gonthier MP, Cheynier V, Donovan JL, et al. Microbial aromatic acid

451. Martin AK. The origin of urinary aromatic compounds excreted by
ruminants. 1. The metabolism of quinic, cyclohexanecarboxylic and non-

metabolites formed in the gut account for a major fraction of the

phenolic aromatic acids to benzoic acid. Br J Nutr. 1982;47(1):139-154.

polyphenols excreted in urine of rats fed red wine polyphenols. J Nutr.

452. Martin AK. The origin of urinary aromatic compounds excreted by

2003;133(2):461-467.
471. Ward NC, Croft KD, Puddey IB, et al. Supplementation with

ruminants. 2. The metabolism of phenolic cinnamic acids to benzoic acid.
Br J Nutr. 1982;47(1):155-164.

grape seed polyphenols results in increased urinary excretion

453. Martin AK. The origin of urinary aromatic compounds excreted by

of 3-hydroxyphenylpropionic Acid, an important metabolite of
proanthocyanidins in humans. J Agric Food Chem. 2004;52(17):5545-

ruminants. 3. The metabolism of phenolic compounds to simple phenols.

5549.

Br J Nutr. 1982;48(3):497-507.

472. Mulder TP, Rietveld AG, van Amelsvoort JM. Consumption of both black

454. Martin AK, Milne JA, Moberly P. The origin of urinary aromatic
compounds excreted by ruminants. 4. The potential use of urine aromatic

tea and green tea results in an increase in the excretion of hippuric acid

acid and phenol outputs as a measure of voluntary food intake. Br J Nutr.

into urine. Am J Clin Nutr. 2005;81(1 Suppl):256S-260S.
473. Van der Heiden C, Wauters, EAK, Ketting D, et al. Gas chromatographic

1983;49(1):87-99.
455. Rios LY, Gonthier MP, Remesy C, et al. Chocolate intake increases urinary

analysis of urinary tyrosine and phenylalanine metabolites in patients with
gastrointestinal disorders. Clin Chim Acta. 1971;34:289-296.

excretion of polyphenol-derived phenolic acids in healthy human

474. Scalbert A, Morand C, Manach C, et al. Absorption and metabolism of

subjects. Am J Clin Nutr. 2003;77(4):912-918.
456. Lenz EM, Bright J, Wilson ID, et al. A 1H NMR-based metabonomic study

polyphenols in the gut and impact on health. Biomed Pharmacother.
2002;56(6):276-282.

of urine and plasma samples obtained from healthy human subjects. J

475. Adamson RH, Bridges JW, Evans ME, et al. Species differences in the

Pharm Biomed Anal. 2003;33(5):1103-1115.
457. Williams RE, Lenz EM, Evans JA, et al. A combined (1)H NMR and

aromatization of quinic acid in vivo and the role of gut bacteria. Biochem
J. 1970;116(3):437-443.

HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker

476. Li C, Lee MJ, Sheng S, et al. Structural identification of two metabolites of

and normal Wistar-derived rats. J Pharm Biomed Anal. 2005;38(3):465-

catechins and their kinetics in human urine and blood after tea ingestion.

471.
458. Child MW, Kennedy A, Walker AW, et al. Studies on the effect of

Chem Res Toxicol. 2000;13(3):177-184.

continuous culture model of the human large gut using FISH techniques.
459. Booth AN, Emerson OH, Jones FT, et al. Urinary metabolites of caffeic and

mass spectrometry technique adopted in a survey on Italian foods and
beverages. Food Addit Contam. 1995;12(1):1-7.

478. Quick A. The study of benzoic acid conjugation in the dog with a direct

chlorogenic acids. J Biol Chem. 1957:51-59.
460. Griffiths LA. Studies on flavonoid metabolism. Identification of the

metabolities of (+)-catechin in rat urine. Biochem J. 1964;92(1):173-179.

461. Dacre JC, Scheline RR, Williams RT. The role of the tissues and gut flora in
the metabolism of [14C]homoprotocatechuic acid in the rat and rabbit. J

Pharm Pharmacol. 1968;20(8):619-625.

acid, benzoic acid and parabens in foods: a new gas chromatography-

FEMS Microbiol Ecol. 2006;55(2):299-310.

477. de Luca C, Passi S, Quattrucci E. Simultaneous determination of sorbic

system retention time on bacterial populations colonizing a three-stage

462. Das NP. Studies on flavonoid metabolism. Degradation of (plus)-catechin
by rat intestinal contents. Biochim Biophys Acta. 1969;177(3):668-670.
463. Van der Heiden C, Wadman SK, Ketting D, et al. Urinary and faecal

excretion of metabolites of tyrosine and phenylalanine in a patient with

quantitative method for hippuric acid. J Biol Chem. 1934:477-490.
479. Temellini A, Mogavero S, Giulianotti PC, et al. Conjugation of
benzoic acid with glycine in human liver and kidney: a study on the
interindividual variability. Xenobiotica. 1993;23(12):1427-1433.
480. Andersson R, Carlsson A, Nordqvist MB, et al. Urinary excretion of
hippuric acid and o-cresol after laboratory exposure of humans to toluene.
Int Arch Occup Environ Health. 1983;53(2):101-108.
481. Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate,
phenylacetate, and phenylpyruvate by negative ion chemical ionization-

cystic fibrosis and severely impaired amino acid absorption. Clin Chim

gas chromatography/mass spectrometry in brain of mouse genetic models

Acta. 1971;31(1):133-141.

of phenylketonuria and non-phenylketonuria hyperphenylalaninemia.

464. Scheline RR, Midtvedt T. Absence of dehydroxylation of caffeic acid in
germ-free rats. Experientia. 1970;26(10):1068-1069.
465. Curtius HC, Mettler M, Ettlinger L. Study of the intestinal tyrosine
metabolism using stable isotopes and gas chromatography-mass
spectrometry. J Chromatogr. 1976;126:569-580.
466. Groenewoud G, Hundt HK. The microbial metabolism of condensed (+)catechins by rat-caecal microflora. Xenobiotica. 1986;16(2):99-107.
467. Pietta PG, Gardana C, Mauri PL. Identification of Gingko biloba flavonol
metabolites after oral administration to humans. J Chromatogr B Biomed
Sci Appl. 1997;693(1):249-255.
468. Deprez S, Brezillon C, Rabot S, et al. Polymeric proanthocyanidins are
catabolized by human colonic microflora into low-molecular-weight
phenolic acids. J Nutr. 2000;130(11):2733-2738.
469. Clifford MN, Copeland EL, Bloxsidge JP, et al. Hippuric acid as a major

Anal Biochem. 2000;280(2):242-249.
482. Martynyuk AE, Glushakov AV, Sumners C, et al. Impaired glutamatergic
synaptic transmission in the PKU brain. Mol Genet Metab. 2005;86 Suppl
1:S34-42.
483. Fischer GM, Nemeti B, Farkas V, et al. Metabolism of carnitine in
phenylacetic acid-treated rats and in patients with phenylketonuria.
Biochim Biophys Acta. 2000;1501(2-3):200-210.
484. Liu J, Li J, Sidell N. Modulation by phenylacetate of early estrogenmediated events in MCF-7 breast cancer cells. Cancer Chemother
Pharmacol. 2006;59:217-225.
485. Shibahara T, Onishi T, Franco OE, et al. Down-regulation of Skp2 is
correlated with p27-associated cell cycle arrest induced by phenylacetate
in human prostate cancer cells. Anticancer Res. 2005;25(3B):1881-1888.
486. Frank L, Avramoglou T, Sainte-Catherine O, et al. Growth inhibition of

excretion product associated with black tea consumption. Xenobiotica.

MCF-7 tumor cell line by phenylacetate linked to functionalized dextran.

2000;30(3):317-326.

J Biomater Sci Polym Ed. 2004;15(10):1305-1315.

487. Li XN, Parikh S, Shu Q, et al. Phenylbutyrate and phenylacetate induce

506. Aura AM, O’Leary KA, Williamson G, et al. Quercetin derivatives

differentiation and inhibit proliferation of human medulloblastoma cells.

are deconjugated and converted to hydroxyphenylacetic acids but

Clin Cancer Res. 2004;10(3):1150-1159.

not methylated by human fecal flora in vitro. J Agric Food Chem.

488. Chang SM, Kuhn JG, Ian Robins H, et al. A study of a different

2002;50(6):1725-1730.
507. Lindblad BS, Alm J, Lundsjo A, et al. Absorption of biological amines

dose-intense infusion schedule of phenylacetate in patients with

of bacterial origin in normal and sick infants. Ciba Found Symp.

recurrent primary brain tumors consortium report. Invest New Drugs.

1979(70):281-291.

2003;21(4):429-433.

508. Machino H, Miki Y, Kawatsu T, et al. Successful dietary control of

489. Thompson P, Balis F, Serabe BM, et al. Pharmacokinetics of phenylacetate
administered as a 30-min infusion in children with refractory cancer.

tyrosinemia II. J Am Acad Dermatol. 1983;9(4):533-539.
509. Endo F, Kitano A, Uehara I, et al. Four-hydroxyphenylpyruvic acid

Cancer Chemother Pharmacol. 2003;52(5):417-423.
490. Sidell N, Pasquali M, Malkapuram S, et al. In vitro and in vivo effects of

oxidase deficiency with normal fumarylacetoacetase: a new variant form of
hereditary hypertyrosinemia. Pediatr Res. 1983;17(2):92-96.

easily administered, low-toxic retinoid and phenylacetate compounds on

510. Endo F, Katoh H, Yamamoto S, et al. A murine model for type III

human neuroblastoma cells. Br J Cancer. 2003;89(2):412-419.
491. Franco OE, Onishi T, Umeda Y, et al. Phenylacetate inhibits growth and

tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic
acid dioxygenase enzyme protein in a novel mouse strain with

modulates cell cycle gene expression in renal cancer cell lines. Anticancer

hypertyrosinemia. Am J Hum Genet. 1991;48(4):704-709.

Res. 2003;23(2B):1637-1642.

511. Endo F, Awata H, Katoh H, et al. A nonsense mutation in the 4-

492. Berg S, Serabe B, Aleksic A, et al. Pharmacokinetics and cerebrospinal
fluid penetration of phenylacetate and phenylbutyrate in the nonhuman

hydroxyphenylpyruvic acid dioxygenase gene (Hpd) causes skipping of

primate. Cancer Chemother Pharmacol. 2001;47(5):385-390.

the constitutive exon and hypertyrosinemia in mouse strain III. Genomics.

493. Russo GL, Della Pietra V, Mercurio C, et al. Protective effects of butyric

1995;25(1):164-169.

512. Khan RI, Onodera R, Amin MR, et al. Aromatic amino acid biosynthesis

acid in colon cancer. Adv Exp Med Biol. 1999;472:131-147.
494. Lambert MA, Moss CW. Production of p-hydroxyhydrocinnamic acid

and production of related compounds from p-hydroxyphenylpyruvic
acid by rumen bacteria, protozoa and their mixture. Amino Acids.

from tyrosine by Peptostreptococcus anaerobius. J Clin Microbiol.

2002;22(2):167-177.

1980;12(2):291-293.
dehydrogenation of 3-phenylpropionic acid: in vitro reaction of 3-

513. Elsden SR, Hilton MG, Waller JM. The end products of the metabolism of

495. Rinaldo P, O’Shea JJ, Welch RD, et al. The enzymatic basis for the

aromatic amino acids by Clostridia. Arch Microbiol. 1976;107(3):283-288.

1990;27(5):501-507.

496. Bennett MJ, Bhala A, Poirier SF, et al. When do gut flora in the newborn

associated enteric disease. Ann Intern Med. 2006;145(10):758-764.

515. Taormina PJ, Bartholomew GW, Dorsa WJ. Incidence of Clostridium

produce 3-phenylpropionic acid? Implications for early diagnosis

perfringens in commercially produced cured raw meat product mixtures

of medium-chain acyl-CoA dehydrogenase deficiency. Clin Chem.

and behavior in cooked products during chilling and refrigerated storage.

1992;38(2):278-281.

497. Bhala A, Bennett MJ, McGowan KL, et al. Limitations of 3-

phenylpropionylglycine in early screening for medium-chain acylcoenzyme A dehydrogenase deficiency. J Pediatr. 1993;122(1):100-103.
498. Bures J, Jergeova Z, Sobotka L, et al. [Excretion of phenol and p-cresol
in the urine in fasting obese individuals and in persons treated with total

enteral nutrition]. Cas Lek Cesk. 1990;129(37):1166-1171.

499. Tamm AO. Biochemical activity of intestinal microflora in adult coeliac
disease. Nahrung. 1984;28(6-7):711-715.

500. Niwa T, Ise M, Miyazaki T, et al. Suppressive effect of an oral sorbent on
the accumulation of p-cresol in the serum of experimental uremic rats.
Nephron. 1993;65(1):82-87.
501. De Preter V, Vanhoutte T, Huys G, et al. Effects of Lactobacillus casei
Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on the
colonic nitrogen-protein metabolism in healthy humans. Am J Physiol
Gastrointest Liver Physiol. 2006;292:G358-G368.
502. Barker JL, Frost JW. Microbial synthesis of p-hydroxybenzoic acid from
glucose. Biotechnol Bioeng. 2001;76(4):376-390.
503. Zhivotnikova NV. [Changes in bioenergy processes in rat liver
mitochondria after exposure to diglycidyl ether of p-hydroxybenzoic
acid]. Gig Sanit. 1990(11):20-22.
504. Ward LA, Johnson KA, Robinson IM, et al. Isolation from swine feces of
a bacterium which decarboxylates p- hydroxyphenylacetic acid to 4methylphenol (p-cresol). Appl Environ Microbiol. 1987;53(1):189-192.
505. Fellaman JH, Buist NR, Kennaway NG. Pitfalls in metabolic studies: the
origin of urinary p-tyramine. Clin Biochem. 1977;10(5):168-170.
514. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-

phenylpropionyl-CoA with various acyl-CoA dehydrogenases. Pediatr Res.

J Food Prot. 2003;66(1):72-81.
516. Delgado S, Suarez A, Mayo B. Identification of dominant bacteria in feces
and colonic mucosa from healthy Spanish adults by culturing and by 16S
rDNA sequence analysis. Dig Dis Sci. 2006;51(4):744-751.
517. Rechner AR, Kuhnle G, Hu H, et al. The metabolism of dietary
polyphenols and the relevance to circulating levels of conjugated
metabolites. Free Radic Res. 2002;36(11):1229-1241.
518. Schwarz G, Bauder R, Speer M, et al. Microbial metabolism of quinoline
and related compounds. II. Degradation of quinoline by Pseudomonas
fluorescens 3, Pseudomonas putida 86 and Rhodococcus spec. B1. Biol
Chem Hoppe Seyler. 1989;370(11):1183-1189.
519. Konishi Y, Kobayashi S. Microbial metabolites of ingested caffeic acid are
absorbed by the monocarboxylic acid transporter (MCT) in intestinal
Caco-2 cell monolayers. J Agric Food Chem. 2004;52(21):6418-6424.
520. Kim HK, Jeong TS, Lee MK, et al. Lipid-lowering efficacy of hesperetin
metabolites in high-cholesterol fed rats. Clin Chim Acta. 2003;327(12):129-137.
521. Moridani MY, Scobie H, Jamshidzadeh A, et al. Caffeic acid, chlorogenic
acid, and dihydrocaffeic acid metabolism: glutathione conjugate
formation. Drug Metab Dispos. 2001;29(11):1432-1439.
522. Shukla OP. Microbial transformation of quinoline by a Pseudomonas sp.
Appl Environ Microbiol. 1986;51(6):1332-1342.
523. Shukla OP. Microbiological degradation of quinoline by Pseudomonas
stutzeri: the coumarin pathway of quinoline catabolism. Microbios.
1989;59(238):47-63.

524. Spence EL, Kawamukai M, Sanvoisin J, et al. Catechol dioxygenases from

544. Haan E, Brown G, Bankier A, et al. Severe illness caused by the products

Escherichia coli (MhpB) and Alcaligenes eutrophus (MpcI): sequence

of bacterial metabolism in a child with a short gut. Eur J Pediatr.

analysis and biochemical properties of a third family of extradiol

1985;144(1):63-65.
545. Caldarini MI, Pons S, D’Agostino D, et al. Abnormal fecal flora in a patient

dioxygenases. J Bacteriol. 1996;178(17):5249-5256.
525. Bugg TD. Overproduction, purification and properties of 2,3-

with short bowel syndrome. An in vitro study on effect of pH on D-lactic
acid production [see comments]. Dig Dis Sci. 1996;41(8):1649-1652.

dihydroxyphenylpropionate 1,2-dioxygenase from Escherichia coli.

546. Bongaerts G, Bakkeren J, Severijnen R, et al. Lactobacilli and acidosis

Biochim Biophys Acta. 1993;1202(2):258-264.
526. Powell-Jackson PR, Maudgal DP, Sharp D, et al. Intestinal bacterial

in children with short small bowel. J Pediatr Gastroenterol Nutr.
2000;30(3):288-293.

metabolism of protein and bile acids: role in pathogenesis of hepatic

547. Bongaerts G, Tolboom J, Naber T, et al. D-lactic acidemia and aciduria

disease after jejuno-ileal bypass surgery. Br J Surg. 1979;66(11):772-775.
527. Tohyama K, Kobayashi Y, Kan T, et al. Effect of lactobacilli on urinary

in pediatric and adult patients with short bowel syndrome. Clin Chem.
1995;41(1):107-110.

indican excretion in gnotobiotic rats and in man. Microbiol Immunol.

548. Zhang DL, Jiang ZW, Jiang J, et al. D-lactic acidosis secondary to short

1981;25(2):101-112.
528. Yoshida K, Hirayama C. Tryptophan metabolism in liver cirrhosis:

bowel syndrome. Postgrad Med J. 2003;79(928):110-112.
549. Dahlquist NR, Perrault J, Callaway CW, et al. D-Lactic acidosis and

influence of oral antibiotics on neuropsychiatric symptoms. Tohoku J Exp
Med. 1984;142(1):35-41.

encephalopathy after jejunoileostomy: response to overfeeding and to

529. Miloszewski K, Kelleher J, Walker BE, et al. Increase in urinary indican

fasting in humans. Mayo Clin Proc. 1984;59(3):141-145.
550. Halverson J, Gale A, Lazarus C. D-lactic acidosis and other complications

excretion in pancreatic steatorrhoea following replacement therapy. Scand

of intestinal bypass surgery. Arch Intern Med. 1984;144(2):357-360.

J Gastroenterol. 1975;10(5):481-485.

551. Smith SM, Eng RH, Buccini F. Use of D-lactic acid measurements in the

530. Lawrie CA, Renwick AG, Sims J. The urinary excretion of bacterial aminoacid metabolites by rats fed saccharin in the diet. Food Chem Toxicol.

diagnosis of bacterial infections. J Infect Dis. 1986;154(4):658-664.
552. Thurn JR, Pierpont GL, Ludvigsen CW, et al. D-lactate encephalopathy.

1985;23(4-5):445-450.
531. Kirkland JL, Vargas E, Lye M. Indican excretion in the elderly. Postgrad

Am J Med. 1985;79(6):717-721.

553. Slyter LL, Rumsey TS. Effect of coliform bacteria, feed deprivation, and

Med J. 1983;59(697):717-719.
532. Smith DF. Effects of age on serum tryptophan and urine indican in

microbial populations changed from forage to concentrates. J Anim Sci.

1982;7(1):55-58.

pH on ruminal D-lactic acid production by steer or continuous-culture

adults given a tryptophan load test. Eur J Drug Metab Pharmacokinet.
533. Aarbakke J, Schjonsby H. Value of urinary simple phenol and indican

determinations in the diagnosis of the stagnant loop syndrome. Scand J
Gastroenterol. 1976;11(4):409-414.

534. Stachow A, Jablonska S, Skiendzielewska A. Intestinal absorption of L-

tryptophan in scleroderma. Acta Derm Venereol. 1976;56(4):257-264.
535. Mayer P, Beeken W. The role of urinary indican as a predictor of bacterial

colonization in the human jejunum. Am J Dig Dis. 1975;20(11):1003
- 1009.

536. Patney NL, Mehrotra MP, Khanna HK, et al. Urinary indican excretion in
cirrhosis of liver. J Assoc Physicians India. 1976;24(5):291-295.

537. Montgomery RD, Haeney MR, Ross IN, et al. The ageing gut: a study
of intestinal absorption in relation to nutrition in the elderly. Q J Med.
1978;47(186):197-124.

538. Ewaschuk JB, Naylor JM, Zello GA. D-lactate in human and ruminant
metabolism. J Nutr. 2005;135(7):1619-1625.
539. Bongaerts GP, Tolboom JJ, Naber AH, et al. Role of bacteria in the
pathogenesis of short bowel syndrome-associated D-lactic acidemia.
Microb Pathog. 1997;22(5):285-293.
540. Bongaerts G, Severijnen R, Skladal D, et al. Yeast mediates lactic acidosis
suppression after antibiotic cocktail treatment in short small bowel? Scand
J Gastroenterol. 2005;40(10):1246-1250.
541. Hudson M, Pocknee R, Mowat NA. D-lactic acidosis in short bowel
syndrome--an examination of possible mechanisms. Q J Med.
1990;74(274):157-163.
542. Vella A, Farrugia G. D-lactic acidosis: pathologic consequence of
saprophytism. Mayo Clin Proc. 1998;73(5):451-456.
543. Traube M, Bock JL, Boyer JL. D-Lactic acidosis after jejunoileal

1991;69(7):3055-3066.

554. Coronado BE, Opal SM, Yoburn DC. Antibiotic-induced D-lactic acidosis.
Ann Intern Med. 1995;122(11):839-842.

555. Jover R, Leon J, Palazon JM, et al. D-lactic acidosis associated with use of
medium-chain triglycerides. Lancet. 1995;346(8970):314.
556. Mason PD. Metabolic acidosis due to D-lactate. Br Med J (Clin Res Ed).
1986;292(6528):1105-1106.
557. Caglayan F, Cakmak M, Caglayan O, et al. Plasma D-lactate levels in
diagnosis of appendicitis. J Invest Surg. 2003;16(4):233-237.
558. Demircan M. Plasma d-lactate level: a useful marker to distinguish
a perforated appendix from acute simple appendicitis. J Invest Surg.
2004;17(3):173-174; discussion 175.
559. Uchida H, Yamamoto H, Kisaki Y, et al. D-lactic acidosis in short-bowel
syndrome managed with antibiotics and probiotics. J Pediatr Surg.
2004;39(4):634-636.
560. Uribarri J, Oh MS, Carroll HJ. D-lactic acidosis. A review of clinical
presentation, biochemical features, and pathophysiologic mechanisms.
Medicine (Baltimore). 1998;77(2):73-82.
561. Murray MJ, Gonze MD, Nowak LR, et al. Serum D(-)-lactate levels as an
aid to diagnosing acute intestinal ischemia. Am J Surg. 1994;167(6):575578.
562. Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the
gastrointestinal tract. Kidney Int. 1996;49(1):1-8.
563. Haschke-Becher E, Baumgartner M, Bachmann C. Assay of D-lactate in
urine of infants and children with reference values taking into account
data below detection limit. Clin Chim Acta. 2000;298(1-2):99-109.
564. Norton D, Crow B, Bishop M, et al. High performance liquid
chromatography-tandem mass spectrometry (HPLC/MS/MS) assay for

bypass: identification of organic anions by nuclear magnetic resonance

chiral separation of lactic acid enantiomers in urine using a teicoplanin

spectroscopy. Ann Intern Med. 1983;98(2):171-173.

based stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci.
2006.

586. Sanaka T, Sugino N, Teraoka S, et al. Therapeutic effects of oral sorbent in

565. Connolly E, Lonnerdal B. D(-)-lactic acid-producing bacteria: safe to use
in infant formulas. NUTAfoods. 2004;3(3):37-49.

undialyzed uremia. Am J Kidney Dis. 1988;12(2):97-103.

566. McDevitt J, Goldman P. Effect of the intestinal flora on the urinary organic

587. Zapata-Sirvent RL, Hansbrough JF, Ohara MM, et al. Bacterial

acid profile of rats ingesting a chemically simplified diet. Food Chem

translocation in burned mice after administration of various diets

Toxicol. 1991;29(2):107-113.

including fiber- and glutamine-enriched enteral formulas. Crit Care Med.

567. Schwartz R, Topley M, Russell JB. Effect of tricarballylic acid, a

1994;22(4):690-696.
588. Nelson JL, Alexander JW, Gianotti L, et al. Influence of dietary fiber on

nonmetabolizable rumen fermentation product of trans-aconitic acid, on
Mg, Ca and Zn utilization of rats. J Nutr. 1988;118(2):183-188.

microbial growth in vitro and bacterial translocation after burn injury in

568. Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs

mice. Nutrition. 1994;10(1):32-36.
589. Nakamura T, Hasebe M, Yamakawa M, et al. Effect of dietary fiber on

of Krebs cycle metabolites and arabinose in two brothers with autistic
features. Clin Chem. 1995;41(8 Pt 1):1094-1104.

bowel mucosal integrity and bacterial translocation in burned rats. J Nutr

569. Pfaller MA. Laboratory aids in the diagnosis of invasive candidiasis.

Sci Vitaminol (Tokyo). 1997;43(4):445-454.
590. Pettersson D, Aman P, Knudsen KE, et al. Intake of rye bread ileostomists

Mycopathologia. 1992;120(2):65-72.
570. Ness MJ, Rennard SI, Vaughn WP, et al. Detection of Candida antigen in

increases ileal excretion of fiber polysaccharide components and organic

bronchoalveolar lavage fluid. Acta Cytol. 1988;32(3):347-352.

acids but does not increase plasma or urine lignans and isoflavonoids. J

571. Marklein G, Weil HP, Rommelsheim K. Laboratory diagnostic possibilities

Nutr. 1996;126(6):1594-1600.
591. Peltonen R, Kjeldsen-Kragh J, Haugen M, et al. Changes of faecal flora

in fungus infections in intensive care patients [Translated]. Anasth

in rheumatoid arthritis during fasting and one-year vegetarian diet. Br J

Intensivther Notfallmed. 1989;24(3):172-176.
572. Yeo SF, Zhang Y, Schafer D, et al. A rapid, automated enzymatic

Rheumatol. 1994;33(7):638-643.

592. Furhman J. Fasting and Eating for Health. New York: St. Martin’s Griffin; 1995.

Microbiol. 2000;38(4):1439-1443.

593. Bouhnik Y, Flourie B, Riottot M, et al. Effects of fructo-oligosaccharides

fluorometric assay for determination of D-arabinitol in serum. J Clin
573. Kern M, Haltrich D, Nidetzky B, et al. Induction of aldose reductase

ingestion on fecal bifidobacteria and selected metabolic indexes of colon
carcinogenesis in healthy humans. Nutr Cancer. 1996;26(1):21-29.

and xylitol dehydrogenase activities in Candida tenuis CBS 4435. FEMS

594. Gianoukakis AG, Cao HJ, Jennings TA, et al. Prostaglandin endoperoxide

Microbiol Lett. 1997;149(1):31-37.
574. Wong B, Bernard EM, Gold JW, et al. The arabinitol appearance rate

1982;146(3):353-359.

575. Tokunaga S, Ohkawa M, Takashima M, et al. Clinical significance of

measurement of serum D-arabinitol levels in candiduria patients. Urol Int.
1992;48(2):195-199.

576. Roboz J. Diagnosis and monitoring of disseminated candidiasis based on
serum/urine D/L-arabinitol ratios. Chirality. 1994;6(2):51-57.

577. Christensson B, Sigmundsdottir G, Larsson L. D-arabinitol--a marker for
invasive candidiasis. Med Mycol. 1999;37(6):391-396.

578. Wells CL, Sirany MS, Blazevic DJ. Evaluation of serum arabinitol as a
diagnostic test for candidiasis. J Clin Microbiol. 1983;18(2):353-357.

579. Holak EJ, Wu J, Spruance SL. Value of serum arabinitol for the
management of Candida infections in clinical practice. Mycopathologia.
1986;93(2):99-104.

580. Lehtonen L, Rantala A, Oksman P, et al. Determination of serum arabinitol
levels by mass spectrometry in patients with postoperative candidiasis.
Eur J Clin Microbiol Infect Dis. 1993;12(5):330-335.
581. Bougnoux ME, Hill C, Moissenet D, et al. Comparison of antibody,
antigen, and metabolite assays for hospitalized patients with disseminated
or peripheral candidiasis. J Clin Microbiol. 1990;28(5):905-909.
582. Sigmundsdottir G, Christensson B, Bjorklund LJ, et al. Urine D-arabinitol/
L-arabinitol ratio in diagnosis of invasive candidiasis in newborn infants. J
Clin Microbiol. 2000;38(8):3039-3042.
583. Lord RS, Burdette CK, Bralley JA. Significance of urinary tartaric acid. Clin
Chem. 2005;51(3):672-673.
584. Eaton KK, Howard JM, Hunnisett A, et al. Abnormal gut fermation:
Laboratory studies reveal deficiency of B vitamins, zinc, and magnesium. J
Nutr Biochem.. 1993;4:635-638.
585. Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the
upper gut in patients with small intestinal bacterial overgrowth syndrome.
Am J Gastroenterol. 1999;94(5):1327-1331.
Physiol. 2001;280(3):C701-708.
595. Hagen T, Korson MS, Wolfsdorf JI. Urinary lactate excretion to monitor the
efficacy of treatment of type I glycogen storage disease. Mol Genet Metab.
2000;70(3):189-195.
596. Unpublished results from Metametrix Clinical Laboratory, 2007, Duluth, GA.

creatine ratio and relevance to the diagnosis of candidiasis. J Infect Dis.

H synthase expression in human thyroid epithelial cells. Am J Physiol Cell

in laboratory animals and humans: estimation from the arabinitol/

597. Dyck LE, Yang CR, Boulton AA. The biosynthesis of p-tyramine, mtyramine, and beta-phenylethylamine by rat striatal slices. J Neurosci Res.
1983;10(2):211-220.
598. Panoutsopoulos GI. Metabolism of 2-phenylethylamine to phenylacetic
acid, via the intermediate phenylacetaldehyde, by freshly prepared and
cryopreserved guinea pig liver slices. In Vivo. 2004;18(6):779-786.
599. Landete JM, Pardo I, Ferrer S. Tyramine and phenylethylamine production
among lactic acid bacteria isolated from wine. Int J Food Microbiol.
2007;115(3):364-368.
600. Kitanaka J, Kitanaka N, Tatsuta T, et al. 2-Phenylethylamine in
combination with l-deprenyl lowers the striatal level of dopamine and
prolongs the duration of the stereotypy in mice. Pharmacol Biochem
Behav. 2005;82(3):488-494.
601. Baxter LR, Jr., Kelly RC, Peter JB, et al. Urinary phenylacetate and
response to methylphenidate. J Psychiatr Res. 1988;22(2):131-139.
602. Sabelli HC, Fawcett J, Gusovsky F, et al. Clinical studies on the
phenylethylamine hypothesis of affective disorder: urine and blood
phenylacetic acid and phenylalanine dietary supplements. J Clin
Psychiatry. 1986;47(2):66-70.
603. Davis BA, Kennedy SH, D’Souza J, et al. Correlations of plasma and
urinary phenylacetic acid and phenylethylamine concentrations with
eating behavior and mood rating scores in brofaromine-treated women
with bulimia nervosa. J Psychiatry Neurosci. 1994;19(4):282-288.
604. Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the
antidepressant effects of exercise? Br J Sports Med. 2001;35(5):342-343.
605. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular
pathways of disease. Exp Mol Pathol. 2007;83(1):84-92.